As filed with the Securities and Exchange Commission on January 31, 2005
Registration No. 333-120449
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Amendment No. 1 to
FORM SB-2
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
VisiJet, Inc.
(Name of small business issuer in its charter)
Delaware 3841 33-0838660
(State or other jurisdiction (Primary Standard Industrial (IRS Employer
of corporation or organization) Classification Code Number) Identification
Number)
192 Technology Drive, Suite Q
Irvine, California 92618
(949) 450-1660
(Address and telephone number of registrant's principal executive offices)
Laurence M. Schreiber
192 Technology Drive, Suite Q
Irvine, California 92618
Ph. (949) 450-1660
Fax:(949) 453-9652
(Name, address and telephone number of agent for service)
Copy of all communications to:
Robert J. Zepfel
Haddan & Zepfel LLP
500 Newport Center Drive, Suite 580
Newport Beach, CA 92660
(949) 706-6000
Fax: (949) 706-6060
Approximate date of commencement of proposed sale to the public: as soon as
practicable after this Registration Statement becomes effective.
If any of the securities being registered on this Form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act, check
the following box: [X]
If this Form is filed to register additional securities for an offering pursuant
to Rule 462 (b) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective
registration statement for the same offering. [ ]
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under
the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under
the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
If delivery of the prospectus is expected to be made pursuant to Rule 434, check
the following box: [ ]
CALCULATION OF REGISTRATION FEE
Title of Each Amount to Be Proposed Maximum Proposed Maximum Amount of
Class of Registered Offering Price Aggregate Registration
Securities to Per Share (1) Offering Price Fee
Be Registered (1)
--------------------------------------------------------------------------------
Common Stock 49,428,637 $ 0.53 $26,197,178 $ 3,083.41
(1) Estimated solely for purposes of calculating the registration fee in
accordance with Rule 457(c) under the Securities Act of 1933, as amended
(the "Act"), based on the closing price for the Registrant's common stock
as reported on the Nasdaq OTC Bulletin Board on January 27, 2005.
The Registrant hereby amends this Registration Statement on such date or dates
as may be necessary to delay its effective date until the Registrant shall file
a further amendment which specifically states that this registration statement
shall thereafter become effective in accordance with Section 8(a) of the
Securities Act of 1933 or until this Registration Statement shall become
effective on such date as the Securities and Exchange Commission, acting
pursuant to said Section 8(a), may determine.
The information in this preliminary prospectus is not complete and may be
changed. We may not sell these securities until the registration statement filed
with the Securities and Exchange Commission is effective. This prospectus is not
an offer to sell these securities, and it is not soliciting offers to buy these
securities in any state where the offer or sale is not permitted.
Subject to completion, dated January 31, 2005
PROSPECTUS
49,428,637 SHARES
VISIJET, INC.
COMMON STOCK
This prospectus relates to the resale by certain selling stockholders of up
to 6,535,258 outstanding shares of Common Stock of VisiJet, Inc., 19,050,523
shares of common stock underlying warrants and 23,842,856 shares underlying
convertible debentures. The selling stockholders may sell the shares at fixed
prices, prevailing market prices at the time of sale, varying prices determined
at the time of sale or at negotiated prices. We will not receive any proceeds
form the resale of shares of common stock by the selling stockholders. We may
receive proceeds from the exercise of warrants held by the selling stockholders,
if and to the extent they are exercised.
Our Common Stock trades on the over-the-counter bulletin board under the
symbol "VJET.OB." The last reported sales price for our common stock on January
27, 2005 was $0.53 per share.
Investment in the shares offered by this prospectus involves a high degree
of risk. You may lose your entire investment. Consider carefully the "risk
factors" beginning on page 4 of this prospectus, before investing.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS
PROSPECTUS IS ACCURATE OR COMPLETE. IT IS ILLEGAL FOR ANYONE TO TELL YOU
OTHERWISE.
The date of this prospectus is,2005.
1
The information in this prospectus is not complete and may be changed
without notice. The selling stockholders may not sell these securities until the
registration statement filed with the Securities and Exchange Commission is
effective. This prospectus is not an offer to sell these securities, and the
selling stockholders are not soliciting offers to buy these securities, in any
state where the offer or sale of these securities is not permitted.
You should rely only on the information contained in this prospectus. We
have not, and the selling stockholders have not, authorized anyone to provide
you with different information. If anyone provides you with different
information, you should not rely on it. The selling stockholders are not making
an offer to sell these securities in any jurisdiction where the offer or sale is
not permitted. You should assume that the information contained in this
prospectus is accurate only as of the date on the front cover of this
prospectus. Our business, financial condition, results of operations and
prospects may have changed since that date.
Table of Contents
Page
----
Prospectus Summary 3
Summary Historical Financial Information 6
Risk Factors 6
Use of Proceeds 11
Nature of Trading Market 11
Dividend Policy 12
Capitalization 12
Management's Discussion and Analysis of Financial Condition
and Results of Operations 12
Plan of Operations 17
Business 19
Legal Proceedings 27
Management 27
Executive Compensation 30
Security Ownership of Certain Beneficial Owners and Management 32
Certain Relationships and Related Transactions 33
Description of Securities 35
Shares Eligible for Resale 36
Selling Stockholders 37
Plan of Distribution 41
Legal Matters 42
Experts 42
Where You Can Find Additional Information 43
Financial Statements 44
2
PROSPECTUS SUMMARY
This following is a summary of the information in this Prospectus. You
should read the entire prospectus carefully, including the more detailed
information regarding our company, the risks of purchasing our common stock
discussed under "risk factors," and our financial statements and the
accompanying notes.
VISIJET, INC.
VisiJet, Inc. ("VisiJet" or "the Company") was incorporated in
California on February 2, 1996 as a wholly owned subsidiary of SurgiJet, Inc. In
May 1999, the Company was spun off from SurgiJet through a distribution of
common stock to its shareholders. In February 2003, the Company completed a
merger agreement with Ponte Nossa Acquisition Corp., a Delaware corporation
incorporated in 1997 ("PNAC"), and became a wholly owned subsidiary of PNAC.
Since this transaction resulted in the shareholders of VisiJet acquiring a
majority of the outstanding shares of PNAC, for financial reporting purposes the
business combination was accounted for as a recapitalization of PNAC (a reverse
acquisition with the Company as the accounting acquirer). Subsequently, PNAC
changed its name to VisiJet, Inc.
The Company is an early-stage medical device company focused on the
marketing and development of ophthalmic surgery products for use in the laser
eye surgery and cataract surgery markets. In May 2004, the Company entered into
an exclusive license agreement with Gebauer Medizintechnik GmbH, of Neuhausen
Germany ("Gebauer"), pursuant to which the Company acquired worldwide marketing,
sales and distribution rights for Gebauer's LASIK and Epi-Lasik products. The
Company began marketing these products in Europe and certain other foreign
countries in which the products have received regulatory approval for sale. In
September 2004 the Company began marketing the Epi-Lasik product in the United
States following receipt of clearance for marketing from the U.S. Food and Drug
Administration. In addition, the Company is conducting research and development
on additional ophthalmic surgery products based on applications of its
proprietary waterjet technology.
THE OFFERING
Shares Offered by Selling Up to 6,535,258 shares held, and up to an
Stockholders aggregate of 42,893,379 shares that may be
acquired by selling stockholders upon the
exercise of outstanding warrants and
conversion of outstanding debt.
Use of Proceeds We will not receive any proceeds from the
sale of shares of common stock being offered
by the selling stockholders. We will,
however, incur all costs associated with
this registration statement and prospectus.
We may receive proceeds from the exercise of
warrants and conversion of outstanding debt,
if and to the extent they are exercised or
converted.
Risk Factors An investment in our common stock involves a
high degree of risk and could result in a
loss of your entire investment.
Shares Outstanding 28,677,520
OTC Symbol VJET.OB
3
OFFICES
Our offices are located at 192 Technology, Suite Q, Irvine, California
92618. Our telephone number is (949)450-1660 and our website is:
WWW.VISIJET.COM. The information on our website is not part of this prospectus.
SUMMARY HISTORICAL FINANCIAL INFORMATION
The following summary historical financial information is derived from
the consolidated financial statements of the Company. The information should be
read in conjunction with the consolidated financial statements, related notes,
and other financial information included herein.
For the Fiscal Years Ended For the Nine Months
December 31, Ended September 30,
(Audited)
2003 2002 2004 2003
------------- ------------- ------------- -------------
Operating Data
Revenue $ -- $ -- $ 1,037,537 $ --
Net income (loss) $ (4,959,152) $ (1,226,676) $ (8,420,653) $ (2,886,090)
Net loss per share $ (0.27) $ (0.16) $ (0.32) $ (0.15)
Weighted average
shares outstanding 18,606,352 7,811,809 26,069,227 18,707,993
Balance Sheet Data:
Current assets $ 124,628 $ 960 $ 1,061,398 $ 224,571
Total assets $ 326,312 $ 48,403 $ 2,997,365 $ 323,456
Current liabilities $ 2,112,373 $ 2,687,967 $ 5,811,843 $ 1,772,120
Total liabilities $ 2,216,975 $ 2,792,134 $ 6,506,015 $ 1,897,376
Stockholders' equity
(deficiency) $ (1,890,663) $ (2,743,731) $ (3,508,650) $ (1,573,920)
RISK FACTORS
Following is a description of all material risk factors related to the
Company's business and an investment in the Company's common stock. Please
consider these risk factors together with the other information presented in
this prospectus, including the financial statements and the notes thereto,
before investing in our common stock. The trading price of our common stock
could decline due to any of the following risks, and you might lose all or part
of your investment.
WE ARE AN EARLY-STAGE BUSINESS WITH A LIMITED OPERATING HISTORY, AND AS A
RESULT, MAKING AN EVALUATION OF OUR BUSINESS PROSPECTS MAY BE DIFFICULT.
We are an early-stage company with limited prior business operations
and operating revenues. You should be aware of the increased risks,
uncertainties, difficulties and expenses we face, and that because of our
limited operating history, you may not have adequate information on which you
can base an evaluation of our business and prospects.
4
OUR FINANCIAL STATEMENTS INCLUDE A GOING CONCERN OPINION FROM OUR OUTSIDE
AUDITORS WHICH RAISES DOUBT AS TO OUR ABILITY TO STAY IN BUSINESS AND MAY LIMIT
OUR ABILITY TO RAISE REQUIRED FUNDING.
The Company received a going concern opinion on its financial
statements for the fiscal years ended December 31, 2003 and 2002. Our auditors
have stated that due to our lack of profitability and our negative working
capital, there is "substantial doubt" about our ability to continue as a going
concern. The going concern opinion from our auditors represents a strong warning
regarding our financial condition and ability to stay in business. In addition,
the going concern opinion may limit our ability to obtain the financing required
to stay in business, in which case you could lose your entire investment.
WE HAVE GENERATED LIMITED REVENUES AND IF WE ARE UNABLE TO GENERATE SUFFICIENT
REVENUES IN THE FUTURE, WE MAY NOT BE ABLE TO CONTINUE OUR BUSINESS.
We are an early-stage company, and prior to May 2004, had not generated
any revenues from operations. We cannot assure our stockholders that our
proposed business plans, as described in this prospectus, will materialize or
prove successful, or that revenues generated through the sale of recently
licensed products, or other potential products currently under development will
be sufficient to result in profitable operations. If we cannot operate
profitably our business may fail and you could lose your entire investment.
OUR NEAR TERM PROSPECTS ARE HIGHLY DEPENDENT ON THE SUCCESSFUL MARKET
INTRODUCTION OF PRODUCTS WE HAVE RECENTLY LICENSED THROUGH A MARKETING,
MANUFACTURING AND DISTRIBUTION AGREEMENT. IF WE ARE UNABLE TO SUCCESSFULLY
INTRODUCE AND MARKET THESE PRODUCTS, WE MAY NOT BE ABLE TO ACHIEVE PROFITABLE
OPERATIONS OUR BUSINESS MAY FAIL.
We have recently acquired certain product lines through a licensing
agreement. We began selling these products in certain foreign markets during the
second quarter of 2004, and in the United States in the third quarter of 2004.
As an investor, you should be aware of the potential difficulties encountered by
an enterprise in the introduction of new products, many of which are beyond our
control, including unanticipated delays in the regulatory approval process and
market introduction, uncertainty with respect to customer acceptance and
potential competition, and potential manufacturing and/or distribution problems.
Our efforts to launch these products may not be successful and, even if
successful, such efforts might not result in profitable operations. If we are
unable to successfully market these products, we will be unable achieve
profitable operations. If we cannot operate profitably our business may fail and
you could lose your entire investment.
WE ARE DEPENDENT ON A THIRD PARTY FOR THE MANUFACTURING AND SUPPLY OF ALL
PRODUCTS CURRENTLY BEING SOLD BY THE COMPANY. IF WE ARE UNABLE TO OBTAIN
PRODUCTS ON A TIMELY BASIS, WE MAY NOT BE ABLE TO ACHIEVE OR MAINTAIN PROFITABLE
OPERATIONS AND OUR BUSINESS MAY FAIL.
All products currently being sold by the Company are manufactured by
the licensor of the products. Any interruptions, delays or other problems
encountered by the licensor in the manufacturing of these products could result
in its inability to supply quantities ordered by the Company on a timely basis,
or at all. If we are unable to obtain products from the manufacturer on a timely
basis, we will be unable to fulfill sales orders as planned and we will not be
able to generate sufficient revenues to achieve or maintain profitable
operations. If we cannot operate profitably you could lose your entire
investment.
GOVERNMENT CLEARANCE IS REQUIRED IN ORDER FOR US TO MARKET OUR PRODUCTS. IF WE
ARE UNABLE TO OBTAIN REQUIRED CLEARANCE ON A TIMELY BASIS, WE MAY NOT BE ABLE TO
GENERATE SUFFICIENT REVENUE TO ACHIEVE OR MAINTAIN PROFITABLE OPERATIONS AND OUR
BUSINESS MAY FAIL.
Our products are considered to be medical devices and as such require
clearance from the United States Food and Drug Administration ("FDA") for sales
in the United States and from comparable regulatory agencies in other markets.
The products currently offered for sale recently obtained have the required
regulatory clearance for sale in Europe and certain other foreign countries, and
certain of the products received clearance for sale in the United States in
5
September 2004. Other licensed products, and products, and certain under
development by the Company, will require FDA or appropriate non-U.S. regulatory
agency clearance prior to initiation of sales. Our ability to obtain timely
regulatory clearance for sales of products under development is dependent on our
ability to obtain adequate financing, on the successful completion of remaining
product development and testing, and on the satisfactory review and approval by
regulatory agencies of required marketing clearance submissions. If these
approvals are not obtained, or are significantly delayed, we may be unable to
generate revenues from product sales necessary for us to achieve or maintain
profitable operations. If we cannot operate profitably our business may fail.
WE HAVE LIMITED FINANCIAL RESOURCES AND ARE DEPENDENT ON RAISING ADDITIONAL
CAPITAL IN ORDER TO SUCCESSFULLY LAUNCH OUR PRODUCTS AND TO BEGIN GENERATING
REVENUES FROM PRODUCT SALES. IF WE ARE UNABLE TO RAISE SUFFICIENT CAPITAL, OUR
BUSINESS MAY FAIL.
Because we have limited financial resources and historical operating
revenues, we need to secure additional funding in order to successfully launch
our products, and to fund operating losses until such time as we can generate
enough revenue to sustain our business. If we are unable to obtain adequate
additional funding, we may not be able to generate sufficient revenues to
achieve profitability. If we cannot operate profitably our business may fail.
CONVERSION OF CONVERTIBLE SECURITIES WILL RESULT IN SIGNIFICANT DILUTION TO OUR
SHAREHOLDERS AND MAY RESULT IN A DECREASE IN THE MARKET PRICE OF OUR COMMON
STOCK.
A significant amount of our debt and equity securities is convertible
into common stock at conversion prices that are either below the current market
price, or that will be determined based on a discount to the market price of the
common stock at the time of conversion. Conversion of such securities into
common stock will result in significant dilution to our shareholders which may
result in a decrease in the market price of our stock.
RAISING ADDITIONAL CAPITAL MAY CAUSE SIGNIFICANT DILUTION TO OUR STOCKHOLDERS
AND MAY RESULT IN INCREASED LOSSES OR REDUCED EARNINGS, WHICH MAY RESULT IN A
DECREASE IN THE MARKET PRICE OF OUR COMMON STOCK.
To secure additional financing, we may have to sell additional stock or
borrow money. Selling additional stock, either privately or publicly, will
dilute the equity interests of our stockholders. If we borrow more money, we
will incur interest expenses which will negatively impact our operating results,
and may also be subject to restrictions in the debt agreement that limit our
operating flexibility. Dilution of existing stockholders and additional interest
expense may result in a lower stock price.
WE HAVE A HISTORY OF LOSSES AND A LARGE ACCUMULATED DEFICIT.
For the fiscal years ended December 31, 2003 and 2002 and for the nine
months ended September 30, 2004, we incurred net losses of $4,959,152,
$1,226,676 and $8,420,653, respectively, and as of September 30, 2004 our
accumulated deficit was $19,196,873. We expect to continue to incur significant
operating, marketing and research and development expenses to support
anticipated operations. We cannot be certain whether we will ever earn a
significant amount of revenues to achieve and maintain profitability. If we
cannot operate profitably our business could fail.
IF OUR RESEARCH AND DEVELOPMENT EFFORTS DO NOT RESULT IN PRODUCTS THAT RECEIVE
CLEARANCE FOR SALE OR THAT ARE SUCCESSFUL IN THE MARKETPLACE, WE MAY NOT BE ABLE
TO GENERATE SUFFICIENT REVENUE TO ACHIEVE OR MAINTAIN PROFITABLE OPERATIONS.
Our waterjet based technologies are in the development stage and
further development and testing is required before they can be submitted for
marketing clearance from the FDA and appropriate foreign regulatory agencies.
Furthermore, even if required marketing clearance is received, our products may
not be successful in the marketplace and may not be able to generate sufficient
revenues to achieve or maintain profitability.
WE ARE DOING BUSINESS IN AN INDUSTRY THAT IS VERY COMPETITIVE. IF WE ARE UNABLE
TO COMPETE SUCCESSFULLY, WE MAY NOT BE ABLE TO GENERATE SUFFICIENT REVENUE TO
ACHIEVE OR MAINTAIN PROFITABLE OPERATIONS AND OUR BUSINESS MAY FAIL.
6
The ophthalmic surgical device industry is very competitive. Our future
success depends on our ability to compete effectively with other manufacturers
and marketers of ophthalmic surgical devices. We may have difficulty competing
with larger, established surgical device companies that have:
* substantially greater financial, technical and marketing
resources;
* larger customer bases;
* better name recognition;
* related product offerings; and
* larger marketing areas.
Companies such as Bausch & Lomb, Advanced Medical Optics, Intralase,
VISX, Alcon, LaserSight, and Nidek are major international providers of
ophthalmic surgical devices relating to LASIK and cataract surgery. These
companies represent a wide array of devices and products, technologies and
approaches. Most of these companies have more resources than we do and,
therefore, a greater opportunity to develop comparable products and bring those
products to market more efficiently than we. If we are not able to compete
effectively with current and future competitors, we will not be able to generate
sufficient revenue to achieve or maintain profitability.
OUR PRODUCTS MAY NOT ACHIEVE ACCEPTANCE IN THE MARKETPLACE OR MAY BECOME
OBSOLETE BASED ON NEW TECHNOLOGY OR CHANGES IN THE MARKETPLACE. IF OUR PRODUCTS
DO NOT ACHIEVE OR MAINTAIN ACCEPTANCE, WE MAY NOT BE ABLE TO GENERATE SUFFICIENT
REVENUE TO ACHIEVE OR MAINTAIN PROFITABLE OPERATIONS AND OUR BUSINESS MAY FAIL.
The demand for our products will be based upon the existence of markets
for the technology and products and the markets for products of others, which
may utilize our technology. The extent to which we may gain a share of our
intended markets will depend, in part, upon the cost effectiveness and
performance of our technology and products when compared to alternative
technologies, which may be conventional or heretofore unknown. If the technology
or products of other companies provide more cost-effective alternatives or
otherwise outperform our technology or products, the demand for our technology
or products may not be strong enough to generate sufficient revenue to achieve
or maintain profitability. If we cannot operate profitably our business may fail
and you could lose your entire investment.
OUR DEVELOPMENT EFFORTS WITH RESPECT TO WATERJET BASED PRODUCTS ARE HIGHLY
DEPENDENT ON OUR PROPRIETARY INTELLECTUAL PROPERTY RIGHTS. FAILURE TO PROTECT
OUR RIGHTS COULD SIGNIFICANTLY IMPAIR OUR BUSINESS AND ENFORCING OUR RIGHTS MAY
CAUSE US TO INCUR SUBSTANTIAL EXPENSE.
Proprietary rights are critically important to us. We currently have
exclusive licenses to thirteen U.S. patents and three foreign patents for our
waterjet technology and we intend to aggressively pursue additional patent
protection for our technologies as we continue to develop them. Although we will
seek to defend our licenses and to protect our other proprietary rights, our
actions may be inadequate to protect our patents and other proprietary rights
from infringement by others, or to prevent others from claiming infringement of
their patents and other proprietary rights.
Policing unauthorized use of our technology is difficult, and some
foreign laws do not provide the same level of protection as U.S. laws.
Litigation may be necessary in the future to enforce our intellectual property
rights, to protect our trade secrets or patents that we may obtain, or to
determine the validity and scope of the proprietary rights of others. Such
litigation could result in substantial costs and diversion of resources, and may
result in decreased earnings and a decline of our stock price.
THE REGISTRATION OF PREVIOUSLY RESTRICTED SHARES AND SHARES UNDERLYING WARRANTS,
CONVERTIBLE DEBENTURES AND CONVERTIBLE PREFERRED STOCK MAY CAUSE OUR STOCK PRICE
TO DECLINE
The resale by the selling stockholders of their previously restricted
shares, including any shares issuable upon the exercise of convertible
securities, will increase the number of our publicly traded shares, which could
depress the market price of our common stock. The issuance of shares upon the
exercise of convertible securities will dilute the percentage of our shares held
by existing stockholders and could also cause our stock price to decline.
7
OUR COMMON STOCK HAS EXPERIENCED IN THE PAST, AND IS EXPECTED TO EXPERIENCE IN
THE FUTURE, SIGNIFICANT PRICE AND VOLUME VOLATILITY, WHICH SUBSTANTIALLY
INCREASES THE RISK THAT YOU MAY NOT BE ABLE TO SELL YOUR SHARES AT OR ABOVE THE
PRICE THAT YOU PAY FOR THE SHARES.
Because of the limited trading market for our common stock, and because
of the possible price volatility, you may not be able to sell your shares of
common stock when you desire to do so. During 2003, and through the date of this
prospectus, our common stock was sold and purchased at prices that ranged from a
high of $2.41 to a low of $0.39 per share. The inability to sell your shares in
a rapidly declining market may substantially increase your risk of loss because
of such illiquidity and because the price for our common stock may suffer
greater declines because of its price volatility.
The price of our stock that will prevail in the market after this
offering may be higher or lower than the price you pay. Certain factors, some of
which are beyond our control, that may cause our share price to fluctuate
significantly include, but are not limited to, the following:
* results of our initial product introduction and sales efforts;
* our ability to obtain timely clearance for marketing in the United
States from the U.S. FDA
* variations in our quarterly operating results;
* our ability to complete the research and development of our
technologies;
* the development of a market for our products;
* changes in market valuations of similar companies;
* announcement by us or our competitors of significant contracts,
acquisitions, strategic partnerships, joint ventures or capital
commitments;
* loss of a major customer or failure to complete significant
transactions;
* additions or departures of key personnel; and
* fluctuations in stock market price and volume.
Additionally, in recent years the stock market in general, and the
Over-the-Counter Bulletin Board and technology stocks in particular, have
experienced extreme price and volume fluctuations. In some cases, these
fluctuations are unrelated or disproportionate to the operating performance of
the underlying company. These market and industry factors may cause a material
decline in our stock price regardless of the progress we make with respect to
our product development and marketing efforts and our operating performance.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus contains forward-looking statements that involve risks
and uncertainties. These include statements about our expectations, plans,
objectives, assumptions or future events. In some cases, you can identify
forward-looking statements by terminology such as "anticipate," "estimate,"
"plans," "potential," "projects," "continuing," "ongoing," "expects,"
"management believes," "we believe," "we intend" and similar expressions. These
statements involve estimates, assumptions and uncertainties that could cause
actual results to differ materially from those expressed for the reasons
described in this prospectus. You should not place undue reliance on these
forward-looking statements.
You should be aware that our actual results could differ materially
from those contained in the forward-looking statements due to a number of
factors such as:
* continued development of our technology;
* dependence on key personnel;
* competitive factors;
* the operation of our business; and
* general economic conditions.
8
The forward-looking statements speak only as of the date on which they
are made, and, except to the extent required by federal securities laws, we
undertake no obligation to update any forward-looking statement to reflect
events or circumstances after the date on which the statement is made or to
reflect the occurrence of unanticipated events. In addition, we cannot assess
the impact of each factor on our actual results to differ materially from those
contained in any forward-looking statements.
USE OF PROCEEDS
We will not receive any proceeds from the sale of shares of common
stock being offered by the selling stockholders. We will, however, incur all
costs associated with this registration statement and prospectus. We may receive
proceeds from the exercise of warrants and conversion of outstanding debt, if
and to the extent they are exercised or converted.
NATURE OF TRADING MARKET
Our stock is quoted on the OTC Bulletin Board under the symbol
"VJET.OB." Until February 2003 the public entity was an inactive, "shell"
company, and so prices before that date may not be indicative of value. The
following table sets forth, for the fiscal quarters indicated, the high and low
closing prices for shares of our Common Stock for the periods noted, as reported
by the National Daily Quotation Service and the Over-the-Counter Bulletin Board.
Quarter Ended High Low
------------- ---- ---
2002:
First Quarter $ .85 $ .85
Second Quarter $ 1.78 $ .86
Third Quarter $ 1.45 $ .77
Fourth Quarter $ 1.45 $ 1.12
2003:
First Quarter $ 2.41 $ 1.22
Second Quarter $ 1.71 $ .94
Third Quarter $ 1.60 $ 1.05
Fourth Quarter $ 1.65 $ 1.10
2004:
First Quarter $ 1.39 $ 0.99
Second Quarter $ 1.10 $ 0.57
Third Quarter $ 0.84 $ 0.49
Fourth Quarter $ 0.57 $ 0.39
On December 31, 2004, the closing price as reported by the OTC
Bulletin Board was $0.39. As of December 31, 2004, there were 28,677,520 shares
of common stock outstanding, held by 224 record holders and approximately 1,500
beneficial holders.
DIVIDEND POLICY
We have never paid cash dividends and have no plans to do so in the
foreseeable future. Our future dividend policy will be determined by our Board
of Directors and will depend upon a number of factors, including our financial
condition and performance, our cash needs and expansion plans, income tax
consequences, and the restrictions that applicable laws and our credit
arrangements then impose.
CAPITALIZATION
The following table sets forth our capitalization as of September 30,
2004. You should read this information in conjunction with our financial
statements and the accompanying notes, and the other financial information
appearing elsewhere in this prospectus.
Long-term debt $ 694,172
=============
9
Stockholders' deficit:
Common stock, $.001 par value
Authorized, 50,000,000 shares
Issued and outstanding,
27,879,663 shares $ 27,880
Additional paid-in capital 15,660,343
Accumulated deficit (19,196,873)
-------------
Total Stockholders' Deficit ($ 3,508,650)
=============
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
The following is management's discussion and analysis of certain
significant factors which have affected the Company's financial position and
operating results during the periods included in the accompanying financial
statements, and should be read in conjunction with such financial statements and
notes thereto.
Certain information included herein contains forward-looking statements
that involve risks and uncertainties within the meaning of Sections 27A of the
Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934.
These sections provide that the safe harbor for forward looking statements does
not apply to statements made in initial public offerings. The words, such as
"may," "would," "could," "anticipate," "estimate," "plans," "potential,"
"projects," "continuing," "ongoing," "expects," "believe," "intend" and similar
expressions and variations thereof are intended to identify forward-looking
statements. These statements appear in a number of places in this Form SB-2 and
include all statements that are not statements of historical fact regarding
intent, belief or current expectations of the Company, our directors or our
officers, with respect to, among other things: (i) our liquidity and capital
resources; (ii) our financing opportunities and plans; (iii) our continued
development of our technology; (iv) market and other trends affecting our future
financial condition; (v) our growth and operating strategy.
Investors and prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance and involve
risks and uncertainties, and that actual results may differ materially from
those projected in the forward-looking statements as a result of various
factors. The factors that might cause such differences include, among others,
the following: (i) we have incurred significant losses since our inception; (ii)
any material inability to successfully develop our products; (iii) any adverse
effect or limitations caused by government regulations; (iv) any adverse effect
on our ability to obtain acceptable financing; (v) competitive factors; and (vi)
other risks including those identified in our other filings with the Securities
and Exchange Commission.
CORPORATE HISTORY
VisiJet (the "Company" or "VisiJet"), formerly known as Ponte Nossa
Acquisition Corp ("PNAC")), is a Delaware corporation engaged in the marketing
and development of surgical equipment for use in the field of ophthalmology.
The Company was incorporated in California on February 2, 1996 as a
wholly owned subsidiary of SurgiJet, Inc ("SurgiJet"), a developer of waterjet
technology for a variety of medical and dental applications. In May 1999, the
Company was spun off from SurgiJet through a distribution of common stock to its
shareholders, after which SurgiJet had no remaining ownership interest in the
Company.
On February 11, 2003 the Company completed a merger with PNAC, a
Delaware corporation incorporated in 1997. Pursuant to the merger agreement
between VisiJet and PNAC (the "Merger Agreement"), the Company merged into PNAC.
Since this transaction resulted in the shareholders of VisiJet acquiring a
majority of the outstanding shares of PNAC, for financial reporting purposes the
business combination was accounted for as a recapitalization of PNAC (a reverse
acquisition with the Company as the accounting acquirer). Subsequently, PNAC
changed its name to VisiJet, Inc.
10
CRITICAL ACCOUNTING POLICIES
The Company's critical accounting policies, including the assumptions
and judgments underlying them, are disclosed in the Notes to the Financial
Statements. At this stage of our development, these policies primarily address
matters of revenue and expense recognition. The Company has consistently applied
these policies in all material respects.
OVERVIEW
VisiJet, Inc. (the "Company" or "VisiJet") is a medical device company
based in Irvine, California focused on the development and marketing of
innovative ophthalmic products used in vision correction ("refractive") surgery
and cataract removal surgery. In May 2004, the Company initiated sales of the
LasiTome and EpiLift systems both of which were obtained pursuant to a license
agreement with Gebauer Medizintechnik GmbH. Both systems may be used in the
LASIK vision correction surgical procedure to expose the cornea prior to
application of the excimer laser for reshaping of the cornea. The LasiTome is a
mechanical device used for cutting a corneal flap, the methodology used in
traditional LASIK procedures. The EpiLift system provides the LASIK surgeon with
an alternative methodology for exposing the cornea in which the epithelium, or
top layer of the eye, is separated in an intact sheet of tissue, and then
returned to its original position for healing following the application of the
laser.
Initial sales of the EpiLift and LasiTome systems were in Europe and
certain other foreign countries in which the products had received required
regulatory clearance for marketing. Marketing of the EpiLift System in the
United States began in September 2004 following receipt of 510(K) clearance for
marketing from the United States Food and Drug Administration ("FDA"). Revenues
from both the EpiLift and LasiTome Systems are generated through both the
initial sale of the respective devices and accessories and through recurring
sales of disposable separators or blades.
The Company also has two ophthalmic surgery products under development
utilizing proprietary waterjet technology. The first is Pulsatome, a device
designed for removal of cataracts using a pulsating stream of saline solution.
The second is Hydrokeratome, a device that uses a high-pressure micro beam of
water to cut a corneal flap during LASIK surgery. Both of these products require
the successful completion of development and testing and receipt of 510(K)
clearance from FDA prior to market introduction.
The primary markets addressed by our products are refractive surgery
and cataract surgery, both of which are strong and continuing to grow. The
refractive surgery market has benefited from an increased demand for laser
vision corrective surgery due to the overall increased acceptance by consumers,
as well as from technological advances that have led to better results and fewer
complications. Cataract surgery is the most frequently performed surgical
procedure, with over 14 million surgeries performed worldwide. As the
development of cataracts is often associated with aging, we expect the demand
for cataract surgery to continue to increase. We believe that our products
address important needs in each of these markets, and that as such, we have an
opportunity to achieve significant revenue growth.
There are numerous factors that could affect our ability to achieve
this revenue growth, including but not limited to:
o Our obtaining adequate financing to support debt obligations
and working capital requirements
o Successful completion of our product development efforts and
receipt of 510(k) marketing clearance with respect to
Pulsatome and Hydrokeratome.
o Market acceptance of our products
o Competition
o Technological advancement
o Overall economic conditions
RESULTS OF OPERATIONS
Nine Months Ended September 30, 2004 Compared To Nine Months Ended September 30,
2003
11
SALES AND COST OF SALES
International sales totaled $1,037,537 and represent revenues
recognized based on sales during the second and third quarter of 2004 of
ophthalmic surgery products acquired through a licensing agreement completed in
May 2004. Cost of sales during the same period totaling $483,234 represents
related product costs associated with these revenues. No sales were recorded
during the nine months ended September 30 2004 in the United States as marketing
approval for the licensed products in the U.S. was not obtained until the middle
of September 2004. Prior to the completion of the product licensing agreement,
the Company did not have any products for sale, and accordingly had no similar
sales revenues or cost of sales activity in the comparable 2003 period.
OPERATING EXPENSES
Operating expenses during the nine months ended September 30, 2004
increased to $7,006,940 from $2,931,790 in 2003 as a result of the following
activity:
2004 2003
------------ ----------
General and Administrative $ 6,415,545 $ 2,054,912
Research and Development 591,395 876,878
------------ ------------
Total Operating Expenses $ 7,006,939 $ 2,931,790
The increase in general and administrative expenses in the 2004 period
is due primarily to the inclusion of $2.9 million of non-cash expenses recorded
in connection with the issuance of common stock, warrants and options during the
period as payment for consulting services and in connection with
dispute/litigation settlements, and non-cash expenses of $546,403 recorded in
connection with the re-pricing of warrants during the second quarter. In
addition, general and administrative expenses during 2004 increased due to
increases in professional fees and consulting, salaries and wages, amortization
expenses related to patents and distribution agreements and sales and marketing
expenses.
The decrease in research and development expenses in the nine months
ended September 30, 2004 period is due primarily to due to limited working
capital availability during the period, and to a reallocation of resources from
research and development to sales and marketing as a result of the initiation of
product sales during the second quarter of 2004.
OTHER INCOME AND EXPENSE
Other expenses during the nine months ended September 30, 2004
increased to $1,967,216 and includes interest expense of $242,275 and non-cash
expenses of $903,802 related to the amortization of debt discount during the
period and $821,139 of non-cash interest expense recorded based on the intrinsic
value of the beneficial conversion feature of convertible debt entered into
during the second and third quarters of 2004. Interest expense in 2004 period
increased from $45,058 in the first nine months of 2003 due to an increase in
total debt outstanding during 2004, and there was no comparable debt discount
amortization expense in the 2003 period.
NET LOSS
As a result of the above revenues and expenses, the net loss for the
nine months ended September 30, 2004 increased to $8,420,653 compared to
$2,886,090 during the comparable 2003 period.
Subject to the availability of cash and working capital, we expect
sales revenue, and related cost of sales to increase significantly during 2005.
In addition, expenses related to sales and marketing and research and
development activities are expected to increase 2005 as we continue to ramp up
our sales and marketing activities related to recently licensed products, and as
we move toward completion of product development and regulatory compliance
efforts and the ultimate product introduction with respect to the Company's
other products under development.
FISCAL YEAR 2003 COMPARED TO FISCAL YEAR 2002
The Company had no sales revenues to report for the years ending
December 31, 2003 and 2002. The net loss for fiscal year 2003 was $4,959,152,
compared to $1,226,676 for fiscal year 2002. This represents a loss per common
share of $(.27) for the year ended December 31, 2003 on basic and diluted shares
outstanding of 18,606,352, as compared to a loss per common share of $(.16) on
basic and diluted shares outstanding of 7,811,809 for the year ended December
31, 2002.
The significantly larger loss in 2003 resulted from increased operating
expenses, as shown below:
2003 2002
Operating Expenses
General and Administrative $3,736,604 $ 751,717
Research and Development 1,256,259 294,736
----------- -----------
$4,992,863 $1,046,453
General and administrative expenses increased to $3,736,604 in 2003
from $751,717 in 2002. Included in the 2003 general and administrative expenses
are non-recurring expenses of approximately $788,500 that were incurred in
connection with the finalization of the Merger Agreement in February 2003. Also
contributing to the increased general and administrative expenses in 2003 were
increases in salaries and wages due to staff additions, increased legal and
accounting fees associated with becoming a public company, increased rent
expense incurred in connection with additional space requirements, increased
royalty expenses related to licensed technology, and increased corporate travel.
Research and development expenses increased to $1,256,259 in 2003 from
$294,736 in 2002. The increase is primarily due to the resumption of activities
related to the development of the Company's ophthalmic surgery products in 2003,
based on the completion of the Merger Agreement and associated financing, that
had been deferred during 2002 due to the lack of funding.
Also included in results of operations in 2003 was a non-recurring gain
of $90,303 recorded based on the restructuring of debt owed to SurgiJet that
occurred in connection with the Merger Agreement, and which resulted in a
decrease in the total amount owed of $90,303.
Interest expense decreased to $56,247 in 2003 from $131,319 in 2002.
The decrease is primarily due to the reduction in notes payable that occurred in
2003 as a result of the completion of the Merger Agreement.
LIQUIDITY AND CAPITAL RESOURCES
Prior to the second quarter of 2004, the Company did not have any
products for sale, and had not generated any revenue from sales or other
operating activities. As such, our principal source of liquidity has been the
private placement of equity securities and the issuance of notes payable and
convertible debt. Based on our history of losses and negative working capital
balance, our financial statements for the year ended December 31, 2003 included
a going concern opinion from our outside auditors, which stated there "is
substantial doubt" about our ability to continue operating as a going concern.
During the first nine months of 2004, the Company utilized $2,949,100
to fund operating activities and $1,204,511 in investing activities, and as of
September 30, 2004, current liabilities exceeded current assets by approximately
$4.75 million.
Financing Activity:
As shown in more detail below, the Company raised net proceeds totaling
$4,136,074 during the first nine months of 2004 through private placements of
debt and equity securities. Of this total, $2,471,125 came from the issuance of
convertible debentures, net of $328,875 of related costs, $1,109,688 came from
the issuance of secured subordinated debenture agreements, net of $140,312 of
related costs and $526,500 resulted from equity private placements, net of
related costs of $58,500. In addition, during this period, the Company received
net proceeds of $28,761 from working capital advances from shareholders and
employees.
PRIVATE EQUITY PLACEMENTS:
Between January 2004 and May 2004 the Company raised gross proceeds of
$585,000 through the private placement of 585,000 shares of common stock to
twelve (12) individual investors, and realized net proceeds of $526,500 after
subtracting related placement agent fees totaling $58,500. In addition to the
common stock, the investors received 5-year warrants to purchase an aggregate of
585,000 shares of common stock at an exercise price of $2.25 per share.
SECURED DEBENTURES:
In February 2004, the Company entered into secured debenture
agreements, as shown below, with an aggregate principal balance of $500,000, and
received net proceeds of $447,500 after subtracting related placement agent fees
and legal expenses totaling $52,500.
Debenture Holder Principal
---------------------------------------- ------------------
Steve and Kathleen Guarino $ 250,000
N.J. Olivieri 100,000
SBI USA, LLC 50,000
Phoenix Capital 50,000
Timothy Roberts 50,000
------------------
$ 500,000
The debentures bear interest at an annual rate of 24%, which is payable
monthly beginning April 1, 2004. In addition, the debenture holders received
warrants to purchase 250,000 shares of the Company's common stock, exercisable
through March 1, 2009, at an exercise price of $1.10 per share.
The principal balance of the debentures is due and payable on the
earlier of (i) thirty (30) days from the date the Registration Statement is
declared effective by the Securities and Exchange Commission, provided that a
specified affiliate of the investors has not defaulted in its obligation to
purchase shares of the Company's common stock, or (ii) twelve (12) months from
the date the Registration Statement is declared effective, or (iii) eighteen
(18) months from the date of the debenture agreement. The debentures are secured
by all accounts and equipment of the Company, now owned, existing or hereafter
acquired.
In October 2004, the Company received a notice of default from the
holders of an aggregate of $400,000 of these debentures due to the non-timely
payment of interest that was owed under the debenture agreements. Subsequent to
the receipt of notice, the Company made the required interest payments and the
Company is in discussions. In connection with discussions with the debenture
holders regarding a resolution of the events of default, in October 2004, the
Company agreed to reduce the exercise price of the original 250,000 warrants
issued in connection with these convertible debenture agreements to $0.75 per
share, and to issue a total of 125,000 additional warrants, also at an exercise
price of $0.75 per share. In January 2005, the Company repaid the entire
$500,000 outstanding principal balance and the secured debenture agreements
were cancelled.
In May 2004, the Company entered into a secured debenture agreement
with HIT Credit Union with a principal balance of $750,000, and received net
proceeds of $662,188 after subtracting related placement agent fees and expenses
totaling $80,000 and prepaid interest totaling $7,812. The principal balance of
the debenture was due and payable on July 5, 2004, and the debentures bear
interest at an annual rate of 15%, which is payable monthly beginning June 1,
2004. In addition, the debenture holder received a warrant to purchase 500,000
shares of the Company's common stock, exercisable through May 6, 2009, at an
exercise price of $0.90 per share. The debenture is secured by 750,000 shares of
the Company's common stock that were issued by the Company as collateral under
this agreement.
The Company did not repay the principal on the scheduled maturity date
of July 5, 2004, and such failure to pay constitutes a default under the
obligation. In October 2004 the debenture holder entered into a forbearance
agreement with the holders of convertible debentures entered into in June and
July 2004 with an aggregate principal amount of $2,000,000, pursuant to which
the debenture holder agreed not to take any action with respect to the
non-payment of the $750,000 principal balance until the earlier of (i) February
2, 2005 and (ii) the date of notice of default from the convertible debenture
holders to the Company. In January 2005, the Company repaid the entire $750,000
outstanding principal balance, plus accrued interest totaling $6,744, the
750,000 shares of the Company's common stock held as collateral on the debt were
returned and the secured debenture agreement was cancelled.
CONVERTIBLE DEBENTURES:
In May 2004, the Company entered into convertible debenture agreements
with Platinum Long Term Growth and Rock II, LLC with principal balances of
$550,000 and $250,000, respectively. After subtracting related placement agent
fees and expenses totaling $105,000, net proceeds to the Company from the
aggregate of the $800,000 principal balance were $695,000. The debentures bear
interest at an annual rate of 10%, which is due and payable on the maturity
date. In addition, the debenture holders received an aggregate of 533,333
warrants to purchase shares of the Company's common stock, exercisable through
May 6, 2009 at an exercise price of $0.90 per share.
The principal balance of these debentures was due and payable on the
earlier of (i) one hundred and five (105) days from the issue date, or (ii) ten
(10) business days from the date the Company's Registration Statement is
declared effective by the Securities and Exchange Commission. As the
Registration Statement was not filed prior to 105 days from the issue date, the
principal balance and accrued interest became due and payable on August 19,
2004. The debentures were secured by an aggregate of 800,000 shares of the
Company's common stock borrowed by the Company pursuant to a security lending
agreement between the Company and a third party. Under certain circumstances,
the outstanding principal of the debentures may be converted into shares of the
Company's common stock based on an initial conversion price of $0.90, subject to
adjustment as defined in the agreement.
The Company was not in compliance with terms of these debenture
agreements due to the non-payment of the principal balance by the scheduled
maturity date in August 2004, and due to its failure to file a Registration
Statement with the Securities and Exchange Commission covering warrants issued
to debenture holders pursuant to the debenture agreement by June 6, 2004, as
required by the registration rights agreement entered into between the Company
and the debenture holders. The failure to pay the principal balance when due and
to file the Registration Statement on a timely basis were events of defaults
under the agreements. In connection with discussions with the debenture holders
regarding a resolution of the events of default, in October 2004, the Company
agreed to reduce the exercise price of the original 533,333 warrants issued from
$0.90 to $0.40 per share, and to issue a total of 533,333 additional warrants,
also at an exercise price of $0.40 per share. In January 2005, Rock II, LLC
agreed to exercise 250,000 warrants at a price of $0.40 for a total of $100,000.
The Company paid the note of $250,000 less the exercise price of $100,000 plus
interest of $8,000 for a total cash payment of $158,000 satisfying the
obligation to Rock II, LLC. The Company paid $550,000 to Platinum Long Term
Growth satisfying the principal balance due. Platinum Long Term Growth agreed to
exercise 81,000 warrants at a price of $0.40 or $32,400 to satisfy the interest
due.
In June 2004, the Company entered into convertible debenture agreements
with Bushido Capital Master Fund, L.P. ("Bushido"), and Bridges & Pipes, LLC
("Bridges & Pipes"), with principal balances of $600,000 and $400,000,
respectively. After subtracting related placement agent fees and expenses
totaling $120,000, net proceeds to the Company from the aggregate of the
$1,000,000 principal balance were $880,000.
Pursuant to the June 2004 agreements, the debentures bear interest at
an annual rate of 8%, which is payable quarterly beginning December 31, 2004,
and the principal balance of the debentures was due and payable on June 24,
2006. In addition, the debenture holders received an aggregate of 150,000 shares
of the company's common stock, and an aggregate of 750,000 warrants to purchase
shares of the Company's common stock, exercisable through June 24, 2009, at an
exercise price of $1.50 per share, provided however that the exercise price with
respect to an aggregate of 500,000 of the warrants is reduced to $0.60 per share
during the period from the date of issuance through the date twelve (12) months
after the Securities and Exchange Commission declares effective a registration
statement registering the resale of shares underlying the warrants. The
debentures were secured by an aggregate of 350,000 shares of the Company's
common stock issued by the Company, and the outstanding principal of the
debentures was convertible, subject to redemption rights of the Company, into
shares of the Company's common stock based on an initial conversion price of
$0.50, subject to adjustment as defined in the agreement.
In connection with these debentures, the Company entered into a
Registration Rights Agreement with the debenture holders related to the warrants
and shares underlying the conversion feature of the debentures that required the
Company to file a Registration Statement with the Securities and Exchange within
30 days of the closing of the transaction. Due to the Company's failure to file
the Registration Statement within 30 days, the Company was not in compliance
with this requirement of the agreement.
In October 2004 the Company received a waiver of the non-compliance in
connection with an amendment to the debenture agreements, pursuant to which the
maturity dates of the debentures were extended to June 24, 2014, the exercise
price of the original 750,000 warrants issued in connection with these
convertible debenture agreements was reduced to $0.40 per share, the debenture
holders received an additional 250,000 warrants at an exercise price of $0.40
per share, and the initial conversion price of the debt was reduced to $0.35. In
addition, in connection with this amendment, the Company released the 350,000
shares of common stock that was being held as collateral, to the note holders.
In January 2005 the amended debenture agreements with Bushido and
Bridges & Pipes were replaced with new convertible debenture agreements in order
to conform the terms of these agreements to the terms of new convertible
debenture agreements with an aggregate principal balance of $6,145,000 entered
into in January 2005, as described below. Under the replacement agreements, the
maturity dates of the debentures were extended to January 14, 2015, and other
principal terms (i.e. interest rate, conversion price, warrants issued and
warrant exercise price) remained the same as in the amended October agreements
described above.
In July 2004, the Company entered into a convertible debenture
agreement with Libertyview Special Opportunities Fund, L.P. ("Libertyview"),
with a principal balance of $1,000,000, and received net proceeds of $896,125
after subtracting related placement agent fees and expenses totaling $103,875.
Pursuant to the July 2004 agreement, the note bears interest, at an annual rate
of 8%, which is due and payable quarterly beginning on October 31, 2004, and the
principal balance of the note, plus any accrued and unpaid interest, was due and
payable on July 23, 2014, provided however, that on or after July 31, 2007 the
Company, at the option of the note holder, may have been obligated to repurchase
the note at a price equal to 100% of the outstanding principal and interest. In
addition, the debenture holders received warrants to purchase 750,000 shares of
the Company's common stock, exercisable through July 23, 2011, at an exercise
price of $1.00 per share. In addition, the outstanding principal of the
debentures was convertible into shares of the Company's common stock, at the
option of the note holder, based on an initial conversion price of $0.54 per
share, subject to adjustment as defined in the agreement.
In connection with these debentures, the Company entered into a
Registration Rights Agreement with the debenture holders related to the warrants
and shares underlying the conversion feature of the debentures that required the
Company to file a Registration Statement with the Securities and Exchange within
30 days of the closing of the transaction. Due to the Company's failure to file
the Registration Statement within 30 days, the Company was not in compliance
with this requirement of the agreement.
In October 2004 the Company received a waiver of the non-compliance in
connection with an amendment to the debenture agreement pursuant to which the
exercise price of the original 750,000 warrants issued in connection with the
convertible debenture agreement was reduced to $0.40 per share, the debenture
holder received an additional 250,000 warrants at an exercise price of $0.40 per
share and the initial conversion price of the debt was reduced to $0.35.
In January 2005 the amended debenture agreement with Libertyview was
replaced with a new convertible debenture agreement in order to conform the
terms of the agreement to the terms of new convertible debenture agreements
entered into in January 2005 with an aggregate principal balance of $4,845,000,
as described below. Under the replacement agreement, the maturity dates of the
debenture was extended to January 14, 2015, and other principal terms (i.e.
interest rate, conversion price, warrants issued and warrant exercise price)
remained the same as in the amended October agreement described above.
Contractual Obligations and Commitments:
The following summarizes our contractual obligations, commercial commitments and
off-balance sheet arrangements at September 30, 2004 and the effect such
obligations could have on our liquidity and cash flow in future periods:
Less Than 1 - 3 3 - 5 Over 5
1 Year Years Years Years Total
---------- ---------- ---------- ---------- ----------
Notes Payable(1) $ 887,660 $ -- $ -- $ -- $ 887,660
Compensation Settlement
Agreements 68,562 -- -- -- 68,562
Accounts Payable 1,096,197 -- -- -- 1,096,197
Accrued Expenses 1,217,962 -- -- -- 1,217,962
Secured Debt (2) 3,050,000 -- -- 1,000,000 4,050,000
Minimum Royalty
Obligations (3) 84,000 168,000 168,000 480,000 900,000
Lease Commitments 3,168 6,336 2,112 -- 11,616
---------- ---------- ---------- ---------- ----------
Total $6,407,549 $ 174,336 $ 170,112 $1,480,000 $8,231,997
========== ========== ========== ========== ==========
---------
(1) Includes an aggregate of $598,774 payable to SurgiJet pursuant to litigation
settlement agreement entered into in October 2004.
(2) Includes principal balance of secured and convertible debt agreements
entered into during first three quarters of 2004. of the total listed as Less
Than 1 year, $2,050,000 was repaid in full in January 2005, and in January 2005,
the maturity date with respect to the remaining $1,000,000 was amended to
January 2015. Amounts noted do not include repayment obligations related to an
aggregate of $850,000 of convertible debt agreements entered into in October
2004, originally due in October 2014 and amended in January 2005 to January
2015, $500,000 of convertible debt entered into in December 2004 that was repaid
in full in January 2005, or an aggregate of $4,485,000 of convertible debt
agreements entered into in January 2005 that are due in January 2015, as
described below.
(3) Term of obligations estimated based on estimated remaining patent life.
Our ability to satisfy the contractual obligations noted above, as well
as our ability to fund on going operating expenses, is dependent on our success
in raising additional capital and in generating working capital from product
sales.
Borrowed Shares:
In connection with collateral requirements of convertible debenture
agreements with Platinum Long Term Growth Fund and Rock II, LLC, the Company
borrowed a total of 800,000 shares of its outstanding common stock from Taika
Investments, Inc. ("Taika") pursuant to a Securities Lending Agreement between
the Company and Taika. In accordance with the terms of this agreement, the
Company is obligated to pay interest on the value of shares borrowed (assuming a
value of $1.00 per share) based on the LIBOR rate plus 50 basis points, and was
obligated to return any borrowed shares by November 30, 2004. In January, the
Company received a one-year extension, to November 30, 2005, of the date by
which any borrowed shares must be returned. In the event of default, the Company
has agreed to file a Registration Statement and to return any shares, within 72
hours, that had not previously been returned by the due date. As of September
30, 2004 the Company had borrowed a total of 800,000 shares pursuant to this
agreement, and the Company had accrued interest expense totaling $25,725.
FINANCING ARRANGEMENTS SUBSEQUENT TO SEPTEMBER 30, 2004
As shown in the following table, in October 2004, the Company entered
into convertible debenture agreements with four private lenders with an
aggregate principal balance of $850,000, and received net proceeds of $788,000
after subtracting related placement agent fees and expenses totaling $62,000.
The notes bear interest, at an annual rate of 8%, which is due and payable
quarterly beginning on December 31, 2004. The principal balance of the note,
plus any accrued and unpaid interest is due and payable on October 6, 2014,
provided however, that on or after October 6, 2007, the Company, at the option
of the note holder, may be obligated to repurchase the note at a price equal to
100% of the outstanding principal and interest. The outstanding principal of the
debentures may be converted into shares of the Company's common stock, at the
option of the note holder, based on an initial conversion price of $0.35 per
share, subject to adjustment as defined in the agreement. In addition, the note
holders received warrants to purchase 850,000 shares of the Company's common
stock, exercisable through October 6, 2009 at an exercise price of $0.40 per
share.
Debenture Holder Principal
------------------------------------------------- ------------------
LibertyView Special Opportunities Fund, LP $ 300,000
Gamma Opportunity Capital Partners, LP 300,000
Bridges & Pipes LLC 150,000
Little Gem Life Sciences Fund, LP 100,000
------------------
Total $ 850,000
In January 2005 the October debenture agreements with Libertyview
Special Opportunities Fund, L.P., Gamma Opportunity Capital Partners, LP,
Bridges & Pipes, LLC, and Little Gem Life Sciences Fund, LP, were replaced with
a new convertible debenture agreements in order to conform the terms of the
October agreements to the terms of new convertible debenture agreements entered
into in January 2005 with an aggregate principal balance of $4,845,000, as
described below. Under the replacement agreements, the maturity dates of the
debentures were extended to January 14, 2015, and other principal terms (i.e.
interest rate, conversion price, warrants issued and warrant exercise price)
remained the same as in the October agreements described above.
In December 2004 the Company entered into a debenture agreement with
Alpha Capital Aktiengesellschaft ("Alpha")with a principal balance of $500,000,
and received net proceeds of $469,000 after subtracting related placement agent
fees and expenses totaling $31,000. The debenture was due and payable on January
27, 2005, and was convertible into shares of the Company's common stock, at the
option of the note holder, based on an conversion price equal to 80% of the
closing bid price of the Company's common stock on the date of conversion, in
the event that the debenture was not repaid on the scheduled maturity date, or
in the event of a default under the agreement. In connection with the debenture,
Alpha received 142,857 shares of the Company's common stock, and 5-year warrants
to purchase 1,250,000 shares of the Company's common stock at an exercise price
of $0.40 per share. In January 2005, the Company repaid the entire $500,000
outstanding principal balance, and the debenture agreement was cancelled.
Also in December, the Company received $125,000 as a subscription from
Greenwhich Growth Fund, Ltd., for a convertible debenture agreement that was
included in the convertible debenture agreements closed in January 2005, as
described below.
As shown in the following table, in January 2005, the Company entered
into convertible debenture agreements with an aggregate principal balance of
$4,845,000, and received net proceeds of $4,569,500 , after subtracting related
placement agent fees and expenses totaling $275,500. The notes bear interest, at
an annual rate of 8%, which is due and payable quarterly beginning March 31,
2005. The principal balance of the note, plus any accrued and unpaid interest is
due and payable on January 14, 2015, provided however, that on or after January
14, 2008 the Company, at the option of the note holder, may be obligated to
repurchase the note at a price equal to 100% of the outstanding principal and
interest. The outstanding principal of the debentures may be converted into
shares of the Company's common stock, at the option of the note holder, based on
an initial conversion price of $0.35 per share, subject to adjustment as defined
in the agreement. In addition, the note holders received warrants to purchase
4,845,000 shares of the Company's common stock, exercisable through January 14,
2010 at an exercise price of $0.40 per share.
Debenture Holder Principal
--------------------------------------------------------- ------------------
Renaissance Capital Growth & Income Fund III, Inc. 1,000,000
Renaissance US Growth Investment Trust, PLC 1,000,000
Roaring Fork Capital SBIC, LP 650,000
Cosair Capital Partners, LP 635,000
BFS US Special Opportunities Trust, PLC 500,000
Republic Aggressive Growth 220,000
Alpha Capital Aktiengesellschaft 350,000
Greenwhich Growth Fund, Ltd. 125,000
Libertyview Special Opportunity Fund 150,000
Little Gem Life Sciences Fund, LP 100,000
Cosair Capital Partners, Ltd. 90,000
Cosair Capital Partners 100, LP 25,000
------------------
Total $ 4,845,000
PREFERRED STOCK
In October 2004 the Company issued 450,000 shares of Series A
Convertible Preferred Stock ("Series A Shares") to Langley Park Investments,
PLC, a United Kingdom corporation ("Langley"). The Company issued the Series A
Shares in exchange for 2,477,974 newly issued Ordinary Shares of Langley, with
an agreed initial value of (pound)1.00 (pound) per share. Consummation of the
transaction was subject to admission of the Langley shares to the London Stock
Exchange ("LSE"), which occurred on September 30, 2004 and the initiation of
trading on the LSE, which began on October 7, 2004. In accordance with the
agreement with Langley, the Company may sell the shares received by it in the
open market on the LSE at any time. On January 7, 2005, the Company sold 500,000
of the Langley shares at a share price of $0.271, or $135,532. The Company
received net proceeds of $134,796 after subtracting related fees of $735.61. As
a result the Company owns 1,977,974 shares of Langley at an approximate market
value $586,356 on January 27, 2005. The Company plans to monitor the market
value of the Langley shares, and may sell shares periodically to support its
working capital needs.
We expect operating expenses, and related cash requirements, to
increase during 2005 in connection with anticipated increased sales and
marketing and product development activities.
The Company is actively pursuing additional financing, and in this
regard is in discussions with several parties related to potential financing
arrangements. The Company believes that actions presently being taken to raise
additional financing, to market products with which near-term operating revenues
and to complete the development of, and bring to market its other ophthalmic
surgical products, will provide capital to satisfy contractual obligations and
to ultimately generate sufficient revenue to support its operations and become
profitable. However, there can be no assurance that any such actions will be
successfully completed, or that such actions will provide sufficient capital
and/or cash flow to permit the Company to stay in business realize its plans.
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE PLANS AND RESULTS
Planned activities discussed above with respect to anticipated
expenditures for sales and marketing, additions of property, plant and equipment
and employees are contingent on our obtaining sufficient funding, as well as on
the success of our final product development and commercialization efforts
related to our internally developed products.
In addition, see "Risk Factors."
PLAN OF OPERATIONS
GENERAL
In 2004 VisiJet began to transition from a research and development
organization to a product marketing and distribution company as a result of the
initiation of sales of our EpiLift and LasiTome product lines, for which we
acquired world-wide marketing and distribution rights through a licensing
agreement finalized in the second quarter of the year. During the next twelve
months our efforts will be aimed at completing this transition as we pursue our
goals of initiating product sales of one or both of our two products under
development, achieving continued revenue growth and achieving profitability.
FINANCING ACTIVITY
In January 2005 the Company entered into new convertible debenture
agreements with an aggregate principal balance of $4,845,000. The Company
expects proceeds from this financing, combined with cash flows anticipated to be
generated through product sales, to be sufficient to satisfy our immediate cash
requirements, and to provide adequate working capital for at least the next
twelve months. As described above under "Liquidity and Capital Resources," we
are currently in discussions with several parties related to additional
potential financing that may be finalized in connection with possible debt
restructuring or strategic product/technology acquisition opportunities.
SALES AND MARKETING ACTIVITY
In connection with the introduction of our EpiLift and LasiTome
products in 2004, the Company established a sales organization in the United
States consisting of four direct employees and eight independent sales
representatives, and a network of distributors providing us marketing and
distribution capabilities in most major industrialized countries. Sales and
marketing efforts during the next twelve months will be increased significantly
in connection with promotional activities related to EpiLift product line, and
the anticipated market introduction during 2005 of our Pulsatome and
Hydrokeratome products currently under development. Planned activities during
this period relating to EpiLift include the training and support of our direct
sales force and distributor network, our attendance and participation at 4-5
major ophthalmic industry trade shows, production of promotional and training
videos and production and placement of media advertising. Activities during this
period relating to our other products under development will be dependent on
progress achieved in the remaining required development, testing and regulatory
activities. Budgeted expenses for sales and marketing during the next twelve
months are approximately $3.8 million.
RESEARCH AND DEVELOPMENT ACTIVITY
Research and development activities during the next twelve months will
be focused on development, testing and regulatory activities required in order
to submit applications to the U.S. Food and Drug Administration for 510(k)
marketing clearance for the two ophthalmic surgery products currently under
development by the Company. These products, as described below, utilize
proprietary waterjet based technology, and are designed to result in faster,
safer and more efficacious surgery. Budgeted research and development
expenditures during the next twelve months are approximately $1.4 million.
1). Pulsatome - an emulsification device designed for the quick
and safe removal of a full range of cataracts.
2). HydroKeratome - A corneal cutting device designed to produce a
bladeless flapcut for the LASIK procedure.
DEVELOPMENT MILESTONES:
Projected
Product Milestone Description Completion Date
------- --------------------- ---------------
Pulsatome
Final hand piece design selection 1st Quarter 2005
Completion and validation of software 1st Quarter 2005
Completion of animal testing 1st Quarter 2005
Preparation and submission of 510(k) application 2nd Quarter 2005
Receipt of 510(k) clearance from US FDA 3rd Quarter 2005
Market introduction 3rd Quarter 2005
Hydrokeratome
Completion and validation of software 1st Quarter 2005
Completion of animal testing 2nd Quarter 2005
Confirmation of device consistency 3rd Quarter 2005
Preparation and submission of 510(k) application 3rd Quarter 2005
Receipt of 510(k) clearance from US FDA 4th Quarter 2005
Market introduction 1st Quarter 2006
PROPERTY, PLANT AND EQUIPMENT
Facilities:
We are currently leasing approximately 4,400 square feet of combined
office, laboratory and warehouse space in Irvine California on a month to month
basis. We are in discussions to lease new facilities in San Clemente, California
pursuant to a longer term lease. We hope to finalize the new lease, complete
required tenant improvements and relocate to the new facility during the first
quarter of 2005. In connection with the new facility, we expect to expend
approximately $125,000 on leasehold improvements required to build out the space
in accordance with our specifications. In addition, we estimate that we will
spend approximately $75,000 on furniture and fixtures, and $25,000 on a
telephone system during the first quarter of 2005 in connection with our
facilities relocation.
Computers and Software:
In order to facilitate our expected growth, and to accommodate our
information systems requirements, we are planning to upgrade our systems with
new computer hardware and software during the first and second quarter of 2005.
In connection with this upgrade, we anticipate utilizing approximately $125,000
to purchase required servers and desk top computers, and approximately $50,000
to purchase new enterprise-wide software.
Research and Product Development and Testing:
In order to support our planned research and product development
activities, we anticipate the following capital expenditures during the first
and second quarter of 2005:
Machine shop equipment $ 50,000
Laboratory equipment 50,000
Quality assurance and testing equipment 50,000
Engineering and product development software 30,000
------------
Total research, product development and testing $ 180,000
EMPLOYEE ADDITIONS
To support projected company growth and increased emphasis on sales,
marketing, distribution and customer training/support, we anticipate hiring a
total of 16 new employees during the next twelve months. Annualized incremental
expenses related to salaries and benefits for the new employees to be hired
during this period are estimated to be approximately $1.1 million, and we expect
to hire the majority of these new employees during the first and second quarter
of 2005.
New Employee Breakdown:
Headcount
Department Additions
---------- ---------
Sales and marketing 8
Customer service 3
Research and development 2
Warehouse and distribution 2
Accounting and administration 1
-----
Total 16
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE PLANS AND RESULTS
Planned activities and projected expenditures discussed above are
contingent on our obtaining sufficient funding, as well as on the success of our
sales efforts related to licensed products, and progress made in our efforts to
complete development and obtain regulatory clearance for marketing of our
internally developed products.
In addition, see "Risk Factors."
BUSINESS
COMPANY BACKGROUND AND SUMMARY
VisiJet is a medical device company focused on the marketing and
development of ophthalmic surgery products for use in the laser eye surgery and
cataract surgery markets. The Company was incorporated on February 2, 1996, as a
wholly owned subsidiary of SurgiJet, Inc. to develop and distribute medical
products based on patented waterjet-based technology licensed from SurgiJet. In
May 1999, the Company was spun off from SurgiJet through a distribution of
common stock to its shareholders, after which SurgiJet had no remaining
ownership interest in the Company.
In December 2002 VisiJet entered into a merger agreement with Ponte
Nossa Acquisition Corp., a Delaware corporation ("the Merger") that had been
incorporated as a blank check company in 1997. The agreement called for the
merger of the two companies into a single company through the merger of an
acquisition subsidiary, VisiJet Acquisition Corporation, into VisiJet. The
merger was consummated on February 11, 2003, and immediately thereafter, VisiJet
was merged into Ponte Nossa Acquisition Corp., and the surviving company's name
was changed to "VisiJet, Inc."
In April 2004, VisiJet entered into an exclusive license agreement with
Gebauer Medizintechnik GmbH, of Neuhausen Germany ("Gebauer"), pursuant to which
we acquired worldwide marketing, sales and distribution rights for Gebauer's
LASIK and Epi-LASIK products. In May 2004, VisiJet began marketing these
products in Europe and certain other foreign countries, where the products have
received regulatory clearance for sale, and began generating revenue from
product sales during the second quarter of 2004. In September 2004, we began
marketing the Epi-Lasik product in the United States, following receipt of
clearance for marketing from the U.S. Food and Drug Administration. The
agreement with Gebauer is for an initial term of three years, with an option to
extend for an additional two years if we meet certain sales standards. During
the term of the agreement we must meet certain minimum purchase requirements in
order to maintain the exclusivity of the arrangement.
In addition, we are engaged in the research and development of
ophthalmic surgery products based upon applications of our proprietary waterjet
technology, designed to result in faster, safer and more efficacious laser eye
and cataract surgery. To date, these efforts have been focused on bringing to
market two products, with different applications and markets.
First is the Pulsatome(R), which utilizes waterjet technology to remove
the cataractous human crystalline lens in the eye during cataract surgery.
Second is the HydroKeratome(R), a device that utilizes waterjet technology to
cut the corneal flap immediately prior to applying an excimer laser in laser eye
surgery to correct myopia, hyperopia and astigmatism.
MARKETS
THE REFRACTIVE SURGERY MARKET
Our products assist in surgical procedures relating to the cornea. The
cornea is the clear window that provides most of the focusing power of the
vision system of the eye, as well as allowing light into the eye. The anterior
surface of the cornea is covered with a thin layer called the epithelium. The
epithelium is covered with a liquid tear film.
Physicians generally treat vision disorders by prescribing eyeglasses
or contact lenses or through ophthalmic surgery, all of which compensate for or
correct the vision error. The principal surgical techniques available to treat
vision disorders are radial keratotomy ("RK"), Photo Refractive Keratectomy
("PRK")/LASIK and Refractive Lamellar Keratoplasty ("RLK"). In RK, PRK/LASIK and
RLK, the object of the surgery is to change the shape of the anterior corneal
surface and to eliminate or reduce refractive error. An additional objective is
to minimize lens aberrations to improve visual acuity, which is not possible
with eyeglasses or contact lenses.
The refractive surgery market in its current form began in late 1995
when the FDA approved the first excimer laser for PRK. Before 1995 refractive
surgery was conducted by various manual, non-laser techniques, the most popular
of which was RK. In RK, the surgeon uses a diamond knife to make radial
incisions in the cornea to flatten it. This technique, and others like it, is
highly dependent on the surgeon's skill, and often produces mixed results.
By contrast, in PRK utilizing the excimer laser, the
computer-controlled laser is programmed to remove the specified amount of
corneal tissue with precision, delivering a consistent outcome. In spite of its
inherent accuracy and predictability, PRK was not widely accepted by patients,
because it uses the laser to burn away the most sensitive top layers of the
cornea. Patients undergoing PRK often experienced considerable pain, and were
left with a persistent cloudiness of the cornea for days or weeks. PRK generally
met the clinical expectations of the surgeon, but failed to satisfy the
patient's desire for comfort and rapid recovery. For this and other reasons, PRK
failed to attain broad market acceptance.
In late 1996 many ophthalmic surgeons started utilizing a new
procedure, Laser In Situ Keratomileusis ("LASIK"), which addressed many of the
negative aspects of PRK from the patient's standpoint, while preserving the
accuracy of PRK. LASIK utilizes a microkeratome, which is a mechanically driven
razor to create a flap in the surface of the cornea. After creation of the flap,
the excimer laser is used on the exposed internal tissue, called the stroma,
underneath the flap. The excimer laser emits ultraviolet light in very short,
high-energy pulses and ablates part of the corneal surface according to a
prescribed spatial pattern, changing the curvature of the anterior corneal
surface. The laser removes a predetermined amount of tissue to achieve the
desired correction, and the hinged flap is reset as closely as possible to its
original position, where it adheres to the underlying stroma. The adherence
increases over a period of many months. The patient's vision is significantly
improved within minutes of surgery.
Because the laser energy is used on the less sensitive inner tissue of
the cornea, the patient experiences very little pain after surgery and there is
generally no clouding of the corneal surface. The patient is usually able to
return to normal function the next day with immediate vision improvement.
In 2003, there were approximately 1.2 million LASIK procedures
performed in the U.S. and over 2.5 million performed worldwide. The success of
LASIK in meeting both surgeon and patient needs, and continued improvements in
technology, have been the principal factors in the growth in the refractive
surgery market in recent years.
Recently, a new refractive surgery technique, referred to as Epi-LASIK,
was introduced. The Epi-LASIK procedure utilizes an automated device to
mechanically separate the epithelium, or outer layer of the cornea, in a sheath,
approximately 30 microns thick. This is in contrast to cutting into the cornea
using a microkeratome blade and creating a flap, from 120 - 180 microns thick,
as is done in the traditional LASIK procedure. Once the epithelium has been
separated, the curvature of the corneal surface is changed to predetermined
specifications using an excimer laser. Following the laser procedure, the
epithelium sheath is then returned to its original position.
THE CATARACT SURGERY MARKET
Currently, the majority of cataract surgical procedures are performed
using an ultrasonic phacoemulsifier device. The phaco, as it is commonly called,
utilizes an ultrasonic generator which vibrates the tip of the phaco hand piece
40,000 times per second. When the tip is introduced into the eye and placed in
contact with the cataractous lens, the lens is gradually reduced to smaller
pieces until it can be aspirated out of the eye.
In the U.S., there were approximately 2.7 million cataract surgical
procedures performed in 2003. The worldwide cataract surgery market is estimated
to be approximately 14.4 million procedures annually. In many developing
countries, cataracts are the leading cause of blindness.
THE COMPANY'S PRODUCTS
EpiLift and LasiTome
Pursuant to its agreement with Gebauer, the Company acquired exclusive
worldwide marketing, sales and distribution rights for Gebauer's LASIK and
Epi-LASIK product lines. The product lines include EpiLift, a mechanical device
used for performing the epithelium separation procedure in Epi-LASIK refractive
surgery, and LasiTome, a mechanical device used for creating a corneal flap in
traditional LASIK surgical procedures
EpiLift:
Traditional LASIK surgical procedures utilize a microkeratome, which is
a mechanically driven razor to cut a flap in the surface of the cornea. After
creation of the flap, an excimer laser is used on the exposed internal tissue,
called the stroma to ablate, or remove part of the corneal surface according to
a prescribed spatial pattern, changing the curvature of the anterior corneal
surface. The laser removes a predetermined amount of tissue to achieve the
desired correction, and the hinged flap is reset as closely as possible to its
original position, where it adheres to the underlying stroma. Although the
traditional LASIK procedure is generally regarded as safe, complications and
side effects that may occur, including dry eye, loss of corneal sensation and
change in structural strength of the eye, generally result from the cutting of
the stromal flap.
The EpiLift System provides the ophthalmic surgeon with an alternative
methodology for exposing the corneal tissue prior to the application of the
excimer laser without cutting into the stroma. The EpiLift System is an
automated device that mechanically separates the epithelium, or outer layer of
the cornea, in an intact sheet of viable tissue. The epithelial sheet is then
temporarily lifted away from the cornea and the laser is applied, as in the
traditional LASIK procedure, to reshape the cornea to the pre-determined
specifications to achieve the desired vision correction. Once the laser
application is completed, the epithelial sheet is returned to its natural
position where it rapidly heals. Because it does not involve cutting the cornea
or creating a permanent flap, the EpiLift System results in a generally safer
procedure with reduced risk of complications.
The complete EpiLift System includes the following components:
Description Quantity
----------- --------
Console 1
Handpiece 1
Footswitch 2
Epi-Head 2
Rings 4
Metal Bands 4
Vacuum Handles 2
Steriboxes 2
In addition to the system components noted above, each procedure
performed requires the use of a disposable Epi-blade. The Epi-Blades are sold
separately, and one Epi-Blade can be used for both eyes of a single patient.
LasiTome:
The LasiTome System is a mechanical device used by ophthalmic surgeons
in traditional LASIK procedures to create the flap required to expose the
corneal tissue prior to the application of the excimer laser. The LasiTome
System utilizes the same components as the EpiLift System, with the only
differences being that the Epi-Head included in the EpiLift System is replaced
with a LASIK Head, and the disposable blades used are LASIK blades instead of
Epi-Blades.
In markets where both EpiLift and LasiTome have received required
regulatory clearance, combination systems are available that include both Epi
and LASIK Heads. This allows the ophthalmic surgeon to reduce their initial
investment in the equipment, as only one set of basic system components is
required, while maintaining the flexibility of using the methodology considered
by the surgeon to be most appropriate for the individual circumstances of the
patient.
In May 2004 the Company began marketing the EpiLift and LasiTome
systems in Europe and certain other countries in which regulatory clearance had
been received prior to completion of the license agreement with Gebauer. Thus
far, interest in our EpiLift and LasiTome systems in Europe and other foreign
markets has been strong, and through September 30, 2004, revenue recognized in
connection with international sales of these products totaled approximately
$1,038,000.
In September 2004 the Company began marketing EpiLift in the United
States, following receipt of clearance for marketing from the U.S. Food and Drug
Administration. We anticipate filing a 510(k) submission requesting marketing
clearance for LasiTome in the United States with the U.S. Food and Drug
Administration in the first quarter of 2005, and expect to initiate LasiTome
sales in the U.S. in the second or third quarters of 2005, follow receipt of
marketing clearance from the FDA.
Countries we are currently doing business with, either in terms of
products already having been sold, or where we have signed or pending
distribution agreements include the following:
Australia Germany Latvia Russia
Austria Greece Lebanon Serbia
Benelux Indonesia Libya Singapore
Czech Republic Israel Lithuania Spain
Denmark Italy Malaysia Sweden
Dubai Japan Nepal Switzerland
Egypt Jordan Norway Turkey
Estonia Korea Portugal United Kingdom
France Kuwait Romania United States
WATERJET TECHNOLOGY AND PRODUCTS UNDER DEVELOPMENT
Waterjet technology is an established method for precision cutting of
materials in a variety of industrial applications. It uses the principle of
pressurizing water to extremely high levels, and allowing the water to escape in
a controlled manner through a very small opening, or orifice. Water jets use the
high pressure beam of water exiting the orifice to cut various materials,
including tile, wood, plastic, metal, and stone. In general, industrial
applications of waterjet technology are used in place of a laser or other device
when the "cut" needs to be quicker, cleaner, and with minimum distortion and
temperature increase.
VisiJet holds an exclusive license with respect to the ophthalmic
applications of a series of U.S. and foreign patents relating to the waterjet
technology. The technology uses a pneumatic-hydraulic pressure intensifier to
produce a collimated high pressure water beam that is approximately the diameter
of a human hair. This self-cleaning, eversharp "hydro-laser" can cut through
tissue at 12mm (.5 inch) per second. The hydraulics are controlled by an
embedded central processing unit with displays, gauges, controls, aspiration and
irrigation fluidics familiar to ophthalmic surgeons.
VisiJet is currently developing two ophthalmic surgical products
utilizing its proprietary waterjet technology. The first is Pulsatome(R), a
device that uses pulsed waterjet technology to remove cataracts, and the second
is Hydrokeratome(R), a device that uses a high-pressure micro beam of water to
cut a corneal flap during LASIK surgery. Although our waterjet based products
under development have different applications, they share certain basic
characteristics. Each of the waterjet products consists of a modular console
with an intensifier and a hand piece. The modular unit is attached to a delivery
tube, which is in turn attached to a hand piece. The hand piece delivers the
water jet to the tissue and its integral aspirator removes any debris tissue and
water through a disposable tube that returns to the console.
PULSATOME(R) CATARACT EMULSIFIER. The Pulsatome(R) Cataract Emulsifier
is an emulsification device designed for the quick and safe removal of the
cataractous human crystalline lens in the eye, a necessary procedure before
installing a new intraocular lens ("IOL"). The device creates a pulsating stream
of saline solution, and the impact from the pulsating fluid emulsifies the
cataractous human lens and breaks the lens into small pieces. The Pulsatome
simultaneously aspirates the emulsified tissue and removes it from the interior
of the eye.
The Pulsatome requires minimal technical skill, as it functions like a
hydraulic eraser or paint brush. No sculpting or lens elevation or rotation is
necessary. The balanced irrigation/aspiration fluidics complement the embedded
CPU controlled micro pulses. The foot switch initiates the mode activity
selected by surgeon for the balanced and ergonomically shaped hand piece.
Based on the experience of our management team and consultants in the
ophthalmic industry, we believe that the waterjet platform of the Pulsatome will
be easier to learn to use and will require less skill than that required by
current ultrasound phaco emulsification devices. The Company also expects that
Pulsatome and its disposable package will be priced in the low range of current
ultrasound devices, which will make it attractive in underdeveloped markets, and
also attractive in the U.S. and other nations where cost containment is
critical.
Assuming successful completion of the remaining development milestones
listed below, we anticipate obtaining clearance for marketing, and market
introduction of Pulsatome in the 3rd quarter of 2005. We anticipate the cost of
the remaining development work outlined to be approximately $190,000.
Projected
Milestone Description Completion Date
--------------------- ---------------
Final hand piece design selection 1st Quarter 2005
Completion and validation of software 1st Quarter 2005
Completion of animal testing 1st Quarter 2005
Preparation and submission of 510(k) application 2nd Quarter 2005
Receipt of 510(k) clearance from US FDA 3rd Quarter 2005
Market introduction 3rd Quarter 2005
HYDROKERATOME(R) CORNEAL CUTTING DEVICE. The HydroKeratome(R) is a
corneal cutting device for use in the LASIK procedure. The HydroKeratome works
by using a high-pressure micro beam of water to force a blunt dissection of
tissue in the path of the water beam. The HydroKeratome uses an embedded CPU
controlled pneumatic-hydraulic pressure intensifier to make the corneal flap.
The suction ring and applanation plate on the hand piece allow holding the eye
centered while the corneal flap is cut underneath the applanation plate. The
water jet traverses perpendicular to the visual axis, driven by a precision
miniature Swiss motor with gear box and encoder. A foot switch controls the
start of the transverse water jet motion, and the travel distance pre-programmed
by the surgeon stops the travel and shuts off the water jet beam. Approximate
travel time is one-half second. The HydroKeratome is designed to address many of
the problems that are common with mechanical "blade" microkeratomes, such as
poor visualization, inconsistent thickness of flaps, hazing, loose flaps, off
center cuts, and lashes caught in gears.
Assuming successful completion of the remaining development milestones
listed below, we anticipate obtaining clearance for marketing in the 4th quarter
of 2005, and to initiate sales of Hydrokeratome in the first quarter of 2006. We
anticipate the cost of the remaining development work outlined to be
approximately $100,000.
Projected
Milestone Description Completion Date
--------------------- ---------------
Completion and validation of software 1st Quarter 2005
Completion of animal testing 2nd Quarter 2005
Confirmation of device consistency 3rd Quarter 2005
Preparation and submission of 510(k) application 3rd Quarter 2005
Receipt of 510(k) clearance from U.S. FDA 4th Quarter 2005
Market introduction 1st Quarter 2006
Development activities for both Pulsatome and Hydrokeratome indicated
above are subject to significant risks and uncertainties. These risks and
uncertainties include, but are not limited to, our ability to obtain sufficient
funding on a timely basis, unanticipated failure of required testing activities,
unexpected delays in completion of milestones and inability to obtain, or delays
in obtaining, required marketing clearance from the U.S. FDA.
COMPETITION
Our EpiLift and LasiTome devices currently on the market are
alternative methodologies used in the first step in LASIK surgery to expose the
cornea prior to application of the excimer laser. EpiLift utilizes a relatively
new technique referred to as Epi-LASIK, in which the epithelium, or outer layer
of the cornea, is mechanically separated in an intact sheet of viable tissue.
The epithelial sheet is then temporarily lifted away from the cornea and the
laser is applied, as in the traditional LASIK procedure, to re-shape the cornea
to the pre-determined specifications. Once the laser application is completed,
the epithelial sheet is returned to its natural position where it rapidly heals.
LasiTome is a mechanical device used in traditional LASIK procedures, referred
to as a microkeratome, that utilizes a metal blade to create a corneal flap to
expose the corneal tissue prior to the application of the excimer laser.
Our Hydrokeratome product, if successfully developed and cleared for
marketing, will provide an additional alternative for creating a corneal flap,
using a high-pressure micro beam of water, instead of a metal blade, to expose
the corneal tissue prior to the application of the excimer laser.
Our Pulsatome product, if successfully developed and cleared for
marketing, will compete in the cataract emulsification market.
COMPETITION IN CREATING THE CORNEAL FLAP
EPI-LASIK COMPANIES - Epi-LASIK devices were first introduced to the
marketplace in 2004, and have not yet captured a significant share of the
corneal flap market. Currently, we are aware of only one company, Norwood Abbey,
with a competing Epi-LASIK product on the market. In addition, we are aware of
two other Epi-LASIK products under development using similar technology that may
become competition in the future if development efforts are completed and
regulatory clearance is received.
MICROKERATOME COMPANIES - The corneal flap market is currently
dominated by microkeratome devices which maintain approximately 89% of the total
market. There are a number of companies that manufacture and or supply
microkeratomes including Bausch & Lomb, Moria, Advanced Medical Optics and
Nidek. All of these companies have significantly greater financial resources,
greater name recognition, larger product offerings and customer bases and longer
operating histories than VisiJet.
LASER COMPANIES - We are aware of one company, Intralase, that has
developed and markets a device for creating a corneal flap utilizing laser
technology that has captured approximately 11% of the total market.
Based on the response to EpiLift received thus far at major refractive
surgery conferences/conventions, and through our meetings and discussions with
practicing ophthalmic surgeons, we believe there is an opportunity for
significant growth in market share for the Epi-LASIK technology. We believe
EpiLift can compete successfully for market share against microkeratome and
laser-based devices primarily based on the higher safety profile and reduced
risk of complications associated with the Epi-LASIK technology, which allows for
the necessary exposure of the corneal tissue without cutting the cornea or
creating a permanent flap. In addition, we believe we can compete effectively
with the Intralase laser device based on the significantly lower device and per
procedure cost of EpiLift. Finally, based on our evaluation of the Norwood Abbey
Epi-LASIK device, we believe that our EpiLift product will compete effectively
with Norwood Abbey's product based on both technical specifications and product
performance.
We believe that the primary competitive advantage of our LasiTome
product, within the microkeratome market, is the interchangeability of the base
components with our EpiLift System. As a result, a surgeon is able to reduce
their investment in the technology, as only one base component system is
required, and is able to maintain the flexibility of using either the
traditional microkeratome approach or the Epi-LASIK approach, based on the
individual patient circumstances.
Our Hydrokeratome product is being developed to provide an alternative
to the traditional microkeratome method of creating a corneal flap, through the
use of high-pressure waterjet technology. We believe that if successfully
developed, the Hydrokeratome will be able to compete in the microkeratome market
as it is being designed to address many of the potential problems associated
with the traditional medal blade microkeratomes, such as poor visualization,
inconsistent thickness of flaps, hazing, loose flaps, off center cuts, and
lashes caught in gears.
COMPETITION IN THE CATARACT EMULSIFICATION MARKET
The primary instrument currently used for cataract removal surgery is
the ultrasonic phacoemulsifier. There are a number of companies that
manufacturer and or supply ultrasound phaco emulsification devices including
Alcon, Bausch & Lomb and Advanced Medical Optics. All of these companies have
significantly greater financial resources, greater name recognition, larger
product offerings and customer bases and longer operating histories than
VisiJet.
Our Pulsatome product under development represents an alternative
approach for the removal of cataracts using high-pressure pulsating waterjet
technology instead of ultrasound. We are aware of only one company, Alcon, that
has a device on the market that uses pulsed waterjet technology to remove
cataracts. The Alcon waterjet technology is incorporated in a combined device
that also includes phaco ultrasound capabilities. Based on the experience of our
management team and consultants in the ophthalmic industry, we believe that the
Pulsatome, if successfully developed, will be easier to use, and will be most
cost effective, and as a result will be able to compete effectively with, and
gain market share from, traditional phaco ultrasound devices. In addition, we
believe that the Pulsatome will compete effectively with the Alcon waterjet
technology as the Pulsatome is being designed to effectively remove a wider
range of cataracts, on a stand-alone basis, and therefore will be priced below
the combined Alcon unit.
COMPETITION FROM NEW TECHNOLOGIES
The medical device industry for ophthalmologic surgery products is
highly competitive. Many other companies are engaged in research and development
activities, and many of these have substantially greater financial, technical
and human resources than VisiJet. As such, they may be better equipped to
develop, manufacture and market their technologies. Accordingly, we also face
competition in the future from new products and technologies that may provide
safer and more cost effective alternatives to our products, or that may render
our products obsolete.
RESEARCH AND DEVELOPMENT
Our research and development efforts are focused on completion of
final product development and testing and securing of regulatory approval for
our two internally developed products, Hydrokeratome and Pulsatome. During the
fiscal years ended December 31, 2003 and 2002, we spent approximately $1.3
million and $295,000, respectively, on research and development activities.
MANUFACTURING
EPILIFT AND LASITOME PRODUCTS:
Manufacturing of our EpiLift and LasiTome products is performed by
Gebauer, pursuant to the Manufacturing, Supply and Distribution agreement
entered into in April 2004. The agreement has an initial term of three years and
provides the Company an option to extend the term for an additional two years,
subject to the Company having achieved certain sales performance milestones.
Under the agreement, Gebauer is obligated to manufacture and supply, and VisiJet
is obligated to purchase, specified minimum quantities of EpiLift and LasiTome
Systems and related blades.
The agreement establishes fixed pricing to VisiJet for all products
manufactured and supplied by Gebauer, and provides for annual price increases,
not to exceed a specified maximum percentage increase. The agreement also
provides that all pricing is to be FOB Gebauer's warehouse facility in Germany,
and that VisiJet will bear all costs of shipment, taxes, customs, duties or
other charges that may be incurred in connection with shipment to VisiJet or
other designated locations.
Under the agreement, Gebauer warants that the products will be
manufactured, tested and packaged in accordance with agreed upon specifications,
and will conform with all applicable laws, regulations and requirements. Under
the agreement, Gebauer provides a one year warranty that the products will be
free of material defects in materials and workmanship. In the event that Gebauer
is unable, for any reason, to supply a specified minimum percentage of VisiJet's
orders, Gebauer is required to qualify a second source for the manufacture of
products on Gebauer's behalf, and Gebauer is obligated to supply all required
manufacturing documentation and training.
INTERNALLY DEVELOPED PRODUCTS:
We plan to outsource manufacturing for our internally developed
products to an ISO 9001 approved local contract manufacturing facility. This
contractor will purchase and stock parts, assemble, test and burn-in units, and
will stock finished goods and ship as required from a bonded warehouse.
GOVERNMENT REGULATION
UNITED STATES. VisiJet's products are medical devices. As such, we are
subject to the relevant provisions and regulations of the Federal Food, Drug and
Cosmetic Act, under which the United States Food and Drug Administration ("FDA")
regulates the manufacture, labeling, distribution, and promotion of medical
devices in the United States. The Act provides that, unless exempted by
regulation, medical devices may not be commercially distributed in the United
States unless they have been approved or cleared by the FDA for marketing. There
are two review procedures by which medical devices can receive such approval or
clearance. Some products may qualify for clearance under a 510(k) notification.
Under the 510(k) procedure, the manufacturer submits to the FDA a pre-market
notification that it intends to begin marketing its product. The notification
must demonstrate that the product is substantially equivalent to another legally
marketed product (i.e., it has the same intended use, is as safe and effective,
and does not raise different questions of safety and effectiveness than does a
legally marketed device).
A successful 510(k) notification results in the issuance of a letter
from the FDA in which the FDA acknowledges the substantial equivalence of the
reviewed device to a legally marketed device and clears the reviewed device for
marketing.
FDA STATUS OF CURRENT PRODUCTS AND PRODUCTS UNDER DEVELOPMENT
EpiLift - In September 2004, VisiJet received a clearance letter from
the FDA with respect to our EpiLift product.
LasiTome - VisiJet anticipates filing a 510(k) application for
marketing clearance of LasiTome in the first quarter of 2005.
HydroKeratome - VisiJet has received successful 510(k) notification
with respect to its initial filing for the HydroKeratome, and has filed a 510(k)
submission with the FDA for upgrades to the product. Before commencement of
marketing the HydroKeratome, we must obtain 510(k) approval from the FDA for the
product enhancements. We are currently addressing issues raised by the FDA in
our product enhancement submission for HydroKeratome, and hope to file our
response during the third quarter of 2005.
Pulsatome - Based on successful completion of required product
development and testing issues, we anticipate filing a 510(k) application for
marketing clearance of Pulsatome in the second quarter of 2005.
In addition to laws and regulations enforced by the FDA, our products
may also be subject to labeling laws and regulations enforced by the United
States Federal Trade Commission ("FTC"). Any additional requirements related to
FTC laws and regulations will be addressed and monitored by the Company's
Regulatory Affairs department, although we do not expect that any such laws
and/or regulations will have a significant impact on our products.
OTHER COUNTRIES. Regulatory requirements in other countries with
respect to marketing of medical device products vary widely. However, the
majority of foreign countries in which we are selling our EpiLift and LasiTome
products allow for marketing based upon the products having received the CE
MARK, which designates compliance with appropriate European regulations. In
addition, these products are UL listed with the Underwriters Laboratories, Inc
for compliance with internationally recognized safety standards, and the EpiLift
product has received 510(k) marketing clearance from the U.S. FDA.
DISTRIBUTION METHODS
VisiJet markets its products in the United States through a direct
sales force consisting of four employees and eight independent sales
representatives. Our sales force consists of personnel with extensive experience
in sales of devices and other ophthalmic products to refractive surgeons. Our
sales and marketing efforts our focused on the following strategies and
activities:
o DRIVE PRODUCT AWARENESS - Increase awareness of EpiLift
through advertising, exhibiting at major industry meetings and
conferences and developing relationships with leading
refractive surgery centers and key industry opinion leaders.
o IDENTIFICATION OF PROSPECTS AND FOLLOW-UP ON PHYSICIAN LEADS -
Identify prospective customers, initiate contact and follow-up
on physician leads through phone calls, email, distribution of
product literature and videos and direct contact as
appropriate.
o VISIT PHYSICIANS - Meet with interested physicians for face to
face follow-up, pig eye demonstrations and live surgical
demonstrations as appropriate.
o CLOSE SALE, TRAINING AND SUPPORT - Complete sale, arrange
third-party lease financing as appropriate, ensure proper
post-sale training and customer service.
Thus far, interest in EpiLift in the United States has been strong. Our
sales force has been actively pursuing leads generated through direct contact
with physicians, and through our attendance at the American Academy of
Ophthalmology, held in New Orleans in October 2004. In addition, we have
completed arrangements for a series of clinical evaluations at six leading
refractive surgery centers in the United States including The Wilmer Eye
Institute, The Cleveland Clinic, Mid Michigan Physician's Group, Minnesota Eye
Consultants, Cullen Eye Institue and Massachusetts Eye and Ear Infirmary.
We are distributing our products internationally through a series of
agreements with distribution companies in major countries that handle other
American and European manufactured ophthalmic products, and that are familiar
with applicable local government rules and regulations, as well as with the
customer base and key ophthalmic surgeons in the region. To date, we have
distributors in major international markets, including the following:
Country Distributor
------- -----------
France Anteis S.A.
Germany Gebauer Medizintechnik GmbH
Italy NewTech SpA
Spain Wavelight/Tetramedics
United Kingdom Kestrel Ophthalmics
Greece Medicare Ltd.
Switzerland Mediconsult AG
Japan Japan Focus Co., Ltd.
In addition, we have ongoing contract negotiations with potential
distributors in other important international markets including China, Hong
Kong, and South Africa.
Although specifics vary based on countries and territories covered, our
international distribution agreements generally provide for a specified term and
exclusive territory, fixed sales prices from VisiJet to the distributor and
minimum purchase quantity requirements for the distributor.
Distribution of our products in countries other than the United States
may be subject to regulation in those countries. In some countries, the
regulations governing such distribution are less burdensome than in the United
States, and we may pursue marketing our products in such countries prior to
receiving permission to market from the FDA in the United States. We will
endeavor to obtain the necessary government approvals in those foreign countries
where we decide to manufacture, market and sell our products.
PATENTS AND TRADEMARKS
Most of the technology utilized by the Company in products under
development is covered by patents owned by SurgiJet, Inc., a developer of
waterjet technology for a variety of medical and dental applications, and
VisiJet's former parent company. We have been granted an exclusive worldwide
license to these patents for ophthalmological applications for the life of the
patents. The license agreements with SurgiJet include twelve issued U.S. patents
and four issued international patents. VisiJet has also exclusive licenses to
certain non-patented technology developed by SurgiJet related to ophthalmic
applications, and holds exclusive licenses for certain registered trademarks,
including VisiJet(R), HydroKeratome(R), and Pulsatome(R). The Company intends to
protect its development work by means of licensing additional patents and
trademarks as necessary and to protect its own inventions with additional patent
applications.
Under the terms of the license agreements with SurgiJet, Inc., entered
into October 23, 1998, VisiJet is obligated to pay a royalty of 7% of revenues
received from sales of the products utilizing licensed patents and technology,
up to $400 million of revenues over the course of the Agreements, and 5% of
revenues thereafter. The license agreements with SurgiJet also provide for a
minimum royalty of $60,000 per year. To date, the Company has paid a total of
$180,000 in minimum royalty payments to SurgiJet, and, as of September 30, 2004
$45,000 in minimum royalty payments were accrued.
On September 17, 2003, VisiJet entered into a license agreement with
Robert M. Campbell, Jr., M.D., pursuant to which the Company obtained exclusive
worldwide rights for all medical applications for a patented technology invented
by Dr. Campbell that provides for the sterile flow of fluid through a surgical
water jet apparatus. The license agreement provides for a royalty of 6% on
revenues from products utilizing licensed technology and is subject to a minimum
royalty of $24,000 per year. To date, $24,000 in minimum royalty payments have
been made, and as of September 30, 2004 $50,000 of the license fee balance owed
was due and payable.
Following is a listing of patents licensed by the Company:
PATENT NUMBER DATE ISSUED EXPIRATION DATE NAME
------------- ------------- --------------- -------------------------------
5,037,431 Aug. 6, 1991 Nov. 3, 2009 Surgical Lance Apparatus
5,322,504 June 21, 1994 May 7, 2012 Method and Apparatus for Tissue
Excision and Removal by Fluid
Jet
5,562,692 Oct. 8, 1996 Oct. 8, 2013 Fluid Jet Surgical Cutting Tool
5,591,184 Jan. 7, 1997 Oct. 13, 2014 Fluid Jet Surgical Cutting
Instrument
5,643,299 July 1, 1997 Jan. 16, 2016 Hydrojet Apparatus for
Refractive Surgery
5,674,226 Oct. 7, 1997 May 7, 2012 Method and Apparatus for Tissue
Excision and Removal by Fluid
Jet
5,735,815 April 7, 1998 July 26, 2013 Method of Using Fluid Jet
Surgical Cutting Tool
5,853,384 Dec. 29, 1998 Dec. 29, 2015 Fluid Jet Surgical Cutting Tool
and Aspiration Device
5,865,790 Feb. 2, 1999 July 26, 2013 Method and Apparatus for Thermal
Phacoemulsification by Fluid
Throttling
6,143,011 Nov. 7, 2000 April 13, 2018 HydroKeratome for Refractive
Surgery
6,312,440 Nov. 6, 2001 April 13, 2018 Fluid Jet Keratome Apparatus and
Method for Refractive Surgery
6,440,103 Aug. 27, 2002 March 17, 2019 Method and Apparatus for Thermal
Emulsification
636345 Feb. 1, 1995 July 18, 2014 Method and Apparatus for Tissue
Excision and Removal by Fluid
Jet (Australia)
677061 Nov. 4, 1997 July 14, 2014 Fluid Jet Surgical Cutting Tool
(Australia)
WO98/36717 Aug. 27, 1998 Aug. 27, 2015 Hydrojet Apparatus for
Refractive Surgery (PCT)
A 61 B 17/32 May 5, 1999 May 5, 2016 Chirurgische Flussigstrahl
Schneidvorrichtung (Germany)
5,620,414 April 15, 1997 April 15,2014 Apparatus and Method for
Effecting Surgical Incision
Through Use of a Fluid Jet
EMPLOYEES
As of December 31, 2004, we had fourteen full-time employees, none of
whom is covered by any collective bargaining agreement. We consider our
relationship with our employees to be good.
DESCRIPTION OF PROPERTY
We lease office, research and warehouse facilities in two adjacent
buildings located in Irvine, California. Our lease, which is currently on a
month to month basis, is for a total of approximately 4,800 square feet, which
we lease for $9,500 per month. Due to the configuration, this space is not
adequate for our current and anticipated future needs. In addition, the current
month to month leasing structure is not an acceptable long term arrangement.
Accordingly, we are currently evaluating options for leasing more suitable
facilities on a longer term basis.
LEGAL PROCEEDINGS
VisiJet is currently engaged in the following legal proceedings:
VisiJet is a defendant in Steven J. Baldwin vs. VisiJet, Inc. et al, a
case pending in San Francisco County Superior Court, filed on February 9,
2004(Case NO. 04-428696). The Plaintiff alleges the VisiJet failed to compensate
him for services performed, prior to the merger with PNAC, pursuant to a
consulting agreement and is seeking monetary damages in the approximate amount
of $450,000. The case is currently in the preliminary stage.
In October 2004, the Company and SurgiJet, its former parent company
entered into a settlement agreement covering all previously outstanding
litigation between the two companies, as well as with SurgiJet's principal
owners and its subsidiary, DentaJet.
In accordance with the settlement agreement, the Company, agreed to pay
a total of $579,774, plus accrued interest at an annual rate of 7.5% from August
31, 2004, as full settlement of previously disputed notes payable to SurgiJet
and DentaJet and related accrued interest. In addition, the Company agreed to
pay a previously disputed note payable to a shareholder of the Company, who is
also a principal owner of SurgiJet, in the amount of $19,000 plus accrued
interest at an annual rate of 10% from December 31, 2002.
In addition, the Company agreed to issue 75,000 shares of its Common
Stock to SurgiJet, granted SurgiJet a security interest in all of its assets and
agreed to provide SurgiJet with a stipulated judgment, which can only be filed
by SurgiJet upon an event of default which remains uncured following 10 days
after receipt of written notice of such default.
Payments on all obligations due pursuant to the settlement agreement
will be made in monthly installments commencing December 1, 2004. The first
payment was in the amount of $30,000, and thereafter monthly payments are
$20,000 through December 2005, and $25,000 from January 1, 2006 until the
obligations are paid in full.
In accordance with the settlement agreement, SurgiJet and its
principals agreed to waive, subject to completion and final report from an
independent accounting firm, claims for additional monies owed to them, and to
dismiss their cross-complaint against the Company, its directors and certain of
its officers seeking additional monetary damages and rescission of the Merger
Agreement.
MANAGEMENT
The officers and directors of VisiJet are as follows:
Director
Name Age Position Since
---- --- -------- -----
Richard H. Keates, M.D.(1)(2) 72 Chairman of the Board 2003
of Directors
Randal A. Bailey 61 President, Chief Executive
Officer and a Director 2003
Laurence M. Schreiber 63 Chief Operating Officer, 2003
Secretary, Treasurer and
a Director
Adam Krupp(1)(2) 41 Director 2003
Norman Schwartz(1)(2) 61 Director 2003
(1) Member of the Executive Committee
(2) Member of the Audit Committee
Dr. Keates has been Chairman of the Board of Directors since February
2003. He is an ophthalmologist, consultant, and professor, and has been a
Professor of Ophthalmology at New York Medical College since 1997. Dr. Keates
has served on various boards of directors, including Frigitronics (NYSE), Med
Chem (NYSE), Autonomous Technologies (NASDAQ) and Chiron Vision. Dr. Keates has
consulted for leading health care companies including IO Lab, Alcon, and Bausch
& Lomb. He is a founding partner of Intelligent Biocides, and has published over
100 articles in ophthalmology. Among his many faculty appointments, Dr. Keates
has been a professor at Ohio State University, Professor and Chairman of the
Ophthalmology Department at the University of California, Irvine. He is the
President of the New York Introcular Lens Society and recently completed his
term as the President of the New York Keratorefractive Society. Dr. Keates
graduated from the University of Pennsylvania and from the Jefferson Medical
College. He completed his Ophthalmology training at Harvard Basic Sciences in
Ophthalmology and The Manhattan Eye, Ear & Throat Hospital.
Mr. Bailey has served as President of VisiJet since February 2003, and
was appointed to the Board of Directors in September 2003. Between 1995 and 2003
he had been affiliated with VisiJet's predecessors in an executive management
capacity. He has more than twenty-five years experience in management roles at
both medical device and pharmaceutical companies. From 1991 to 1995, Mr. Bailey
was the leader of the sales organization of Pharmacia Ophthalmics, Inc. Between
1989 and 1991, Mr. Bailey was the Vice President of Sales and Marketing for
Novoste, Inc. (NASDAQ) a start up cardiovascular company. Mr. Bailey was a
co-founder and Vice President of Sales and Marketing for Chiron Vision, Inc.,
which was acquired by Bausch & Lomb in 1997. Chiron Vision, now Bausch & Lomb
Surgical, is a leader in the manufacturing and sales of ophthalmic devices
worldwide. From 1980 to 1986 Mr. Bailey was the initial Vice President of Sales
and Marketing for Allergan Medical Optics, Inc.
Mr. Schreiber has served as Chief Operating Officer, Secretary and
Treasurer of VisiJet since February 2003, and was appointed to the Board of
Directors in September 2003. Prior to February 2003, Mr. Schreiber was an
executive officer and a member of the Board of Directors of Ponte Nossa
Acquisition Corporation, where he played an integral role in the merger between
Ponte Nossa and VisiJet that was finalized in February 2003. Prior to joining
Ponte Nossa in 2001, he founded Diversified International, a multilevel
marketing system, and served as Chief Executive Officer of Learn America, a
multimedia productions company combining advanced computer technology and
educational systems. Mr. Schreiber also served as President and a director of
Philibus Systems, a private educational system, and was President of Advanced
Nutritional Associates, which distributed health care products in the United
Kingdom and Europe. He has developed an independent sales distribution system
for Herbalife, and pioneered markets in the United Kingdom, Spain and Israel.
Mr. Krupp has over eighteen years of business experience with emerging
growth companies. He is currently a Managing Director and a member of the
Executive Committee of CS Technology, Inc, a New York based technology
consulting firm. Prior to joining CS Technology, Inc., Mr. Krupp spent ten years
in the real estate industry working for several organizations in development,
construction, and leasing. Mr. Krupp holds a B.A. from the University of
Michigan and an M.S. from New York University.
Mr. Schwartz has been a member of the board of directors since February
2003, and has served as VisiJet's contract and legal coordinator since March
2003. Mr. Schwartz has over thirty years of experience in providing legal and
financial advice to individuals and companies. He has acted as Chief Financial
Officer and president of several companies, both public and private, including
Acubid International, Ameritrust, and Farm Energy Corp. He served on the Board
of International Acuvision Systems, a public company that developed and patented
vision Training equipment. He is an active member of the Arizona Bar
Association. Mr. Schwartz graduated from Arizona State University, completed his
JD at the University Of Arizona, and received his LLM in taxation from New York
University.
Directors hold office until a successor is elected and qualified or
until their earlier resignation in the manner provided in the Bylaws.
Scientific Advisor
Richard Lindstrom, M.D. is the Chief Ophthalmic Consultant to VisiJet,
and is in charge of assisting and advising us in connection with product
development in the ophthalmic surgical arena. After serving as Clinical
Professor of Ophthalmology at the University of Minnesota from 1980 to 1990, Dr.
Lindstrom entered private practice and now directs an outpatient clinic adjacent
to the Phillips Eye Institute in Minneapolis. He conceptualized the Phillips Eye
Institute Center for Teaching and Research, a state-of-the-art ophthalmic
research and surgical skills education facility, where he currently serves as
Medical Director. Dr. Lindstrom plays an active role in the teaching program at
the Phillips Eye Institute and at the University of Minnesota Hospital. He also
serves as an Associate Director of the Minnesota Lions Eye Bank. Dr. Lindstrom
holds 27 patents in ophthalmology in intraocular lens implant technology,
corneal preservation, irrigation solutions, viscoelastic solutions, intracorneal
lenses, and associated surgical instruments. Dr. Lindstrom serves on the editing
board of a variety of medical journals, including Journal of Cataract and
Refractive Surgery, Ophthalmic Surgery, European Journal of Implant and
Refractive Surgery, Implants in Ophthalmology, Ocular Surgery News,
Ophthalmology Times, and Journal Review of Ophthalmology. He is Chief Medical
Advisor to Laser Vision Centers and Vision 21 Centers.
EXECUTIVE COMPENSATION
The following table summarizes the annual compensation paid to our
named executive officers during the three years ended December 31, 2003:
Long Term Compensation
----------------------------------
Annual Compensation Awards
-------------------------------------- ----------------------------------
Other Annual Securities
Salary Bonus Compensation Restricted Underlying All Other
Name and Principal Position Year ($) ($) ($) Stock Awards Options
Compensation
------------------------------ ---------- ------------ --------- --------------- ----------------- ---------------- ---------------
Randal A. Bailey, 2003 165,000 - 6,800 - 200,000 62,500
President and Chief 2002 - - - - - -
Executive Officer (1)(2) 2001 - - - - - -
Laurence M. Schreiber, 2003 97,000 - 22,500 - 200,000 -
Chief Operating Officer, 2002 - - - - - -
Treasurer, Secretary (2) 2001 - - - - - -
Larry Hood, 2003 122,500 - - - 75,000 83,333
Director of Research and 2002 - - - - - -
Development, Chief Engineer 2001 - - - - - -
(1)(2)
-----------
(1) During 2003, VisiJet issued 164,319 shares of common stock, and issued a
two year promissory note in the amount of $150,000 to Mr. Bailey and
46,948 shares of common stock, and issued a one year promissory note in
the amount of $100,000 to Mr. Hood in satisfaction of an aggregate of
$700,000 of unpaid compensation accrued between 1999 and 2002. Amounts
noted as All Other Compensation represent respective payments made by
the Company pursuant to these promissory notes.
(2) Messrs. Bailey, Schreiber, and Hood became President and CEO, Chief
Operating Officer, Director. of Research & Development respectively, on
March 1, 2003 and earned consulting income from January to February
2003. Amounts noted as Other Annual Compensation represent respective
consulting fees paid in 2003 prior to March 1, 2003. Messrs. Bailey,
Schreiber and Hood did not receive any compensation from VisiJet in 2001
or 2002.
Stock Options
On November 10, 2003, the Board of Directors adopted the VisiJet, Inc.
2003 Stock Option Plan. The Option Plan provides for the grant of incentive and
non-qualified stock options to selected employees, the grant of non-qualified
options to selected consultants and to directors and advisory board members. The
Option Plan is administered by the Compensation Committee of the Board of
Directors and authorizes the grant of options for 3,000,000 shares. The
Compensation Committee determines the individual employees and consultants who
participate under the Plan, the terms and conditions of options, the option
price, the vesting schedule of options and other terms and conditions of the
options granted pursuant thereto.
As of December 31, 2004, a total of 2,460,000 options to purchase
shares of our common stock were outstanding pursuant to the 2003 Option Plan.
The following table summarizes information concerning stock options
granted during the fiscal year ended December 31, 2003 to the named executive
officers:
Percent of
Total
Number of options/SARs
Securities granted
underlying to Exercise
options/SARs employees or base
granted in fiscal price Expiration
Name (#) year ($/Sh) date
--------------------------------------------------------------------------------
Randal A. Bailey 200,000 17.17% $1.10 November 10, 2014
Laurence M. Schreiber 200,000 17.17% $1.10 November 10, 2014
No named executive officer exercised options in the fiscal year ended
December 31, 2003. The following table presents the number and values of
exercisable and unexercisable options as of December 31, 2003:
Number of
securities Value of
underlying unexercised in-
unexercised the-money
options/SARS at options/SARs at
FY-end (#) FY-end ($)
Name Exercisable/Unexercisable Exercisable/Unexercisable
--------------------------------------------------------------------------------
Randal A. Bailey 25,000/175,000 $6,000/$42,000
Laurence M. Schreiber 25,000/175,000 $6,000/$42,000
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT
The table below lists the beneficial ownership of our common stock, as
of December 31, 2004, by each person known by us to be the beneficial owner of
more than 5% of our common stock, by each of our directors and officers, and by
all of our directors and officers as a group.
Name and Address of Number of Shares Percent
Beneficial Owner Beneficially Owned(1)(2) of Class
-------------------------------------------------------------------------------
Renaissance Capital (4) 9,642,857(3) 25.16%
8080 N. Central Expressway,
Suite 210-LB59
Dallas, TX 75206
Roaring Fork Capital
Management, LLC (5) 2,507,143(3) 8.04%
5310 DTC Parkway, Suite I
Greenwood Village, CO 80111
Lance Doherty 4,585,758(3) 15.55%
9342 Jeronimo Road
Irvine, CA 92618
Liberty View Special 6,544,260(3) 16.62%
Opportunities Fund(6)
111 River Street, Suite 1000
Hoboken, NJ 07030
Financial Entrepreneurs, Inc. (7) 3,383,001(3) 11.68%
300 South 4th Street
Las Vegas, Nevada 89101
David E. Eisenberg Trust (8) 2,950,000(3) 9.70%
520 Madison, 38th Floor
New York, NY 10022
Corsair Capital (9) 2,892,857(3) 9.16%
350 Madison Ave, 9th Floor
New York, NY 10017
Alpha Capital Aktiengesellschaft(10) 2,758,571(3) 8.79%
Pradafant 7
Furstentums 9490
Vaduz Liechtentstein
Bushido Capital Master Fund, LP(11) 3,139,549(3) 8.87%
275 Seventh Avenue, Suite 2000
New York, NY 10001
Bridges & PIPES, LLC(12) 2,742,681(3) 7.74%
830 3rd Avenue, 14th Floor
New York, NY 10022
Taika Investments, Inc.(13) 2,200,000 7.67%
Calle Los Mangos C/Alameda
Edificio Los Mangos PB
OFC 1 y 2
La Campina
Caracas 1030
Venezuela
Ronald P. Russo, Jr. 2,188,456(3) 7.23%
275 Maidson Ave, 6th Floor
New York, NY 10016
Lewis Family Interest, LP (14) 1,950,000(3) 6.63%
520 Madison, 38th Floor
New York, NY 10022
Randal A. Bailey ** 510,357(3) 1.80%
192 Technology, Suite Q
Irvine, CA 92618
Richard H. Keates, M.D.** 425,000(3) 1.47%
20 Sutton Place South
New York, NY 10022
Laurence Schreiber** 243,478(3) *
192 Technology, Suite Q
Irvine, CA 92618
Norman Schwartz** 125,664(3) *
192 Technology, Suite Q
Irvine, CA 92618
Adam Krupp** 50,000(3) *
535 Eighth Avenue, 14th Floor
New York, NY 10018
All directors and executive
officers as a group (5 persons) 1,354,499(3) 4.68%
---------
* Denotes less than one percent. ** Denotes Member of the Board of Directors.
(1) Except as set forth, the persons named in the table have sole voting and
investment power with respect to all shares shown as beneficially owned by
them.
(2) Applicable percentage of ownership is based on 28,677,520 shares
outstanding as of December 31, 2004, together with applicable warrants,
options and convertible debt for such stockholder. Beneficial ownership is
determined in accordance with the rules of the SEC and includes voting and
investment power with respect to shares. Shares subject to options,
warrants and convertible debt currently exercisable/convertible or
exercisable/convertible within 60 days after December 31, 2004 are included
in the number of shares beneficially owned and are deemed outstanding for
purposes of computing the percentage ownership of the person holding such
options or warrants, but are not deemed outstanding for computing the
percentage of any other stockholder.
(3) Includes shares issuable upon exercise of currently exercisable options or
warrants, or conversion of debt.
(4) Controlled by Robert C. Pearson. Includes securities owned by Renaissance
US Growth Investment Trust, PLC., Renaissance Capital Growth & Income Fund
III, Inc., and BFS US Special Opportunities Trust, PLC.
(5) Controlled by Gene McCulley.
(6) Controlled by Ryan Hay
(7) Controlled by Norton Cooper
(8) Controlled by David E. Eisenberg
(9) Controlled by Jay Petschek. Includes securites owned by Corsair Capital
Partners, LP., Corsair Capital Investors, Ltd., and Corsair Capital
Partners 100, LP.
(10) Controlled by Konrad Ackerman
(11) Controlled by Louis Rabman
(12) Controlled by David Fuchs
(13) Controlled by Carlos Fernandez
(14) Controlled by Peter C. Lewis
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
During 2002, VisiJet issued a promissory note for $345,000 to Financial
Entrepreneurs Incorporated ("FEI"), one of our principal stockholders. In
February of 2003, in connection with the merger, FEI converted the promissory
note held by it, plus accrued interest, into 378,997 shares of Common Stock at a
conversion rate of $1.00 per share. Also in February 2003, under an agreement
entered into in connection with the merger, we agreed to assume a promissory
note originally issued to FEI by PNAC prior to the merger in the amount of
$193,163. As of September 30, 2004 the outstanding principal amount was $278,886
and accrued interest was $45,791.
In February of 2003, VisiJet issued 164,319 shares of Common Stock to
Randal A. Bailey, its President and Chief Executive Officer, in cancellation of
$350,000 of unpaid salary. VisiJet also issued Bailey a two year promissory note
for $150,000 in satisfaction of unpaid salary. The note bears interest at a rate
of 3.5% per annum, and calls for twenty-four equal monthly installments. At
September 30, 2004, the unpaid principal and accrued interest payable on the
note were $43,564 and $6,154, respectively.
In February of 2003, pursuant to an agreement entered into in
connection with the merger between Ponte Nossa Acquisition Corp. and VisiJet,
FEI cancelled 7,957,000 shares of VisiJet Common Stock owned by it, and VisiJet
issued FEI a five year warrant to purchase 1,543,000 shares of Common Stock at
an exercise price of $5.00 per share.
During 2003, and through September 30, 2004, the Company paid finders
fees totaling $52,500 and $15,000, respectively, to FEI in connection with
amounts raised through private equity placements by the Company. In addition
during 2003, the Company recorded consulting expenses totaling $75,000 to FEI,
that were added to an outstanding note payable with the corporation, and
reimbursed the corporation for travel expenses related to business of the
Company totaling $19,279.
In February 2003, the Company issued five-year warrants to purchase
25,000 shares of its Common Stock at an exercise price of $3.00 per share, to
Laurence Schreiber, a director and officer of the Company, pursuant to an
agreement entered into in connection with the merger.
In March of 2003, we began making consulting payments of $2,500 per
month to M & N Consulting, a corporation owned by Norman Schwartz, a director of
VisiJet, for consulting services provided by Mr. Schwartz. In June of 2003, the
payments were increased to $5,000 per month. Through December 31, 2003
consulting fees and related expenses totaling $41,250 and $2,604, respectively,
were expensed pursuant to this arrangement, of which $2,500 is included in
accounts payable at December 31, 2003. During the nine months ended September
30, 2004 the Company recorded $47,250 in consulting fees pursuant to this
agreement, and as of September 30, 2004 $6,500 related to this agreement was
included in accounts payable. In addition, in September 2003, VisiJet issued
150,000 shares of Common Stock to M & N Consulting for services provided by Mr.
Schwartz in connection with the finalization of the merger with Ponte Nossa. In
connection with the issuance of these shares, VisiJet recorded consulting
expenses of $225,000, based on the fair market value of the common stock at the
date of issuance. Subsequent to the issuance of these shares, beneficial
ownership with respect to 100,000 shares was transferred by M & N Consulting to
Laurence Schreiber, Secretary/Chief Financial Officer and a Director.
In February of 2003, VisiJet entered into a consulting agreement with
Richard H. Keates, M.D., a director. Pursuant to this agreement, Dr. Keates
receives a monthly retainer of $5,000 per month plus a fee of $1,500 per day for
consulting work performed. Through December 31, 2003 consulting fees and related
expenses totaling $118,000 and $24,581, respectively, were recorded pursuant to
this agreement, of which $14,721 is included in accounts payable at December 31,
2003. In January 2004, the agreement was modified to provide for a Monthly
retainer of $15,000, and to eliminate the per diem rate. During the nine months
ended September 30, 2004 the Company recorded $135,000 of consulting fees in
connection with this agreement. As of September 30, 2004, $28,509 related to
this agreement was included in accounts payable at September 30, 2004.
In February 2003, the Company paid consulting fees in the amount of
$110,000 to a corporation controlled by Peter Lewis and David Eisenberg, two
shareholders, each of whom own beneficially in excess of 5% of the outstanding
shares of common stock of the Company, related to services provided in
connection with the finalization of the Merger Agreement. In April 2003, the
Company entered into a consulting agreement with this corporation pursuant to
which, the Corporation is entitled to receive a monthly fee of $15,000, provided
however that payment of accrued fees is not payable by the Company until such
time as the Company has a minimum cash balance of $2.5 million. Pursuant to this
agreement, $135,000 in consulting fees were recorded during both 2003, and for
the nine months ended September 30, 2004, and as of September 30, 2004 a total
of $270,000 was included in accrued liabilities. During 2003, the Company
recorded finders fee expenses totaling $30,000 for amounts earned by Peter Lewis
and the corporation, in connection with private equity placements by the
Company. Of the total finders fees earned, $15,000 was paid during 2003, and
$15,000 is included in accrued expenses at December 31, 2003 and September 30,
2004.
In July 2003, Richard H. Keates, M.D., a director, purchased 100,000
shares of the Company's common stock in a private placement of equity securities
for $100,000. In connection with this investment, Dr. Keates also received
100,000 5-year warrants to purchase common stock at an exercise price of $2.25.
In November 2003 and October 2004, directors received options to
purchase shares of the company's common stock as follows:
Grant Date November 10, 2003 October 20, 2004
Exercise Price $1.10 $0.40
Director Options Options
-------- ------- -------
Laurence Schreiber 200,000 200,000
Randal Bailey 200,000 200,000
Richard H. Keates, M.D. 200,000 200,000
Norman Schwartz 75,000 100,000
Adam Krupp 25,000 25,000
In April 2004, the Company and FEI entered into an agreement pursuant
to which FEI loaned the Company shares owned by FEI, for use by the Company as
collateral in subsequent financing transactions. In return, the Company agreed
to reduce the exercise price of 1,543,000 warrants previously issued to FEI from
$5.00 per share to $1.00 per share. In connection with the warrant re-pricing
the Company recorded a non-cash expense of $546,403 during the second quarter
based on a Black-Scholes model valuation.
In April 2004, the Company and Taika Investments, Inc. a corporation
that beneficially owns in excess of 5% of the outstanding shares of Common Stock
of the Company, entered into an agreement pursuant to which Taika agreed to make
available 3 million shares of the Company's common stock, for use by the Company
in subsequent financing transactions. In accordance with the terms of this
agreement, the Company is obligated to pay interest on the value of shares
borrowed (assuming a value of $1.00 per share) based on the LIBOR rate plus 50
basis points, and must return the borrowed shares by November 30, 2004. In
January, the Company received a one-year extension, to November 30, 2005, of the
date by which any borrowed shares must be returned. In the event of default, the
Company has agreed to file a Registration Statement and to return any shares,
within 72 hours, that had not previously been returned by the due date. As of
September 30, 2004 the Company had borrowed a total of 800,000 shares pursuant
to this agreement, and the Company had accrued interest expense totaling
$25,725.
In May 2004 the Company received a working capital advance in the
amount of $200,000 from an individual related to the controlling stockholder of
FEI, and in June 2004, the advance was repaid.
In October 1998 VisiJet and SurgiJet, Inc., the former parent company
of VisiJet, and an entity controlled by Lance Doherty, who beneficially owns in
excess of 5% of the outstanding shares of common stock of the Company, entered
into a patent license agreement. This agreement, amended in November 2002,
requires VisiJet to pay a royalty of 7% of revenues received from sales of the
products utilizing licensed patents and technology, up to $400 million of
revenues over the course of the Agreements, and 5% of revenues thereafter. The
agreement provides for a minimum royalty of $60,000 per year. To date, the
Company has paid a total of $180,000 in minimum royalty payments to SurgiJet,
and, as of September 30, 2004 $45,000 in minimum royalty payments were accrued.
Also, in November 2004, the Company and SurgiJet entered into a
litigation settlement agreement pursuant to which the parties agreed to settle
all previously outstanding litigation between the two companies, as well as with
SurgiJet's principal owners and its subsidiary, DentaJet. In accordance with the
settlement agreement, the Company, agreed to pay a total of $579,774, plus
accrued interest at an annual rate of 7.5% from August 31, 2004, as full
settlement of previously disputed notes payable to SurgiJet and DentaJet and
related accrued interest which the Company was carrying on its books in the
aggregate amount of $580,718. In addition, the Company agreed to pay a
previously disputed note payable to Lance Doherty in the amount of $19,000 plus
accrued interest at an annual rate of 10% from December 31, 2002, which the
Company was carrying on its books in the aggregate amount of $24,678. In
addition, the Company agreed to issue 75,000 shares of its Common Stock to
SurgiJet, granted SurgiJet a security interest in all of its assets and agreed
to provide SurgiJet with a stipulated judgment, which can only be filed by
SurgiJet upon an event of default which remains uncured following 10 days after
receipt of written notice of such default. Payments on all obligations due
pursuant to the settlement agreement will be made in monthly installments
commencing December 1, 2004. The first payment was in the amount of $30,000, and
thereafter monthly payments are $20,000 through December 2005, and $25,000 from
January 1, 2006 until the obligations are paid in full.
In June 2004, the Company entered into convertible debenture agreements
with Bushido Capital Master Fund, L.P. ("Bushido"), and Bridges & Pipes, LLC
("Bridges & Pipes"), with principal balances of $600,000 and $400,000,
respectively. After subtracting related placement agent fees and expenses
totaling $120,000, net proceeds to the Company from the aggregate of the
$1,000,000 principal balance were $880,000.
Pursuant to the June 2004 agreements, the debentures bear interest at
an annual rate of 8%, which is payable quarterly beginning December 31, 2004,
and the principal balance of the debentures was due and payable on June 24,
2006. In addition, the debenture holders received an aggregate of 150,000 shares
of the company's common stock, and an aggregate of 750,000 warrants to purchase
shares of the Company's common stock, exercisable through June 24, 2009, at an
exercise price of $1.50 per share, provided however that the exercise price with
respect to an aggregate of 500,000 of the warrants is reduced to $0.60 per share
during the period from the date of issuance through the date twelve (12) months
after the Securities and Exchange Commission declares effective a registration
statement registering the resale of shares underlying the warrants. The
debentures were secured by an aggregate of 350,000 shares of the Company's
common stock issued by the Company, and the outstanding principal of the
debentures was convertible, subject to redemption rights of the Company, into
shares of the Company's common stock based on an initial conversion price of
$0.50, subject to adjustment as defined in the agreement.
In connection with these debentures, the Company entered into a
Registration Rights Agreement with the debenture holders related to the
warrantsand shares underlying the conversion feature of the debentures that
required the Company to file a Registration Statement with the Securities and
Exchange within 30 days of the closing of the transaction. Due to the Company's
failure to file the Registration Statement within 30 days, the Company was not
in compliance with this requirement of the agreement.
In October 2004 the Company received a waiver of the non-compliance in
connection with an amendment to the debenture agreements pursuant to which the
maturity dates of the debentures were extended to June 24, 2014, the exercise
price of the original 750,000 warrants issued in connection with these
convertible debenture agreements was reduced to $0.40 per share, the debenture
holders received an additional 250,000 warrants at an exercise price of $0.40
per share and the initial conversion price of the debt was reduced to $0.35. In
addition, in connection with this amendment, the Company released the 350,000
shares of common stock that was being held as collateral, to the note holders.
In January 2005 the amended debenture agreements with Bushido and
Bridges & Pipes were replaced with new convertible debenture agreements in order
to conform the terms of these agreements to the terms of new convertible
debenture agreements with an aggregate principal balance of $4,845,000 entered
into in January 2005, as described below. Under the replacement agreements, the
maturity dates of the debentures were extended to January 14, 2015, and other
principal terms (i.e. interest rate, conversion price, warrants issued and
warrant exercise price) remained the same as in the amended October agreements
described above.
In July 2004, the Company entered into a convertible debenture
agreement with Libertyview Special Opportunities Fund, L.P. ("Libertyview"),
with a principal balance of $1,000,000, and received net proceeds of $896,125
after subtracting related placement agent fees and expenses totaling $103,875.
Pursuant to the July 2004 agreement, the note bears interest, at an annual rate
of 8%, which is due and payable quarterly beginning on October 31, 2004, and the
principal balance of the note, plus any accrued and unpaid interest, was due and
payable on July 23, 2014, provided however, that on or after July 31, 2007 the
Company, at the option of the note holder, may have been obligated to repurchase
the note at a price equal to 100% of the outstanding principal and interest. In
addition, the debenture holders received warrants to purchase 750,000 shares of
the Company's common stock, exercisable through July 23, 2011, at an exercise
price of $1.00 per share. In addition, the outstanding principal of the
debentures was convertible into shares of the Company's common stock, at the
option of the note holder, based on an initial conversion price of $0.54 per
share, subject to adjustment as defined in the agreement.
In connection with these debentures, the Company entered into a
Registration Rights Agreement with the debenture holders related to the warrants
and shares underlying the conversion feature of the debentures that required the
Company to file a Registration Statement with the Securities and Exchange within
30 days of the closing of the transaction. Due to the Company's failure to file
the Registration Statement within 30 days, the Company was not in compliance
with this requirement of the agreement.
In October 2004 the Company received a waiver of the non-compliance in
connection with an amendment to the debenture agreement pursuant to which the
exercise price of the original 750,000 warrants issued in connection with the
convertible debenture agreement was reduced to $0.40 per share, the debenture
holder received an additional 250,000 warrants at an exercise price of $0.40 per
share and the initial conversion price of the debt was reduced to $0.35.
In January 2005 the amended debenture agreement with Libertyview was
replaced with a new convertible debenture agreement in order to conform the
terms of the agreement to the terms of new convertible debenture agreements
entered into in January 2005 with an aggregate principal balance of $4,845,000,
as described below. Under the replacement agreement, the maturity dates of the
debenture was extended to January 14, 2015, and other principal terms (i.e.
interest rate, conversion price, warrants issued and warrant exercise price)
remained the same as in the October amended October agreement described above.
In December 2004 the Company entered into a debenture agreement with
Alpha Capital Aktiengesellschaft ("Alpha")with a principal balance of $500,000.
The debenture was due and payable on January 27, 2005, and was convertible into
shares of the Company's common stock, at the option of the note holder, based on
an conversion price equal to 80% of the closing bid price of the Company's
common stock on the date of conversion, in the event that the debenture was not
repaid on the scheduled maturity date, or in the event of a default under the
agreement. In connection with the debenture, Alpha received 142,857 shares of
the Company's common stock, and 5-year warrants to purchase 1,250,000 shares of
the Company's common stock at an exercise price of $0.40 per share. In January
2005, the Company repaid the entire $500,000 outstanding principal balance, and
the debenture agreement was cancelled.
In January 2005, the Company entered into convertible debenture
agreements with Renaissance Capital ("Renaissance"), Roaring Fork Capital SBIC
("Roaring Fork") and Alpha with principal balances of $2,500,000, $650,000 and
$350,000, respectively. The notes bear interest, at an annual rate of 8%, which
is due and payable quarterly beginning March 31, 2005. The principal balance of
the notes, plus any accrued and unpaid interest is due and payable on January
14, 2015, provided however, that on or after January 14, 2008 the Company, at
the option of the note holder, may be obligated to repurchase the note at a
price equal to 100% of the outstanding principal and interest. The outstanding
principal of the debentures may be converted into shares of the Company's common
stock, at the option of the note holder, based on an initial conversion price of
$0.35 per share, subject to adjustment as defined in the agreement. In addition,
Renaissance received warrants to purchase 2,500,000 shares of the Company's
common stock, Roaring Fork received warrants to purchase 650,000 shares of the
Company's common stock and Alpha received warrants to purchase 350,000 shares of
the Company's common stock, all of which are exercisable through January 14,
2010 at an exercise price of $0.40 per share. Alpha also received 15,714 shares
of the Company's stock as a commission.
DESCRIPTION OF SECURITIES
The following summary is a description of our common stock and certain
provisions of our Certificate of Incorporation, Bylaws and Delaware law.
GENERAL
Our authorized capital consists of 100,000,000 shares of common stock,
par value $.001 per share and 10,000,000 shares of preferred stock, par value
$.001 per share.
Common Stock
As of December 31, 2004, we had 28,677,520 shares of Common Stock
outstanding. Each share is entitled to one vote at all meetings of our
stockholders. All shares of our common stock are equal to each other with
respect to liquidation rights and dividend rights. There are no preemptive
rights to purchase any additional shares of our common stock. In the event of
our liquidation, dissolution or winding up, holders of our common stock will be
entitled to receive, on a pro rata basis, all of our assets remaining after
satisfaction of all liabilities and preferences of outstanding preferred stock,
if any. Neither our Certificate of Incorporation nor our Bylaws contain any
provisions which limit or restrict the ability of another person to take over
our company.
Preferred Stock
SERIES A CONVERTIBLE PREFERRED
As of October 15, 2004, we had 450,000 shares of Series A Convertible
Preferred Stock ("Series A Preferred Stock")outstanding. The Preferred Stock was
issued with an aggregate stated value of $4,500,000 and is nonvoting, except as
required by Delaware law. The holders of the Series A Preferred Stock are not
entitled to receive any dividends, and the Series A Preferred Stock is
convertible, at any time at the holder's option, for a period of three years
from the date of issuance, into shares of our Common Stock. The number of shares
of Common Stock to be issued upon conversion is determined by dividing the
stated value being converted by the conversion price then in effect. The
conversion price of the Series A Preferred Stock is the lower of (i) $0.609 per
share and (ii) eighty percent of the lowest closing bid price of the Common
Stock in the ten trading days preceding the date of conversion, but in no event
less than $.18 per share. The conversion price is subject to further adjustment
based on anti-dilution provisions. Any shares not previously converted are
automatically converted at the expiration of the three year period
OPTIONS AND WARRANTS
As of October 15, 2004, we had outstanding options to purchase an
aggregate of 1,145,000 shares of our Common Stock pursuant to our 2003 Stock
Option Plan, at a weighted-average exercise price of $1.10 per share. These
options are held by directors, officers, key employees and consultants. As of
October 15, 2004, options to purchase 370,000 shares were exercisable.
As of October 15, 2004 we also have outstanding warrants to purchase
18,749,146 shares of our Common Stock, with a weighted-average exercise price of
$1.57 per share.
TRANSFER AGENT
The transfer agent for our common stock is Nevada Agency and Trust
Company, Reno, Nevada.
SHARES ELIGIBLE FOR RESALE
Future sales of a substantial number of shares of our common stock in
the public market could adversely affect market prices prevailing from time to
time. Under the terms of this offering, the shares of common stock offered may
be resold without restriction or further registration under the Securities Act
of 1933, except that any shares purchased by our "affiliates," as that term is
defined under the Securities Act, may generally only be sold in compliance with
Rule 144 under the Securities Act.
Certain shares of our outstanding common stock were issued and sold by
us in private transactions in reliance upon exemptions from registration under
the Securities Act and have not been registered for resale. Additional shares
may be issued pursuant to outstanding warrants and options. Such shares may be
sold only pursuant to an effective registration statement filed by us or an
applicable exemption, including the exemption contained in Rule 144 promulgated
under the Securities Act.
In general, under Rule 144 as currently in effect, a stockholder,
including one of our affiliates, may sell shares of common stock after at least
one year has elapsed since such shares were acquired from us or our affiliate.
The number of shares of common stock which may be sold within any three-month
period is limited to the greater of: (i) one percent of our then outstanding
common stock, or (ii) the average weekly trading volume in our common stock
during the four calendar weeks preceding the date on which notice of such sale
was filed under Rule 144. Certain other requirements of Rule 144 concerning
availability of public information, manner of sale and notice of sale must also
be satisfied. In addition, a stockholder who is not our affiliate, who has not
been our affiliate for 90 days prior to the sale, and who has beneficially owned
shares acquired from us or our affiliate for over two years may resell the
shares of common stock without compliance with many of the foregoing
requirements under Rule 144.
SELLING STOCKHOLDERS
The shares are being offered by certain selling stockholders. To our
knowledge, except as shown in the table below, none of the selling shareholders
are broker-dealers, or affiliates of broker-dealers. The selling stockholders
may offer and sell up to 49,428,637 shares now owned by them or issuable to them
upon the exercise of warrants and conversion of debt.
The selling stockholders may from time to time offer and sell any or
all of the shares that are registered under this prospectus. Because the selling
stockholders are not obligated to sell their shares, and because the selling
stockholders may also acquire publicly traded shares of our common stock, we
cannot estimate how many shares the selling stockholders will own after the
offering.
All expenses incurred with respect to the registration of the shares
will be borne by us, but we will not be obligated to pay any underwriting fees,
discounts, commissions or other expenses incurred by the selling stockholders in
connection with the sale of their shares.
The following table sets forth, with respect to the selling
stockholders (i) the number of shares of common stock beneficially owned as of
December 31, 2004 and prior to the offering contemplated hereby, (ii) the
maximum number of shares of common stock which may be sold by the selling
stockholder under this prospectus, and (iii) the number of shares of common
stock which will be owned after the offering by the selling stockholder:
Prior to Offering After Offering (1)
----------------------- --------------------
Name Shares Percent Offered Shares Percent
------------------------- ------ ------- ------- ------ -------
Libertyview Special Opportunities
Fund, LP* (2) 6,544,260 18.64% 6,544,260 - 0.00%
Renaissance US Growth Investment
Trust, PLC (3) 3,857,143 11.86% 3,857,143 - 0.00%
BFS US Special Opportunities
Trust, PLC (3) 3,857,143 11.86% 3,857,143 - 0.00%
Bushido Capital Master Fund LP (4) 3,139,549 9.99% 3,139,549 - 0.00%
Alpha Capital Aktiengesellschaft(5) 2,758,571 8.79% 2,758,571 - 0.00%
Bridges & Pipes LLC (6) 2,742,681 8.80% 2,742,681 - 0.00%
Roaring Fork Capital
SBIC, LP(7) 2,507,143 8.04% 2,507,143 - 0.00%
Corsair Capital Partners, LP(8) 2,449,286 7.87% 2,449,286 - 0.00%
Ronald P. Russo, Jr. 2,188,456 7.15% 2,188,456 - 0.00%
Rennaissance Capital Growth &
Income Fund III, Inc.(3) 1,928,571 6.30% 1,928,571 - 0.00%
Stan Chessed 1,407,000 4.79% 1,407,000 - 0.00%
Gamma Opportunity Capital
Partners (9) 1,352,632 4.50% 1,352,632 - 0.00%
639604 Ontario Limited(10) 1,250,000 4.18% 1,250,000 - 0.00%
Wyatt Landesmann 965,000 3.30% 965,000 - 0.00%
Mallos Living Trust(11) 900,000 3.09% 900,000 - 0.00%
Republic Aggressive Growth Fund(12) 848,571 2.87% 848,571 - 0.00%
Little Gem Life Sciences
Fund, LLC (13) 836,591 2.83% 836,591 - 0.00%
Platinum Long Term Growth (14) 733,332 2.49% 733,332 - 0.00%
Prior to Offering After Offering (1)
----------------------- --------------------
Name Shares Percent Offered Shares Percent
------------------------- ------ ------- ------- ------ -------
HIT Credit Union (15) 500,000 1.71% 500,000 - 0.00%
Greenwhich Growth Fund, Ltd.(16) 482,143 1.65% 482,143 - 0.00%
Fridolin Fackelmayer 400,000 1.39% 400,000 - 0.00%
Marshalarts, LLC (17) 400,000 1.39% 400,000 - 0.00%
Cethron Property Management Inc.(18) 350,000 1.21% 350,000 - 0.00%
Corsair Capital Investors, Ltd.(8) 347,143 1.20% 347,143 - 0.00%
Rock II, LLC (19) 333,334 1.15% 333,334 - 0.00%
Stuart Russo 302,395 1.05% 302,395 - 0.00%
US Euro Securities, Inc.*(20) 243,162 0.84% 243,162 - 0.00%
Brandon D. Cohen 220,000 0.76% 220,000 - 0.00%
Transcontinental Financial
Resources(21) 200,000 0.69% 200,000 - 0.00%
Wachovia Securities C/F Charles
Pierce IRA(22) 200,000 0.69% 200,000 - 0.00%
Elizabeth Wheeler 200,000 0.69% 200,000 - 0.00%
Mark Wheeler 200,000 0.69% 200,000 - 0.00%
Mark M. Wheeler IRA 200,000 0.69% 200,000 - 0.00%
Zorina Bennett 200,000 0.69% 200,000 - 0.00%
Charles E. Blair 200,000 0.69% 200,000 - 0.00%
John P. Dempsey 200,000 0.69% 200,000 - 0.00%
Stephen & Kathleen Guarino 187,500 0.65% 187,500 - 0.00%
Sattinwood Inc.(23) 160,000 0.56% 160,000 - 0.00%
Westcap Securities*(24) 150,000 0.52% 150,000 - 0.00%
Shipman & Goodwin LLP Profit
Sharing Plan FBO James T. Betts(25) 100,000 0.35% 100,000 - 0.00%
James T. Betts, Trustee U/A T.J. and
H.M. Betts Dated May 26, 1983(25) 100,000 0.35% 100,000 - 0.00%
Roman Feldman & Irina Krym, JTTEN 100,000 0.35% 100,000 - 0.00%
One Six Partners(26) 100,000 0.35% 100,000 - 0.00%
Goren Brothers LP(27) 100,000 0.35% 100,000 - 0.00%
Alan Gray 100,000 0.35% 100,000 - 0.00%
J. Charles Pierce 100,000 0.35% 100,000 - 0.00%
Olen C. Wilson 100,000 0.35% 100,000 - 0.00%
Prior to Offering After Offering (1)
----------------------- --------------------
Name Shares Percent Offered Shares Percent
------------------------- ------ ------- ------- ------ -------
Richard L. Tuch 100,000 0.35% 100,000 - 0.00%
Richard Payne & Sherry Payne 100,000 0.35% 100,000 - 0.00%
Jon Bolker 100,000 0.35% 100,000 - 0.00%
Porter Family Trust(28) 100,000 0.35% 100,000 - 0.00%
Brooke Niemi 100,000 0.35% 100,000 - 0.00%
Douglas G. May 100,000 0.35% 100,000 - 0.00%
James V. May 100,000 0.35% 100,000 - 0.00%
Capital Investment Services, Inc.*(29) 100,000 0.35% 100,000 - 0.00%
Asher Gottesman 100,000 0.35% 100,000 - 0.00%
Corsair Capital Partners 100, LP(8) 96,429 0.34% 96,429 - 0.00%
Martin A. Benowitz 75,000 0.26% 75,000 - 0.00%
N.J. Olivieri 75,000 0.26% 75,000 - 0.00%
Smedly Hendrickson 70,000 0.24% 70,000 - 0.00%
Ascendiant Capital Group, LLC*(30) 60,000 0.21% 60,000 - 0.00%
George Haralanpoudis 56,156 0.20% 56,156 - 0.00%
Zach Alcyone & Anne Alcyone 50,000 0.17% 50,000 - 0.00%
Felix Aronsky 50,000 0.17% 50,000 - 0.00%
Daniela Brabner-Smith 50,000 0.17% 50,000 - 0.00%
Robert M. Campbell Jr. 50,000 0.17% 50,000 - 0.00%
Hoa Le Duong 50,000 0.17% 50,000 - 0.00%
Vallery Dubovikov 50,000 0.17% 50,000 - 0.00%
Steven Efman 50,000 0.17% 50,000 - 0.00%
Fred Efman 50,000 0.17% 50,000 - 0.00%
Marvin Schwartz 50,000 0.17% 50,000 - 0.00%
Vladamir Lieberman 50,000 0.17% 50,000 - 0.00%
Richard Monka 50,000 0.17% 50,000 - 0.00%
Mikhail Nemets 50,000 0.17% 50,000 - 0.00%
Alexander Onik 50,000 0.17% 50,000 - 0.00%
Roslyn Pinkus and Frank Pinkus 50,000 0.17% 50,000 - 0.00%
Van S. Bohne 50,000 0.17% 50,000 - 0.00%
Michael Bergman 50,000 0.17% 50,000 - 0.00%
Michael Hamblett 50,000 0.17% 50,000 - 0.00%
Larry L. Hood(31) 246,948 0.86% 46,948 200,000 0.69%
Michael Cimaron 45,000 0.16% 45,000 - 0.00%
Prior to Offering After Offering (1)
----------------------- --------------------
Name Shares Percent Offered Shares Percent
------------------------- ------ ------- ------- ------ -------
SBI USA, LLC(15) 37,500 0.13% 37,500 - 0.00%
Phoenix Capital, Inc.(32) 37,500 0.13% 37,500 - 0.00%
Timothy Roberts 37,500 0.13% 37,500 - 0.00%
Jay Standish 30,000 0.10% 30,000 - 0.00%
Alan Stone & Co., Ltd.(33) 27,000 0.09% 27,000 - 0.00%
Thomas DeMele 25,000 0.09% 25,000 - 0.00%
Robert F. Kull 25,000 0.09% 25,000 - 0.00%
Ranchers Management Service Inc.
Profit Sharing Plan(34) 25,000 0.9% 25,000 - 0.00%
Starboard Capital*(35) 25,000 0.09% 25,000 - 0.00%
Anthony Spatacco 25,000 0.09% 25,000 - 0.00%
David Bench 20,000 0.07% 20,000 - 0.00%
Asher & Danielle Weinfeld, JTTEN 19,200 0.07% 19,200 - 0.00%
Kenneth D. & Ethne S. Katz, JTTEN 16,000 0.06% 16,000 - 0.00%
Mordechai & Melanie Smith, JTTEN 16,000 0.06% 16,000 - 0.00%
Hershel & Lara Goulson, JTTEN 16,000 0.06% 16,000 - 0.00%
Simon & Eva Weinfeld, JTTEN 12,800 0.04% 12,800 - 0.00%
Rand Brenner 9,000 0.03% 9,000 - 0.00%
Tafkid, LLC (36) 9,000 0.03% 9,000 - 0.00%
----------
* Denotes entity that is a broker-dealer or an affiliate of broker-dealer.
(1) For purposes of this table, we have assumed that the Selling Stockholders
will sell in this offering all shares offered.
(2) Controlled by Ryan Hay. Includes 5,094,260 shares underlying $1,450,000
principal balance of convertible debt based on initial conversion price of
$0.35.
(3) Controlled by Robert Pearson Includes 7,142,857 shares underlying an
aggregate $2,500,000 principal balance of convertible debt based on initial
conversion price of $0.35.
(4) Controlled by Louis Rabman. Includes 1,714,286 shares underlying $600,000
principal balance of convertible debt based on initial conversion price of
$0.35.
(5) Controlled by Konrad Ackerman. Includes 1,428,571 shares underlying
$350,000 principal balance of convertible debt based on initial conversion
price of $0.35.
(6) Controlled by David Fuchs. Includes 1,571,429 shares underlying $550,000
principal balance of convertible debt based on initial conversion price of
$0.35.
(7) Controlled by Gene McCully. Includes 1,857,143 shares underlying $650,000
principal balance of convertible debt based on initial conversion price of
$0.35.
(8) Controlled by Jay Petschek. Includes 2,142,858 shares underlying an
aggregate $750,000 principal balance of convertible debt based on initial
conversion price of $0.35.
(9) Controlled by Jonathon P. Knight. Includes 857,143 shares underlying
$300,000 principal balance of convertible debt based on initial conversion
price of $0.35.
(10) Controlled by Melvyn Solmon
(11) Controlled by C. Thomas Mallos and Barbara K. Mallos, trustees.
(12) Controlled by Matt Drillman. Includes 624,571 shares underlying $220,000
principal balance of convertible debt based on initial conversion price of
$0.35
(13) Controlled by Jeffrey Benison. Includes 571,428 shares underlying $200,000
principal balance of convertible debt based on initial conversion price of
$0.35
(14) Controlled by Mark Nordlitch
(15) Controlled by Shelly Singhal
(16) Controlled by Evan Schemenauer. Includes 357,143 shares underlying $125,000
principal balance of convertible debt based on initial conversion price of
$0.35.
(17) Controlled by Dana Marshall Cook
(18) Controlled by Robert I. Adatto
(19) Controlled by Mike Grady
(20) Controlled by Ronald P. Russo, Jr.
(21) Controlled by Kenneth Rubinstein
(22) Controlled by Charles Pierce
(23) Controlled by Yosef Ram
(24) Controlled by Thomas Rubin
(25) Controlled by James T. Betts
(26) Controlled by Robert Gopen
(27) Controlled by James G. Goren and Alexander M. Goren
(28) Controlled by Sanford Porter, trustee
(29) Controlled by Robert J. Escobio
(30) Controlled by Bradley J. Wilhite
(31) Mr. Hood is VisiJet's Chief Engineer.
(32) Controlled by Roger Tischenor
(33) Controlled by Alan Stone
(34) Controlled by Robert L. Kull
(35) Controlled by Anthony Spatacco
(36) Controlled by Antony Gordon
PLAN OF DISTRIBUTION
GENERAL
Shares of common stock offered through this prospectus may be sold from
time to time directly by the selling stockholders or, alternatively, through
underwriters, broker-dealers or agents. If the shares are sold through
underwriters, broker-dealers or agents, the selling stockholders will be
responsible for underwriting discounts or commissions or agents' commissions.
Shares may be sold in one or more transactions at fixed prices, at prevailing
market prices at the time of sale, at varying prices determined at the time of
sale or at negotiated prices. Sales may be effected in transactions (which may
involve block transactions) (i) in the over-the-counter market, (ii) on any
securities exchange or quotation service on which the shares may be listed or
quoted at the time of sale, (iii) in transactions otherwise than in the
over-the- counter market or on such exchanges or services, or (iv) through the
writing of options. In connection with sales of shares or otherwise, the selling
stockholders may enter into hedging transactions with broker-dealers, which may
in turn engage in short sales of the shares in the course of hedging positions
they assume. The selling stockholders may also sell our common stock short and
deliver shares to close out short positions, or loan or pledge shares to
broker-dealers that in turn may sell such securities.
The selling stockholders will act independently from us in making decisions
with respect to the manner, timing, price and size of each sale. The selling
stockholders may sell the shares in any manner permitted by law, including one
or more of the following:
* a block trade in which a broker-dealer engaged by a selling
stockholder will attempt to sell the Shares as agent, but may position
and resell a portion of the block as principal to facilitate the
transaction;
* purchases by a broker-dealer as principal and resale by such
broker-dealer for its account under this prospectus;
* an over-the-counter distribution in accordance with the rules of the
OTC Bulletin Board;
* ordinary brokerage transactions in which the broker solicits
purchasers; and
* privately negotiated transactions.
In the event that the sale of any shares covered by this prospectus
qualifies for an exemption from the registration requirements of the Securities
Act, such shares may be sold pursuant to that exemption rather than pursuant to
this prospectus.
USE OF UNDERWRITERS, BROKERS, DEALERS OR AGENTS
If the selling stockholders effect sales of shares through underwriters,
brokers, dealers or agents, such underwriters, brokers, dealers or agents may
receive compensation in the form of discounts, concessions or commissions from
the selling stockholders or commissions from purchasers of common stock for whom
they may act as agent (which discounts, concessions or commissions as to
particular underwriters, brokers, dealers or agents may be in excess of those
customary in the types of transactions involved). Any brokers, dealers or agents
that participate in the distribution of the shares may be deemed to be
underwriters, and any profit on the sale of common stock by them and any
discounts, concessions or commissions received by any such underwriters,
brokers, dealers or agents may be deemed to be underwriting discounts and
commissions under the Securities Act.
If a selling stockholder sells shares through an underwriter, broker,
dealer or agent, it may agree to indemnify such underwriter, broker, dealer or
agent against certain liabilities arising from such sale, including liabilities
arising under the Securities Act.
PENNY STOCK RULE
THE "PENNY STOCK RULE" COULD MAKE IT DIFFICULT FOR BROKERS AND DEALERS TO TRADE
IN OUR STOCK, WHICH COULD CAUSE THE MARKET FOR OUR STOCK TO BE LESS LIQUID,
WHICH COULD CAUSE THE PRICE OF OUR STOCK TO DECLINE.
Trading of our common stock on the OTC Bulletin Board may be subject to
certain provisions of the Securities Exchange Act of 1934, commonly referred to
as the "penny stock" rule. A penny stock is generally defined to be any equity
security that has a market price less than $5.00 per share, subject to certain
exceptions. If our stock is deemed to be a penny stock, trading in our stock
will be subject to additional sales practice requirements on broker-dealers.
These may require a broker dealer to:
* make a special suitability determination for purchasers of our
shares;
* receive the purchaser's written consent to the transaction prior
to the purchase; and
* deliver to a prospective purchaser of our stock, prior to the first
transaction, a risk disclosure document relating to the penny stock
market.
Consequently, penny stock rules may restrict the ability of broker- dealers
to trade and/or maintain a market in our common stock. Also, prospective
investors may not want to get involved with the additional administrative
requirements, which may have a material adverse effect on the trading of our
shares.
LEGAL MATTERS
The validity of the issuance of the common stock offered hereby will be
passed upon for us by Haddan & Zepfel LLP, Newport Beach, California.
EXPERTS
The financial statements of VisiJet as of and for the years ended December
31, 2003 and 2002, appearing in this prospectus have been audited by Peterson &
Co., LLP, Certified Public Accountants, as set forth in their report thereon
appearing elsewhere herein, and are included in reliance upon such reports given
upon the authority of such firm as experts in accounting and auditing.
WHERE YOU CAN FIND ADDITIONAL INFORMATION
VisiJet files current, quarterly and annual reports with the SEC on forms
8-K, 10-QSB and 10-KSB. VisiJet has filed with the SEC under the Securities Act
of 1933 a registration statement on Form SB-2 with respect to the shares being
offered in this offering. This prospectus does not contain all of the
information set forth in the registration statement, certain items of which are
omitted in accordance with the rules and regulations of the SEC. The omitted
information may be inspected and copied at the Public Reference Room maintained
by the SEC at Judiciary Plaza, 450 Fifth Street, N.W., Washington, D.C. 20549.
You can obtain information about operation of the Public Reference Room by
calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet site that
contains reports, proxy and information statements, and other information
regarding issuers that file electronically with the SEC at HTTP://WWW.SEC.GOV.
Copies of such material can be obtained from the public reference section of the
SEC at prescribed rates. Statements contained in this prospectus as to the
contents of any contract or other document filed as an exhibit to the
registration statement are not necessarily complete and in each instance
reference is made to the copy of the document filed as an exhibit to the
registration statement, each statement made in this prospectus relating to such
documents being qualified in all respect by such reference.
For further information with respect to VisiJet and the securities being
offered hereby, reference is hereby made to the registration statement,
including the exhibits thereto and the financial statements, notes, and
schedules filed as a part thereof.
VISIJET, INC.
(A Development Stage Company)
AUDITED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2003 AND 2002
AND
UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2004
INDEX
-----
Page
----
Independent Auditor's Report 45
Balance Sheets, December 31, 2003 and 2002 46
Statements of Operations for the years ended December 31, 2003 and
2002 and for the period February 2, 1996 (inception) to
December 31, 2003 47
Statements of Changes in Stockholders' Deficit for the years ended
December 31, 2003 and 2002 48
Statements of Cash Flows for the years ended December 31, 2003
and 2002 and for the period February 2, 1996 (inception) to
December 31, 2003 49
Notes to Financial Statements, December 31, 2003 50
Balance Sheets, September 30, 2004 (unaudited) and December 31, 2003 67
Unaudited Statements of Operations for the Three and Nine Months
Ended September 30, 2004 and 2003 68
Unaudited Statements of Cash Flows for the Nine Months
Ended September 30, 2004 69
Unaudited Statements of Changes in Stockholders' Deficit for the
nine months September 30, 2004
Notes to Unaudited Financial Statements 70
INDEPENDENT AUDITOR'S REPORT
Board of Directors and Stockholders
VISIJET, INC.
(A Development Stage Company)
Irvine, California
We have audited the accompanying balance sheets of VisiJet, Inc. (A Development
Stage Company) as of December 31, 2003 and 2002, and the related statements of
operations, shareholders' equity (deficit), and cash flows for the years then
ended. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audits to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of VisiJet, Inc. (A Development
Stage Company) as of December 31, 2003 and 2002 and the results of its
operations and its cash flows for the years then ended and for the period from
February 2, 1996 (inception) to December 31, 2003, in conformity with accounting
principles generally accepted in the United States of America.
As discussed in Note 1 to the financial statements, VisiJet, Inc. (A Development
Stage Company) has reported accumulated losses during the development stage
aggregating $10,776,219 and without additional financing, lacks sufficient
working capital to fund operations beyond March 2004, which raises substantial
doubt about its ability to continue as a going concern. Management's plans in
regard to these matters are also described in Note 1. The financial statements
do not include any adjustments to reflect the possible future effects on the
recoverability and classifications of assets or the amounts and classification
of liabilities that may result from the outcome of this uncertainty.
/s/ Peterson & Co., LLP
March 26, 2004 (except for Note 14 for which
the date is April 14, 2004)
VisiJet, Inc.
(A development stage company)
Balance Sheets
December 31,
2003 2002
------------- -------------
ASSETS
Current assets:
Cash and cash equivalents $ 35,879 $ 960
Prepaid expenses 88,749 --
------------- -------------
Total current assets 124,628 960
Property and equipment, net 104,440 47,443
Patents and trademarks, net 97,244 --
------------- -------------
Total assets $ 326,312 $ 48,403
============= =============
LIABILITIES AND SHAREHOLDER'S DEFICIT
Current liabilities:
Accounts payable $ 679,885 $ 196,985
Compensation settlement agreement - current portion 86,708 595,833
Accrued interest 109,232 160,837
Accrued expenses 481,106 130,469
Royalty payable 60,000 60,000
Notes payable to related parties 681,442 1,543,843
Notes payable - current portion 14,000 --
------------- -------------
Total current liabilities 2,112,373 2,687,967
Compensation settlement agreement, net of current portion 17,458 104,167
Notes payable to related parties, net of current portion 87,144 --
------------- -------------
Total liabilities 2,216,975 2,792,134
------------- -------------
Shareholders' deficit:
Common stock, no par value; no shares authorized or issued at December 31,
2003, and 10,000,000 shares authorized;
7,997,735 shares issued and outstanding at December 31, 2002, -- 615,248
Common stock, 50,000,000 shares authorized, $.001 par value,
21,691,163 shares issued and outstanding at December 31, 2003, and
no shares authorized or issued at December 31, 2002 21,691 --
Preferred stock, 10,000,000 shares authorized, $.001 par value,
no shares outstanding at December 31, 2003 and no shares authorized
or issued at December 31, 2002 -- --
Preferred stock, no par value; 5,000,000 shares authorized;
no shares outstanding at December 31, 2003
140,306 Series A shares issued and outstanding at December 31,2002, -- 550,000
no shares outstanding at December 31, 2003
636,364 Series B shares authorized; 363,946 shares issued and
outstanding at December 31, 2002, -- 1,908,088
Additional paid in capital 7,845,365
Common stock subscriptions 1,018,500 --
Deficit accumulated during development stage (10,776,219) (5,817,067)
------------- -------------
Shareholders' deficit (1,890,663) (2,743,731)
------------- -------------
Total liabilities and shareholders' deficit $ 326,312 $ 48,403
============= =============
The accompanying notes are an integral part of these financial statements
46
VisiJet, Inc.
(A development stage company)
Statements of Operations
For the period
Twelve months ended December 31, February 2, 1996
(inception) to
2003 2002 Dec 31, 2003
------------- ------------- -------------
Operating expenses:
General and administrative expenses $ 3,736,604 $ 751,717 $ 5,568,736
Research and development expenses 1,256,259 294,736 4,858,009
------------- ------------- -------------
Total operating expenses 4,992,863 1,046,453 10,426,745
------------- ------------- -------------
Loss from operations (4,992,863) (1,046,453) (10,426,745)
Other income (expense):
Interest income 455 455
Interest expense (56,247) (131,319) (364,245)
Gain on debt restructure 90,303 90,303
Loss on judgment (21,483)
Loss on disposal of assets (48,104) (48,104)
------------- ------------- -------------
Total other expense 34,511 (179,423) (343,074)
------------- ------------- -------------
Loss before provision for taxes (4,958,352) (1,225,876) (10,769,819)
Provision for Income taxes 800 800 6,400
------------- ------------- -------------
Net loss $ (4,959,152) $ (1,226,676) $(10,776,219)
============= ============= =============
Net loss per common share - basic and diluted $ (0.27) $ (0.16) $ (2.01)
============= ============= =============
Basic and diluted weighted average
number of common shares outstanding 18,606,352 7,811,809 5,351,763
============= ============= =============
The accompanying notes are an integral part of these financial statements
47
VisiJet, Inc.
(A development stage company)
Statement of Shareholders' Equity
Deficit
Accumulated Net
Common Stock Preferred Stock Common Additional during the
Shareholders'
----------------------- ----------------------- Stock Paid In Development Equity
Shares Amount Shares Amount Subscription Capital Stage
(Deficit)
------------ ---------- --------- ------------ ------------- ------------ ------------- ------------
Balance,
December 31, 2001 7,673,401 $ 608,761 504,252 $ 2,458,088 -- -- $ (4,590,391) $(1,523,542)
============ ========== ========= ============ ============= ============ ============= ============
Common stock issued
for services 324,334 6,487 -- -- -- -- $ (1,226,676) $(1,220,189)
------------ ---------- --------- ------------ ------------- ------------ ------------- ------------
Balance,
December 31, 2002 7,997,735 $ 615,248 504,252 $ 2,458,088 -- -- $ (5,817,067) $(2,743,731)
============ ========== ========= ============ ============= ============ ============= ============
Common stock issued
for consideration
of merger, net of
shares cancelled 6,084,000 6,084 -- -- -- $ 8,058 -- 14,142
Common stock issued
in connection with
private placement
and debt conversion 3,528,481 3,528 -- -- -- 1,130,152 -- 1,133,680
Common stock issued
upon conversion of
preferred shares 826,530 (606,424) (504,252) (2,458,088) -- 3,064,512 -- --
Common stock issued in
connection with debt
conversion 378,997 379 -- -- -- 378,618 -- 378,997
Common stock issued in
connection with
settlement agreements 211,267 211 -- -- -- 449,789 -- 450,000
Common stock issued for
services 60,069 60 -- -- -- 1,141 -- 1,201
Common stock canceled (204,409) (204) -- -- -- 204 -- --
Common stock issued
in connection with
post-merger placements 2,712,500 2,713 -- -- -- 2,689,777 -- 2,692,490
Costs of private
placements -- -- -- -- -- (228,700) -- (228,700)
Common stock given
for services 150,000 150 -- -- -- 224,850 -- 225,000
Common stock
subscriptions -- -- -- -- $ 1,018,500 -- -- 1,018,500
Merger shares
reconciliation (54,007) (54) -- -- -- 54 -- --
Warrants issued
for services -- -- -- -- -- 33,483 -- 33,483
Options issued
for services -- -- -- -- -- 93,427 -- 93,427
Net Loss -- -- -- -- -- -- (4,959,152) (4,959,152)
------------ ---------- --------- ------------ ------------- ------------ ------------- ------------
Balance,
December 31, 2003 21,691,163 $ 21,691 -- -- $ 1,018,500 $ 7,845,365 $(10,776,219) $(1,890,663)
============ ========== ========= ============ ============= ============ ============= ============
The accompanying notes are an integral part of these financial statements
48
VisiJet, Inc.
(A development stage company)
Statements of Cash Flows
For the period
February 2, 1996
Twelve months ended December 31, (inception) to
2003 2002 December 31, 2003
------------- ------------- -------------
Cash flows from operating activities
Net loss $ (4,959,152) $ (1,226,676) $(10,776,219)
Adjustment to reconcile net loss to net
cash used by operating activities:
Depreciation 23,949 13,627 312,311
Loss from disposal of fixed assets -- 48,104 48,104
Common stock issued for services 353,111 6,487 455,468
Gain from Debt Restructure (90,303) -- (90,303)
Changes in assets and liabilities: -- --
Prepaid expenses (88,749) -- (88,749)
Accounts payable and other accrued expenses 482,900 (33,172) 679,885
Compensation settlement agreement (145,834) 291,651 104,166
Royalties payable -- 60,000 60,000
Foreign exchange effect on notes payable 3,121 -- 3,121
Accrued fees 180,848 -- 181,648
Accrued paid time off 55,191 -- 55,191
Accrued judgment 39,598 -- 169,267
Accrued patent payable 75,000 -- 75,000
Accrued interest 40,044 42,389 200,881
------------- ------------- -------------
Net cash used by operating activities (4,030,276) (797,590) (8,610,229)
------------- ------------- -------------
Cash flows from investing activities
Acquisition of property and equipment (78,190) (4,633) (462,099)
Acquisition of patents (100,000) -- (100,000)
------------- ------------- -------------
Net cash used in investing activities (178,190) (4,633) (562,099)
------------- ------------- -------------
Cash flows from financing activities
Advance from related party 337,543 830,665 1,908,868
Repayment of advances from related parties (185,138) (27,482) (212,620)
Repayment of notes payable (20,000) -- (20,000)
Proceeds from issuance of common stock, net 3,027,790 -- 3,990,681
Proceeds from common stock subscriptions 1,018,500 -- 1,018,500
Proceeds from issuance and conversion of preferred stock, net -- -- 2,458,088
Cash acquired in reverse merger 30,693 -- 30,693
Interest converted to equity in connection with merger 33,997 -- 33,997
------------- ------------- -------------
Net cash provided by financing activities 4,243,385 803,183 9,208,207
------------- ------------- -------------
Net increase in cash 34,919 960 35,879
Cash, beginning of period 960 -- --
------------- ------------- -------------
Cash, end of period $ 35,879 $ 960 $ 35,879
============= ============= =============
Supplemental disclosures of cash flow information
Conversion of Debt to Equity 1,398,677
Conversion of Series A preferred stock to common stock 550,000
Conversion of Series B preferred stock to common stock 1,908,088
Fair value of net liabilities assumed at date of reverse merger 189,458
The accompanying notes are an integral part of these financial statements
49
VISIJET, INC.
(A DEVELOPMENT STAGE COMPANY )
NOTES TO FINANCIAL STATEMENTS
NOTE 1 - NATURE OF OPERATIONS
-----------------------------
VisiJet, Inc. ("VisiJet", or "the Company"), a Delaware corporation, is
a development stage company engaged in the research and development of
surgical equipment for use in the field of ophthalmology based on
proprietary waterjet technology. Potential customers include
physicians, surgical centers and hospitals. The Company's efforts
through December 31, 2003, have been principally devoted to
organizational activities, raising capital and research and development
efforts. To date, the Company has not received any revenues from
product sales.
HISTORY AND MERGER
The Company was incorporated in California on February 2, 1996 as a
wholly owned subsidiary of SurgiJet, Inc ("SurgiJet"). In May 1999, the
Company was spun off from SurgiJet through a distribution of common
stock to its shareholders, after which SurgiJet had no remaining
ownership interest in the Company. In connection with this spin-off
transaction, certain operating assets and liabilities were assumed by
the Company.
On February 11, 2003 the Company completed a merger with Ponte Nossa
Acquisition Corp., a Delaware corporation incorporated in 1997
("PNAC"). Pursuant to the merger agreement between VisiJet and PNAC
(the "Merger Agreement"), the Company became a wholly owned subsidiary
of PNAC. Since this transaction resulted in the shareholders of VisiJet
acquiring a majority of the outstanding shares of PNAC, for financial
reporting purposes the business combination was accounted for as a
recapitalization of PNAC (a reverse acquisition with the Company as the
accounting acquirer). Subsequently, PNAC changed its name to VisiJet,
Inc. See Note 7.
As a result of the merger, the following assets were acquired and
liabilities were assumed:
Assets:
Cash $ 30,693
Liabilities:
Notes payable to related parties (220,151)
-----------
Net liabilities assumed $ (189,458)
===========
GOING CONCERN
The Company has incurred net operating losses since inception, has
generated no revenue, and has working capital and stockholders'
deficits. The Company is likely to incur substantial and increasing
operating losses as it continues its research and development efforts
until such time, if ever, as product sales, royalties, license and
development and other fees can generate sufficient revenue to fund its
continuing operations. The Company's future capital requirements will
50
NOTE 1 - NATURE OF OPERATIONS (CONTINUED)
depend on many factors, including but not limited to the Company's
ability to finalize development and successfully market its waterjet
technology, overall product development costs including the cost of
clinical trials and competing technological and market developments.
To address the going concern issue, the Company has been attempting to
secure additional financing that will be adequate to fund its
operations until such time as sufficient revenue from product sales or
other operating activities are being generated. In this regard, as
discussed in more detail in Note 14, in April 2004, the Company entered
into two stock purchase agreements, that if finalized and funded, would
result in initial gross proceeds to the Company of $9.5 million.
Completion of this financing, and receipt of funding by the Company, is
contingent on the effectiveness of a Registration Statement, which the
Company has recently filed with the United States Securities and
Exchange Commission covering the resale of the shares of common stock
and the shares of common stock underlying the warrants. Whereas the
Company believes that the funding contemplated by these stock purchase
agreements will be obtained in a timely manner, there can be no
assurances that the Registration Statement will be declared effective,
or that the anticipated proceeds will be received by the Company.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
---------------------------------------------------
RESEARCH AND DEVELOPMENT COSTS
Research and development costs are charged to expense as incurred.
Certain corporate overhead expenses, such as professional fees,
salaries, rent and travel are allocated to research and development
based on estimates made by management.
STOCK-BASED COMPENSATION
The Company measures compensation expense related to the grant of stock
options and stock-based awards to employees in accordance with the
provisions of Accounting Principles Board ("APB") Opinion No. 25, under
which compensation expense, if any, is generally based on the
difference between the exercise price of an option, or the amount paid
for the award and the market price or fair value of the underlying
common stock at the date of the award. Stock-based compensation
arrangements involving non-employees are accounted for under Statement
of Financial Accounting Standards ("SFAS") No. 123, "ACCOUNTING FOR
STOCK-BASED COMPENSATION," under which such arrangements are accounted
for based on the fair value of the option or award. The Company adopted
the disclosure requirements of SFAS No. 148, "ACCOUNTING FOR
STOCK-BASED COMPENSATION - TRANSITION AND DISCLOSURE," an amendment of
SFAS No. 123 as of January 1, 2003, which require certain disclosures
about stock-based employee compensation plans in an entity's accounting
policy note.
Those disclosures include a tabular format of pro forma net income and,
if applicable, earnings per share under the fair value method if the
intrinsic value method is used in any period presented.
51
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
The adoption of SFAS No. 148 did not have a material impact to these
consolidated financial statements and the disclosure requirements are
included below.
On November 10, 2003, the Board of Directors adopted the VisiJet, Inc.
2003 Stock Option Plan. The Option Plan provides for the grant of
incentive and non-qualified stock options to selected employees, the
grant of non-qualified options to selected consultants and to directors
and advisory board members. The Option Plan is administered by the
Compensation Committee of the Board of Directors and authorizes the
grant of options for 3,000,000 shares. The Compensation Committee
determines the individual employees and consultants who participate
under the Plan, the terms and conditions of options, the option price,
the vesting schedule of options and other terms and conditions of the
options granted pursuant thereto.
During the fourth quarter of 2003, the Company issued 125,000 stock
options to consultants to purchase the Company's common stock in
exchange for services rendered. The Company has accounted for these
issuances in accordance with SFAS No. 123 and has recorded an expense
of $93,427 representing the fair value of the options using a
Black-Scholes option-pricing model. The options are exercisable at
price of $1.10 per share and have a term of 10 years.
Also during the fourth quarter of 2003, the Company issued options to
employees and directors to purchase 1,040,000 shares of its common
stock, at an exercise price of $1.10. All options granted during the
period have a term of ten years and were issued at an exercise price
equal to the market value of the underlying stock at the date of grant.
As of December 31, 2003 a total of 1,165,000 options to purchase shares
of the Company's common stock were outstanding pursuant to the 2003
Plan.
A summary of changes in common stock options during 2003 and 2002
follows:
Number of Weighted Average Exercisable
Shares Exercise Price Shares
-----------------------------------------
Outstanding at December 31, 2002 -- -- --
Granted 1,165,000 $ 1.10 390,000
Forfeited -- -- --
Cancelled -- -- --
Outstanding at December 31, 2003 1,165,000 $ 1.10 390,000
SFAS No. 123 requires the Company to provide pro forma information
regarding net income (loss) and income (loss) per share as if
compensation cost for the Company's stock option issuances had been
determined in accordance with the fair value based method prescribed in
SFAS No. 123. The Company estimates the fair value of each stock option
at the grant date by using the Black-Scholes option-pricing model with
the following assumptions used for grants in fiscal 2003: dividend
yield of zero percent, risk-free interest rate of 3.29%, expected life
of five years, and expected volatility of 83.82%.
52
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Under the accounting provisions of SFAS No. 123, as amended by SFAS No.
148, the Company's pro forma net loss and loss per share for the years
ended December 31, 2003 and 2002 would have been as follows:
2003 2002
---- ----
Net Loss:
As reported $ (4,959,152) $ (1,226,676)
SFAS No. 123 effect (308,724) --
------------- -------------
Pro forma net loss $ (5,267,876) $ (1,226,676)
============= =============
Loss per share:
As reported $ (0.27) $ (0.16)
============= =============
Pro forma $ (0.28) $ (0.16)
============= =============
Basic and diluted weighted
average shares outstanding 18,606,352 7,811,809
============= =============
The following table summarizes information about stock options
outstanding at December 31, 2003:
Weighted
Average Weighted Weighted
Remaining Average Average
Exercise Number Life in Exercise Number Exercise
Price Outstanding Years Price Exercisable Price
----- ----------- ----- ----- ----------- -----
$1.10 1,165,000 9.83 $1.10 390,000 $1.10
SEGMENT INFORMATION
The Company complies with SFAS No. 131, "DISCLOSURES ABOUT SEGMENTS OF
AN ENTERPRISE AND RELATED INFORMATION" that requires public business
enterprises to report information regarding reportable operating
segments. SFAS No. 131 supersedes SFAS No. 14, "FINANCIAL REPORTING FOR
SEGMENTS OF A BUSINESS ENTERPRISE."
During 2003 and 2002, the Company had only one primary business unit,
the research and development of ophthalmic surgical instruments.
Accordingly, separate operating segment information is not being
presented.
DEPRECIATION
Depreciation of property and equipment is computed using the
straight-line method over estimated useful lives ranging from three to
five years.
USE OF ESTIMATES
The preparation of the financial statements in conformity with
accounting principles generally accepted in the United States of
America requires management to make estimates and assumptions that
affect the amounts reported in the financial statements and
accompanying notes. Actual results could differ from those estimates.
53
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
IMPAIRMENT OF LONG-LIVED ASSETS
The Company reviews long-lived assets and certain identifiable
intangibles for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable.
Recoverability of assets to be held and used is measured by a
comparison of the carrying amount of an asset to the future net cash
flows expected to be generated by the asset. If such assets are
considered to be impaired, the impairment to be recognized is measured
by the amount by which the carrying amount of the assets exceeds the
fair value of the assets. Assets to be disposed of are reported at the
lower of the carrying amount or fair value less costs to sell.
LOSS PER SHARE
The Company calculates loss per share in accordance with SFAS No. 128,
"EARNINGS PER SHARE," and Securities and Exchange Commission ("SEC")
Staff Accounting Bulletin ("SAB") No. 98. Accordingly, basic loss per
share is computed using the weighted average number of common shares
and diluted loss per share are computed based on the weighted average
number of common shares and all common equivalent shares outstanding
during the period in which they are dilutive. Common equivalent shares
consist of shares issuable upon the exercise of stock options, using
the treasury stock method, or warrants; common equivalent shares are
excluded from the calculation if their effect is anti-dilutive.
INCOME TAXES
The Company utilizes the asset and liability method of accounting for
income taxes. Under this method, deferred tax assets and liabilities
are recognized for the estimated future tax consequences attributable
to differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax basis and
operating loss and tax credit carryforwards. Deferred tax assets and
liabilities are measured using enacted tax rates expected to apply to
taxable income in the years in which those temporary differences are
expected to be recovered or settled. The effect on deferred tax assets
and liabilities of a change in tax rates is recognized in income in the
period that includes the enactment date.
RECLASSIFICATIONS
Certain reclassifications have been made to the financial statements of
the prior year and for the period February 2, 1996 (inception) to
December 31, 2003 in order to conform to current year presentation.
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
In November 2002, the FASB issued Interpretation No. 45, "GUARANTOR'S
ACCOUNTING AND DISCLOSURE REQUIREMENTS FOR GUARANTEES, INCLUDING
INDIRECT GUARANTEES OF INDEBTEDNESS OF OTHERS" - an interpretation of
SFAS Nos. 5, 57 and 107 and rescission of FASB Interpretation No. 34.
This Interpretation elaborates on the disclosures to be made by a
guarantor in its interim and annual financial statements about its
obligations under certain guarantees that it has issued. It also
54
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
clarifies that a guarantor is required to recognize, at the inception
of a guarantee, a liability for the fair value of the obligation
undertaken in issuing the guarantee. The initial recognition and
measurement provisions of this Interpretation are applicable on a
prospective basis to guarantees issued or modified after December 31,
2002. Implementation of these provisions of the Interpretation is not
expected to have a material impact on the
Company's consolidated financial statements. The disclosure
requirements of the Interpretation are effective for financial
statements of interim or annual periods ended after December 15, 2002,
and have been adopted in the accompanying consolidated financial
statements with no additional disclosure required.
In December 2002, FASB issued SFAS No. 148, ACCOUNTING FOR STOCK-BASED
COMPENSATION, TRANSITION AND DISCLOSURE ("SFAS 148"). SFAS 148 amends
the disclosure requirements of SFAS No. 123 "Accounting for Stock-Based
Compensation" ("SFAS 123") to require prominent disclosures in both
interim and annual financial statements about the method of accounting
for stock-based employee compensation and the effect of the method used
on reported results. SFAS 148 also amends SFAS 123 to provide
alternative methods of transition for a voluntary change to the fair
value based method of accounting for stock-based employee compensation.
As the Company has decided not to voluntarily adopt the SFAS 123 fair
value method of accounting for stock-based employee compensation, the
new transition alternatives of SFAS 148 will not have a material impact
on its financial position or results of operations. The Company adopted
the quarterly footnote disclosure of the fair value based method of
accounting for stock-based employee compensation as of the beginning of
fiscal 2003, although no options were issued by the Company until the
fourth quarter of 2003.
NOTE 3 - PROPERTY AND EQUIPMENT
-------------------------------
At December 31, property and equipment consist of the following:
2003 2002
---------- ----------
Computer and test equipment $ 82,584 $ 21,833
Furniture and fixtures 33,505 16,067
Trade show equipment 47,002 47,002
---------- ----------
163,091 84,902
Less: Accumulated depreciation (58,651) (37,459)
---------- ----------
$ 104,440 $ 47,443
========== ==========
Depreciation expense for the years ended December 31, 2003 and 2002
amounted to $21,193 and $13,627, respectively. Depreciation expense for
the period from February 2, 1996 (inception) to December 31, 2003 was
$309,555.
55
NOTE 4 - LICENSE AGREEMENT
--------------------------
During 2003, the Company entered into a license agreement with the
inventor of a patented technology through which the Company obtained
exclusive worldwide rights for all medical applications for the
technology that provides for the sterile flow of fluid through a
surgical water jet apparatus. The purchase price of the license has
been capitalized and is being amortized on a straight-line basis over
the remaining life of the patent. The license agreement provides for
royalty payments based on the sale of products utilizing licensed
technology and for minimum annual royalty payments. See Note 6 -
Commitments.
At December 31, license agreements consist of:
2003 2002
---------- ---------
License agreements $ 100,000 $ --
Less: accumulated amortization (2,756) --
---------- ---------
$ 97,224 $ --
========== =========
Amortization expense for the years ended December 31, 2003 and 2002
amounted to $2,756 and $0, respectively. Amortization expense for the
period from February 2, 1996 (inception) to December 31, 2003 was
$2,756.
NOTE 5 - NOTES PAYABLE - RELATED PARTIES
----------------------------------------
SURGIJET, INC.
On October 23, 1998, the Company issued a demand promissory note in the
amount of $400,000 in favor of SurgiJet, Inc., a company then related
through common shareholders. Interest accrued on the unpaid principal
at a variable interest rate based on the prime rate totaled $139,955 on
February 11, 2003. In connection with the Merger Agreement, an
amendment to the note was executed on February 11, 2003 under which the
accrued interest was reduced to $49,652 and scheduled principal and
interest payments were established. Under the amended note, the first
payment of $30,000 was due on February 11, 2003 with equal monthly
installments of $15,000, including interest due on the first of each
month, and all outstanding principal and interest is due and payable
upon successful completion of the Company's 2002 financial statements.
As a result of the amendment, the Company recorded a $90,303 gain based
on the difference between the total accrued interest expense included
on the amended note and the total interest of $139,955 previously
accrued. Through December 31, 2003 payments totaling $45,000 were made
by the Company, resulting in an outstanding principal balance of
$360,976 at December 31, 2003, of which $87,144 is classified as
long-term debt, and accrued interest payable of $43,676.
As discussed more fully at Note 11, the validity of the underlying
note, as well as the amended note is disputed by the Company, and is a
subject of on-going litigation between the Company and SurgiJet.
Pending the outcome of the litigation, the Company ceased making
scheduled payments on this note.
56
NOTE 5 - NOTES PAYABLE - RELATED PARTIES (CONTINUED)
DENTAJET, INC.
During 2002, the Company entered into a promissory note for a principal
sum of $91,000, plus interest at the rate of 10% per annum with
DentaJet Inc. ("DentaJet"), a Company then related through common
shareholders. During 2002, the Company borrowed an additional $70,000
from, and made payments totaling $27,482 to DentaJet, resulting in an
outstanding principal balance of $133,518 at December 31, 2002.
Interest expense related to this note totaling $9,567 was recorded by
the Company in 2002, and was included in accrued interest payable at
December 31, 2002. During 2003, the Company borrowed an additional
$2,000 from DentaJet, and recorded interest expense totaling $15,178
related to this note. As of December 31, 2003 the outstanding principal
balance and accrued interest payable on this noted totaled $135,518 and
$24,745, respectively. Pursuant to the Merger Agreement, the loan is
due and payable upon successful completion of an independent audit of
the Company's 2002 financial statements.
As discussed more fully at Note 11, the validity of this note is being
disputed by the Company, and is a subject of on-going litigation
between the Company and SurgiJet.
FINANCIAL ENTREPRENEURS, INC. ("FEI")
During 2002 the Company entered into a promissory note agreement with
FEI, a significant shareholder of the Company. The note was due on
demand and was non-interest bearing. In connection with the Merger
Agreement, FEI converted the outstanding note balance at the date of
the merger, $378,997 into 378,997 shares of the Company's common stock.
There was no beneficial conversion feature on this note.
In connection with the Merger Agreement, the Company assumed a
promissory note during 2003 originally entered into between PNAC and
FEI during 2002. The note is payable on demand and bears interest at an
annual rate of 7.5%. Upon consummation of the merger in February 2003,
the outstanding principal and accrued interest payable balances were
$206,649 and $11,462, respectively. During 2003, the Company added net
borrowings of $43,476 to the note, and accrued additional interest
expense of $17,072, resulting in an outstanding principal balance and
accrued interest payable balances at December 31, 2003 of $250,125 and
$28,534, respectively.
SHAREHOLDERS
During 2002, the Company entered into a promissory note with Lance
Doherty, a significant shareholder of the Company, for a principal sum
of $19,000 plus interest at the rate of 10% per annum. As of December
31, 2003 the outstanding principal balance of this note was $19,000,
and accrued interest payable totaled $3,920. Pursuant to the Merger
Agreement, this note is due and payable upon successful completion of
an independent audit of the Company's 2002 financial statements. As
discussed more fully at Note 11, the validity of this note is being
disputed by the Company, and is a subject of on-going litigation
between the Company and Mr. Doherty.
57
NOTE 5 - NOTES PAYABLE - RELATED PARTIES (CONTINUED)
In addition, during 2002 the Company recorded a liability of $2,967
related to expenses paid by Rex Doherty, a significant shareholder of
the Company. Pursuant to the Merger Agreement, this liability, plus
interest at the rate of 10% per annum, is due and payable upon
successful completion of an independent audit of the Company's 2002
financial statements. At December 31, 2003, the outstanding liability
and accrued interest payable related to this debt are $2,967 and $298,
respectively. As discussed more fully at Note 11, the validity of this
liability is being disputed by the Company, and is a subject of
on-going litigation between the Company and Mr. Doherty.
PONTE NOSSA ACQUISITION CORPORATION ("PNAC")
During 2002, the Company entered into various loan agreements with PNAC
to provide funding to facilitate transactions contemplated by the then
pending merger with the Company. Principal and accrued interest on the
notes were due on the earlier of i) the date on which the closing of
the transactions of the merger agreement by and between the Company and
PNAC, ii) termination of the merger agreement, iii) sale of the Company
or iv) the maturity date. The notes were collateralized by a security
interest in certain assets and common stock of the Company.
At December 31, 2002, notes payable to PNAC consisted of the following:
Note payable - PNAC
Senior secured promissory notes,
interest at 3% per annum, due May 2003 $236,000
Note payable - PNAC
Working capital note, interest at 10% per annum,
due August 2003 309,752
Note payable - PNAC
Milestone note payable,
interest at 10% per annum, due August 2003 97,606
---------
$643,358
=========
At December 31, 2002, accrued interest payable on the above notes was
$12,354.
During 2003, prior to the completion of the Merger Agreement, the
Company borrowed an additional $115,073, pursuant to the working
capital note referenced above, and accrued additional interest expense
in the amount of $2,495. As a result of the Merger Agreement, the
outstanding principal and accrued interest payable balances related to
these notes, in the aggregate amount of $773,280 were eliminated, and
as of December 31, 2003 there are no remaining outstanding balances.
NOTE 6 - COMMITMENTS
--------------------
OPERATING LEASES
The Company leases approximately 5,100 square feet of office and
laboratory space in Irvine, California at a total rent, inclusive of
common area charges, of $7,600 per month under a lease that runs
through April 20, 2004. Rent expense was $82,398 and $62,160 for the
years ended
58
NOTE 6 - COMMITMENTS (CONTINUED)
December 31, 2003 and 2002, respectively. Rent expense for the period
from February 2, 1996 (inception) to December 31, 2003 was $376,246.
The Company also leases certain office equipment under operating
leases.
The approximate future minimum annual rental payments under operating
leases as of December 31, 2003 are as fo1lows:
Year Ending December 31,
------------------------
2004 $ 31,037
2005 3,168
2006 3,168
2007 3,168
2008 1,188
LICENSE AGREEMENTS
Under the terms of the technology license agreements with SurgiJet, the
Company is obligated to pay a royalty of 7% of revenues received from
sales of the products, up to $400 million of revenues over the course
of the agreements, and 5% of revenues thereafter. The license
agreements with SurgiJet also provide for a minimum royalty of $60,000
per year that may be used as a credit toward payment future royalties
due on product sales.
Under the terms of the patent license agreement entered into during
2003, the Company is obligated to pay a royalty of 6% of net sales of
products utilizing the licensed patent technology. The license
agreement also provides for a minimum royalty of $24,000 per year that
may be used as a credit toward payment future royalties due on product
sales.
NOTE 7 - SHAREHOLDERS' EQUITY (DEFICIT)
---------------------------------------
MERGER
In connection with the completion of the Merger Agreement in February
2003, the Company agreed to issue a total of 8,600,000 shares of common
stock and 1,720,000 warrants to purchase common stock in exchange for
all of the outstanding common and preferred stock of Visijet prior to
the merger, and in exchange for services rendered by three individuals
prior to the merger. In addition, the Company issued an aggregate of
3,528,481 shares of common stock and warrants to purchase 4,528,481
shares of common stock at an initial exercise price of $1.00 per share
(with the exercise price increasing by $0.50 per share each year) to
certain private investors in connection with the conversion of debt
totaling $569,680, and a private placement investment of $564,000, that
occurred concurrently with the consummation of the merger.
Based on a reconciliation of share activity recorded in connection with
the merger, the Company recorded an adjustment during the fourth
quarter of 2003 to reduce the number of outstanding shares of common
stock by 54,007.
Pursuant to the Merger Agreement, PNAC shareholders received a total of
6,084,000 shares of the Company's common stock upon consummation of the
59
NOTE 7 - SHAREHOLDERS' EQUITY (DEFICIT) (CONTINUED)
merger. In a separate agreement entered into in connection with the
merger, FEI converted a promissory note held by it into 378,997 shares
of common stock at a conversion rate of $1.00 per share. Also, FEI
agreed to cancel 7,957,000 shares of the PNAC stock owned by it prior
to completion of the Merger Agreement, and the Company issued FEI a
five year warrant to purchase 1,543,000 shares of common stock at an
exercise price of $5.00 per share.
OTHER COMMON STOCK ACTIVITY
In February 2003, the Company issued 211,267 shares of common stock to
two employees in satisfaction of unpaid salary accrued prior to the
merger. See Note 9 - Settlement Agreements and Loan Payable.
In September 2003, the Company issued 150,000 shares of common stock to
a consultant in connection with services rendered. See Note 13 -
Related Party Transactions.
During 2003, the Company issued 2,712,500 shares of common stock, and
five year warrants to purchase 3,711,000 shares of the Company's common
stock at an exercise price of $2.25 per share in connection with
private equity placements. In addition, the Company recorded common
stock subscriptions in the amount of $918,500 based on proceeds
received from private placements for which the stock has not yet been
issued, and reclassified $100,000 to common stock subscriptions based
on pre-merger private placement funds received for which the stock has
not yet been issued.
OTHER WARRANT ACTIVITY
During 2002 and 2003, PNAC issued common stock warrants to purchase
235,000 shares and 270,000 shares of common stock, respectively, in
connection with private equity placements that occurred prior to
completion of the Merger Agreement that remained outstanding subsequent
to the merger. The warrants are exercisable for a period of five years
at an exercise price of $2.50.
Pursuant to an agreement entered into in connection with the merger,
the Company issued a five-year warrants to purchase 25,000 shares of
its common stock at an exercise price of $3.00, each to an officer of
the Company and a former officer of PNAC.
During 2003, the Company issued 5-year warrants to purchase 3,711,000
shares of its common stock, at an exercise price of $2.25 per share, in
connection with private equity placements. In addition, during 2003,
the Company issued 5-year warrants to purchase 45,000 shares of its
common stock, at an exercise price of $1.23 per share, for services
rendered to the Company. In connection with the 45,000 warrants issued
for services rendered, the Company recorded consulting expense in the
amount of $33,483 based on the fair value of the warrants using a
Black-Scholes model valuation.
The following table summarizes the number of outstanding common stock
warrants in 2003 and 2002:
60
NOTE 7 - SHAREHOLDERS' EQUITY (DEFICIT) (CONTINUED)
Weighted Average
Number Exercise Price
----------- -----------------
Outstanding at December 31, 2001 - -
Granted 235,000 $2.50
Forfeited - -
Exercised - -
----------- -----------------
Outstanding at December 31, 2002 235,000 $2.50
Granted 11,867,480 $2.53
Forfeited - -
Exercised - -
----------- -----------------
Outstanding at December 31, 2003 12,102,480 $2.53
The following table summarizes additional information with respect to
outstanding common stock warrants at December 31, 2003:
Number Weighted Average Life Number
Exercise Price Outstanding Remaining in Months Exercisable
-------------- ------------ --------------------- -----------
$1.00 4,528,480 49 3,528,480
$1.23 45,000 55 45,000
$2.25 3,711,000 58 3,711,000
$2.50 505,000 46 505,000
$3.00 50,000 49 50,000
$5.00 3,263,000 49 3,263,000
------------ -----------
12,102,480 11,102,480
============ ===========
NOTE 8 - INCOME TAXES
---------------------
The provision for income taxes consist of the following for the years
ended December 31:
2002 2001
------------ ------------
Current:
Federal $ -- $ --
State 800 800
------------ ------------
Total provision $ 800 $ 800
============ ============
The components of the net deferred income tax assets are as follows as
of December 31:
2003 2002
------------ ------------
Deferred income tax assets:
Net operating loss carry forward $ 4,192,639 $ 2,398,000
Other temporary timing adjustments 400,764 257,000
------------ ------------
4,593,403 2,655,000
Deferred tax liability:
State taxes (37,585) (191,000)
------------ ------------
Deferred income tax asset, net before
Valuation allowance 4,555,818 2,464,000
Less: valuation allowance (4,555,818) (2,464,000)
------------ ------------
Deferred income tax asset, net $ -- $ --
============ ============
61
NOTE 8 - INCOME TAXES (CONTINUED)
---------------------------------
Since 1996, the company has generated a net operating loss (NOL) of
approximately $5,404,011. The total carry forward amounts are available
to offset future taxable income and expire in various years through
2022. The ability to use some or all of this carryforward is limited by
future events such as a failure to generate positive taxable income or
a change in ownership as stated under the rules of Internal Revenue
Code Section 382.
The net deferred tax asset is primarily associated with its net
operating loss carryforwards, state taxes and other timing adjustments.
The Company has recorded a valuation allowance for the entire amount
due to the uncertainty surrounding the likelihood of the Company
generating sufficient taxable income in the future.
NOTE 9 - SETTLEMENT AGREEMENTS AND LOAN PAYABLE
-----------------------------------------------
On November 4, 2002, the Company entered into settlement agreements
with Randal A. Bailey, its President and Chief Executive Officer, and
Larry Hood, its Director of Engineering, related to accrued, but unpaid
fees for consulting services previously rendered by them in the
aggregate of $700,000. Under the agreements a total of $450,000 was
converted into 211,267 shares of the Company's common stock based upon
the closing price on the effective date the merger, of which Mr. Bailey
received 164,319 shares and Mr. Hood received 46,948 shares. The
balance owed of $250,000 was converted into two-year notes payable,
that bear interest at an annual rate of 3.5% and provide for the
principal to be paid over twenty-four equal installments. At December
31, 2003, the balance on these notes was $104,166, of which $17,458 is
classified as long-term, and accrued interest payable was $6,330.
NOTE 10 - SELECTED QUARTERLY DATA
---------------------------------
------ Quarter Ended ------
2003 March 31 June 30 September 30 December 31 Total
----------------------- ------------- ------------- -------------- -------------- --------------
Expenses $ 814,387.00 $ 885,338.00 $1,239,737.00 $2,053,401.00 $4,992,863.00
------------- ------------- -------------- -------------- --------------
Operating loss (814,387) (885,338) (1,239,737) (2,053,401) (4,992,863)
Interest Expense (14,336) (17,037) (5,944) (18,930) (56,247)
Other income (expense) 26 361 90,303 (732) 89,958
------------- ------------- -------------- -------------- --------------
Net loss $ (828,697) $ (902,014) $ (1,155,378) $ (2,073,063) $ (4,959,152)
============= ============= ============== ============== ==============
Loss per share $ (0.06) $ (0.046) $ (0.056) $ (0.10) $ (0.27)
============= ============= ============== ============== ==============
Weighted average shares
Outstanding 14,171,631 19,533,294 20,468,856 21,179,696 18,606,352
============= ============= ============== ============== ==============
62
NOTE 10 - SELECTED QUARTERLY DATA (CONTINUED)
---------------------------------------------
Quarter Ended Quarter Ended Quarter Ended Quarter Ended
2002 March 31 June 30 September 30 December 31 Total
----------------------- ------------- ------------- -------------- -------------- --------------
Expenses 142,008 353,344 253,573 297,528 1,046,453
------------- ------------- -------------- -------------- --------------
Operating loss (142,008) (353,344) (253,573) (297,528) (1,046,453)
Interest Expense (17,754) (22,944) (68,681) (131,319) (21,940)
Other income (expenses) -- -- -- (48,904) (48,904)
------------- ------------- -------------- -------------- --------------
Net loss $ (159,762) $ (376,288) $ (275,513) $ (415,113) $ (1,226,676)
============= ============= ============== ============== ==============
Loss per share $ (0.020) $ (0.048) $ (0.040) $ (0.052) $ (0.16)
============= ============= ============== ============== ==============
Weighted average shares
Outstanding 7,713,943 7,817,735 7,817,735 7,916,811 7,811,809
============= ============= ============== ============== ==============
NOTE 11 - CONTINGENCIES
-----------------------
During 2003, the Company initiated litigation against SurgiJet, Inc.,
its former parent company, and certain directors, officers and
shareholders of SurgiJet. The action was initially filed by the Company
for a judicial determination that a $400,000 Promissory Note issued by
the Company and payable to SurgiJet "SurgiJet Note"), prior to the
completion of the Merger Agreement, is not enforceable, and for
recovery of payments previously made on the note. Subsequently, a
challenge of the validity of other notes payable carried on the
Company's books at the effective date of the Merger Agreement,
including notes to Dentajet, Lance Doherty (former President of VisiJet
and beneficial owner of more than 5% of its outstanding Common Stock)
and Rex Doherty was added to the litigation. SurgiJet and its
principals filed a cross-action against the Company, and its directors
and certain officers, seeking damages of approximately $800,000,
rescission of the Merger Agreement, other specified damages, interest
and attorney's fees.
In the cross-complaint, SurgiJet and its principals allege breach of
the Merger Agreement between the Company and SurgiJet, breach of an
Assumption of Liabilities Agreement (including Notes Payable to
DentaJet, Lance Doherty and Rex Doherty) entered into in connection
with the Merger Agreement, and breach of the SurgiJet Note, along with
fraud and unfair business practices.
The Company's management believes that the cross-complaint is merely a
diversionary effort by SurgiJet to draw attention away from the main
action. The Company believes the allegations to the cross-complaint are
wholly without merit and plans to vigorously pursue its claims and
contest the cross-complaint.
63
NOTE 11 - CONTINGENCIES (CONTINUED)
-----------------------------------
The Company is also a defendant in an action filed by an individual
claiming entitlement to a finder's fee arising out of the merger
between Ponte Nossa and Visijet. The complaint alleges that the
plaintiff is entitled to 105,000 shares of the Company's common stock.
In January 2004 the Company and plaintiff reached a settlement in this
matter whereby the Company agreed to issue plaintiff 45,000 shares of
the Company's common stock as full settlement of the claim.
The Company is also a defendant in a breach of contract claim from an
outside provider of accounting services for work performed for the
Company prior to the effective date of the Merger Agreement for
$43,500, plus interest. The Company has denied the allegations of the
complaint and is vigorously contesting the action.
In December 2003, a former consultant who had performed services for
the Company prior to the effective date of the Merger Agreement
obtained a judgment award in the amount of $40,398 from the Labor
Commissioner of the State of California in an action related to claimed
unpaid wages and expenses previously filed against the Company.
Although the Company has filed an appeal in the California Superior
Court contesting the action taken by the Labor Commissioner, an accrual
for the awarded amount has been recorded as of December 31, 2003
pending the outcome of the appeal.
In January 2004, the Company was served a summons which named the
Company and certain of its officers as defendants in an action filed by
a corporation claiming it was owed fees related to professional
employment placement services in the approximate amount of $114,500.
The Company denies the allegations of the complaint and plans to
vigorously contest the action.
NOTE 12 - RESTATEMENT
---------------------
During the 2002 audit, it was discovered that certain accounting
matters related to the financial statements for the year ended December
31, 2001 required restatement. The Company's prior management
overstated expenses in 2001 by recording $93,595 of accrued personal
expense of the Company's prior management, as general and
administrative and research and development expenses. The financial
statements for the year ended December 31, 2001 have been restated to
decrease operating expenses by $93,595. In addition, it was discovered
that certain general and administrative expenses and research and
development expenses related to the period ended December 31, 2001 were
included in the financial statements for the year ended December 31,
2002. The financial statements for the year ended December 31, 2001
have been restated for this error by increasing operating expenses by
$129,166.
The net effect of these adjustments was to increase net loss $35,571
for the year ended December 31, 2001 as shown below:
64
NOTE 12 - RESTATEMENT (CONTINUED)
As Reported As Restated
----------- -----------
General and administrative expenses $ 436,122 $ 458,773
Research and development expenses 944,745 957,665
----------- -----------
Total operating expenses 1,380,867 1,416,438
=========== ===========
Net loss $1,439,602 $1,475,173
=========== ===========
NOTE 13 - RELATED PARTY TRANSACTIONS
------------------------------------
During 2003, the Company began making consulting payments of $2,500 per
month to a corporation owned by a director of the Company. In June of
2003, the payments were increased to $5,000 per month. Through December
31, 2003 consulting fees and related expenses totaling $41,250 and
$2,604, respectively, were expensed, of which $2,500 is included in
accounts payable at December 31, 2003. In addition, in September 2003,
the Company issued 150,000 shares of common stock to the corporation
for services provided by in connection with the finalization of the
Merger Agreement. In connection with the issuance of these shares, the
Company recorded consulting expenses of $225,000, based on the fair
market value of the common stock at the date of issuance.
In February 2003, the Company entered into a consulting agreement with
director of the Company. Pursuant to this agreement, the director
receives a monthly retainer of $5,000 per month plus a fee of $1,500
per day for consulting work performed. Through December 31, 2003
consulting fees and related expenses totaling $118,000 and $24,581,
respectively, were recorded pursuant to this agreement, of which
$14,721 is included in accounts payable at December 31, 2003.
In February 2003, the Company paid consulting fees in the amount of
$110,000 to a corporation controlled by the two shareholders, each of
whom own beneficially in excess of 5% of the outstanding shares of
common stock of the Company, related to services provided in connection
with the finalization of the Merger Agreement. In April 2003, the
Company entered into a consulting agreement with this corporation
pursuant which, the Corporation is entitled to receive a monthly fee of
$15,000, provided however that payment of accrued fees is not payable
by the Company until such time as the Company has a minimum cash
balance of $2.5 million. Through December 31, 2003 a total of $135,000
in fees has been expensed and accrued pursuant to this agreement.
During 2003, the Company recorded finders fee expenses totaling $30,000
for amounts earned by one of these shareholders and the corporation, in
connection with private equity placements by the Company. Of the total
finders fees earned, $15,000 was paid during the year and $15,000 is
included in accrued expenses at December 31, 2003.
During 2003, the Company paid finders fee expenses in the amount of
$52,500, to a corporation controlled by an individual who beneficially
owns in excess of 5% of the outstanding shares of common stock of the
Company. In addition, during 2003, the Company recorded consulting
expenses totaling $75,000 that were added to an outstanding note
payable with the corporation, and reimbursed the corporation for travel
expenses related to business of the Company totaling $19,279.
65
NOTE 14 - SUBSEQUENT EVENTS
---------------------------
In February 2004, the Company entered into a bridge financing
agreements with five (5) accredited investors pursuant to which the
Company issued a total of $500,000 of secured subordinated debentures
and received net proceeds of $447,500 after subtracting related
placement agent fees and legal expenses totaling $52,500. The
debentures bear interest at an annual rate of 24%, which is payable
monthly beginning April 1, 2004. In addition, the debenture holders
received an aggregate of 250,000 warrants to purchase shares of the
Company's common stock, through March 1, 2009, at an exercise price of
$1.10
The principal balance of the debentures is due and payable on the
earlier of (i) thirty (30) days from the date the Company's
registration statement filed on Form SB-2 is declared effective by the
Securities and Exchange Commission, provided that SBI (as defined in
the Registration Statement) has not defaulted in its obligation to
purchase shares of the Company's common stock or (ii) twelve (12)
months from the date the Registration Statement is declared effective
or (iii) eighteen (18) months from the date of the date of the
debenture agreement.
In April 2004, the Company entered into stock purchase agreements with
two (2) private equity investment funds pursuant to which the funds
agreed to purchase and aggregate of 4,750,000 shares of the Company's
common stock for a total amount of $9,500,000. In addition, under the
agreements, one of the funds would receive 5-year warrants to purchase
up to 1,900,000 shares of the Company's common stock at a price of
$2.00 per share. Completion of this financing and related funding is
contingent on the effectiveness of a registration statement filed with
the Securities and Exchange Commission covering the resale of the
shares of common stock and the shares of common stock underlying the
warrants.
66
VisiJet, Inc.
Balance Sheets
September 30, December 31,
2004 2003
------------- -------------
(Unaudited) (Audited)
ASSETS
Current assets:
Cash and cash equivalents $ 14,342 $ 35,879
Accounts receivable 332,105 --
Inventory 317,003 --
Prepaid expenses 395,948 68,749
Prepaid royalty 2,000 20,000
------------- -------------
Total current assets 1,061,398 124,628
Property and equipment, net 96,522 104,440
Distribution agreement, net 1,749,288 --
Patents and trademarks, net 90,157 97,244
------------- -------------
Total assets $ 2,997,365 $ 326,312
============= =============
LIABILITIES AND SHAREHOLDER'S DEFICIT
Current liabilities:
Accounts payable $ 1,096,197 $ 679,885
Customer deposits 16,720 --
Compensation settlement agreement - current portion 68,562 86,708
Accrued interest 183,061 109,232
Accrued expenses 1,018,181 481,106
Royalty payable 45,000 60,000
Notes payable to related parties 877,660 681,442
Notes payable 10,000 14,000
Convertible debenture debt, net 1,330,513 --
Secured debenture debt, net 1,165,949 --
------------- -------------
Total current liabilities 5,811,843 2,112,373
Compensation settlement agreement, net of current portion -- 17,458
Notes payable to related parties, net of current portion -- 87,144
Convertible debenture debt - long term , net 694,172 --
------------- -------------
Total liabilities 6,506,015 2,216,975
------------- -------------
Shareholders' deficit:
Common stock, 50,000,000 shares authorized, $.001 par value,
27,879,663 shares issued and outstanding at September 30, 2004, and
21,691,163 shares issued and outstanding at December 31, 2003 27,880 21,691
Preferred stock, 10,000,000 shares authorized, $.001 par value,
no shares outstanding at September 30, 2004 or at December 31, 2003 -- --
Additional paid in capital 15,660,343 7,845,365
Common stock subscriptions -- 1,018,500
Deficit accumulated during development stage (19,196,873) (10,776,219)
------------- -------------
Shareholders' deficit (3,508,650) (1,890,663)
------------- -------------
Total liabilities and shareholders' deficit $ 2,997,365 $ 326,312
============= =============
The accompanying notes are an integral part of these financial statements.
VisiJet, Inc.
Statements of Operations
(Unaudited)
Three months Three months Nine months Nine months
ended ended ended ended
September 30, 2004 September 30, 2003 September 30, 2004 September 30, 2003
------------------ ------------------ ------------------ ------------------
Sales - International $ 982,567 $ -- $ 1,037,537 $ --
Cost of Goods Sold 456,400 -- 483,234 --
------------- ------------- ------------- -------------
Gross Profit 526,167 -- 554,303 --
------------- ------------- ------------- -------------
Operating expenses:
General and administrative expenses 1,400,569 680,639 6,415,545 2,054,912
Research and development expenses 182,414 559,098 591,395 876,878
------------- ------------- ------------- -------------
Total operating expenses 1,582,983 1,239,737 7,006,940 2,931,790
------------- ------------- ------------- -------------
Loss from operations (1,056,816) (1,239,737) (6,452,637) (2,931,790)
Other income (expense):
Interest income -- -- -- 455
Amortization of debt discount (328,670) -- (903,802) --
Interest expense (388,515) (5,944) (1,063,414) (45,058)
Gain on debt restructure -- 90,303 -- 90,303
------------- ------------- ------------- -------------
Total other expense (717,185) 84,359 (1,967,216) 45,700
------------- ------------- ------------- -------------
Loss before provision for taxes (1,774,001) (1,155,378) (8,419,853) (2,886,090)
Provision for Income taxes -- -- 800 --
------------- ------------- ------------- -------------
Net loss $ (1,774,001) $ (1,155,378) $ (8,420,653) $ (2,886,090)
============= ============= ============= =============
Net loss per common share - basic and diluted $ (0.06) $ (0.06) $ (0.32) $ (0.15)
============= ============= ============= =============
Basic and diluted weighted average
number of common shares outstanding 29,429,663 20,468,856 26,069,227 18,707,993
============= ============= ============= =============
The accompanying notes are an integral part of these financial statements
4
VisiJet, Inc.
Statements of Cash Flows
(Unaudited)
Nine months ended September 30,
2004 2003
---- ----
Cash flows from operating activities
Net loss $(8,420,653) $(2,886,090)
Adjustment to reconcile net loss to net cash used by operating activities:
Depreciation and amortization 182,728 13,992
Debt discount amortization 903,802 --
Interest expense associated with the beneficial
conversion of the convertible debt 821,139 --
Common stock, options, warrants issued for services 2,894,335 1,201
Fee paid for guarantee 546,403 --
Gain from debt restructure -- (90,303)
Changes in assets and liabilities:
Accounts receivable (332,105) --
Prepaid expenses (309,199) (104,667)
Inventory (317,003) --
Accounts payable 416,311 528,254
Customer deposits 16,720 --
Compensation settlement agreement (35,604) (102,085)
Royalties payable (15,000) (15,000)
Other accrued expenses 537,074 --
Accrued interest 161,952 36,922
------------ ------------
Net cash used by operating activities (2,949,100) (2,617,776)
------------ ------------
Cash flows from investing activities:
Acquisition of property and equipment (15,611) (65,433)
Purchase of distribution agreement (1,188,900) --
------------ ------------
Net cash used in investing activities (1,204,511) (65,433)
------------ ------------
Cash flows from financing activities:
Advance from related party 229,361 231,725
Repayment of advances from related parties (200,600) (166,156)
Repayment of notes payable (4,000) 30,013
Proceeds from secured debenture 1,109,688 --
Proceeds form convertible debt 2,471,125 --
Proceeds from private placements 526,500 2,641,881
Cash acquired in reverse merger -- 30,693
Interest converted to equity in connection with merger -- 33,997
------------ ------------
Net cash provided by financing activities 4,132,074 2,802,153
------------ ------------
Net increase/(decrease)in cash (21,537) 118,944
Cash, beginning of period 35,879 960
------------ ------------
Cash, end of period $ 14,342 $ 119,904
============ ============
Supplemental disclosures of cash flow information
Interest paid $ 90,214 $ --
Taxes paid 800 1,600
Debenture costs and fees 534,190
Non-cash transactions
Reclass of interest to current liability 80,313
Warrants issued in connection with secured debenture 1,195,290
Common Stock issued in connection with secured debenture 106,350
Common Stock issued as collateral 1,100
The accompanying notes are an integral part of these financial statements
Visijet, Inc.
Statement of Shareholders' Equity
Deficit
Accumulated Net
Common Stock Additional during the Shareholders'
----------------------------- Common Stock Paid In Development Equity
Shares Amount Subscriptions Capital Stage (Deficit)
------------- ------------- ------------- ------------- ------------- -------------
Balance, December 31, 2003 21,691,163 $ 21,691 $ 1,018,500 $ 7,845,365 $(10,776,219) $ (1,890,663)
============= ============= ============= ============= ============= =============
Common stock issued in
connection with private
placements 585,000 585 -- 584,415 -- 585,000
Costs of private placements -- -- -- (58,500) -- (58,500)
Common stock given for
services 2,530,000 2,530 -- 2,429,570 -- 2,432,100
Common stock subscriptions 998,500 999 (1,018,500) 1,017,501 -- --
Common stock issued for
distribution agreement 750,000 750 -- 711,750 -- 712,500
Common stock pledged for
debt as collateral 1,100,000 1,100 -- (1,100) -- --
Common stock issued with
debt agreement 150,000 150 -- 106,350 -- 106,500
Common stock issued for
litigation settlement 75,000 75 -- 59,175 -- 59,250
Warrants issued for services -- -- -- 175,469 -- 175,469
Warrants issued for secured
debenture debt -- -- -- 417,975 -- 417,975
Warrants issued for
convertible debt -- -- -- 824,470 -- 824,470
Warrants issued for Debt
Guarantee -- -- -- 546,403 -- 546,403
Warrants issued for
commissions -- -- -- 180,361 -- 180,361
Intrinsic value of
beneficial conversion -- -- -- -- 821,139 --
Net Loss -- -- -- -- (8,420,654) (7,599,515)
------------- ------------- ------------- ------------- ------------- -------------
Balance, September 30, 2004 -- $ 27,880 $ -- $ 15,660,343 (19,196,873) $ (3,508,650)
============= ============= ============= ============= ============= =============
The accompanying notes are an integral part of these financial statements
VISIJET, INC.
NOTES TO FINANCIAL STATEMENTS
NOTE 1 - NATURE OF OPERATIONS
HISTORY AND MERGER
VisiJet, Inc. ("VisiJet", or "the Company") is a medical device company
focused on the marketing and development of ophthalmic surgery products for use
in the laser eye surgery and cataract surgery markets. Through June 30, 2004,
the Company was in the development stage, as its efforts had been principally
devoted to organizational activities, raising capital and research and
development. However, based on operating revenues generated by the Company in
the third quarter of 2004, the Company is no longer considered to be in the
development stage.
The Company was incorporated on February 2, 1996, as a wholly owned
subsidiary of SurgiJet, Inc. to develop and distribute medical products based on
patented waterjet-based technology licensed from SurgiJet. In May 1999, the
Company was spun off from SurgiJet through a distribution of common stock to its
shareholders, after which SurgiJet had no remaining ownership interest in the
Company.
In December 2002 VisiJet entered into a merger agreement with Ponte
Nossa Acquisition Corp., a Delaware corporation ("the Merger") that had been
incorporated as a blank check company in 1997. The agreement called for the
merger of the two companies into a single company through the merger of an
acquisition subsidiary, VisiJet Acquisition Corporation, into VisiJet. The
merger was consummated on February 11, 2003, and immediately thereafter, VisiJet
was merged into Ponte Nossa Acquisition Corp., and the surviving company's name
was changed to "VisiJet, Inc."
In May 2004, the Company entered into a Manufacturing, Supply and
Distribution Agreement with a German company pursuant to which the Company
acquired exclusive worldwide distribution, sales and marketing rights for
ophthalmic surgical products used in LASIK refractive surgery procedures. In May
2004, the Company began marketing these products in Europe and certain other
foreign countries, where the products have received regulatory approval for
sale. In September 2004 the Company began marketing in the United States
following receipt of approval for marketing from the U.S. Food and Drug
Administration. In addition, the Company is conducting research and development
on additional ophthalmic surgery products based on applications of its
proprietary waterjet technology.
BASIS OF PRESENTATION
The accompanying financial statements are unaudited and do not include
certain information and disclosures required by accounting principles generally
accepted in the United States of America for complete financial statements.
However, in the opinion of management, all adjustments, consisting only of
normal recurring adjustments considered necessary to present fairly the
Company's financial position and results of operations, have been included.
These interim financial statements should be read in conjunction with the
financial statements and related notes included in the Company's Annual Report
on Form 10-KSB for the year ended December 31, 2003. Results for interim periods
are not necessarily indicative of trends or of results for a full year.
NATURE OF OPERATIONS (Continued)
GOING CONCERN
The accompanying unaudited consolidated financial statements have been
prepared using the going concern basis of accounting, which contemplates the
realization of assets and the satisfaction of liabilities in the normal course
of business. As more fully discussed in the Company's Annual Report on Form
10-KSB for the year ended December 31, 2003, the Company's audited financial
statements included a "going concern" qualification from its independent
auditors due to the Company's losses accumulated during the development stage
and lack of working capital.
For the three and nine months ended September 30, 2004, the Company
incurred net losses of $1,531,149 and $7,599,515, respectively, and as of
September 30, 2004, the Company's current liabilities exceeded its current
assets by approximately $4.7 million. The Company's future capital requirements
will depend on many factors, including but not limited to the Company's ability
to successfully market and generate operating revenue through product sales, its
ability to finalize development and successfully market its waterjet technology,
its on-going operational expenses and overall product development costs,
including the cost of clinical trials, and competing technological and market
developments.
To address the going concern issue, the Company has continued to raise
operating capital through private placements of debt and equity securities, and
is currently in discussions with several parties regarding additional financing
arrangements. In addition, during the second quarter of 2004, the Company
initiated sales of ophthalmic surgery products acquired through an exclusive
worldwide marketing and distribution license agreement that was finalized in May
2004. The Company expects that revenue and cash flow from sales of these
products will contribute significantly to its future operating results and
working capital requirements.
7
NATURE OF OPERATIONS (Continued)
While the Company believes that the additional financing arrangements
will be completed, and that near-term operating revenues and cash flow will be
generated from the recently completed license agreement, there can be no
assurance that new financing will be completed or that the proceeds from new
financing received by the Company and/or that revenues generated from product
sales will be sufficient for the Company to meet its contractual obligations and
on-going operating expenses.
The accompanying consolidated financial statements do not include any
adjustments that might result from the resolution of these matters.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
REVENUE RECOGNITION
Revenue from product sales relates to sales of ophthalmic surgical
products pursuant to the Manufacturing, Supply and Distribution Agreement
completed in May 2004. Revenue from such sales is recognized when the earnings
process is complete, as evidenced by an agreement with the customer, transfer of
title and acceptance, a firm price and probable collection.
RESEARCH AND DEVELOPMENT COSTS
Research and development costs are charged to expense as incurred.
Certain corporate overhead expenses, such as professional fees, salaries, rent
and travel are allocated to research and development based on estimates made by
management.
INVENTORY
Inventory is valued at lower of cost or market. Reserves for
obsolescence or slow moving inventory are recorded when such conditions are
identified. As of September 30, 2004 no such reserves were considered necessary.
ACCOUNTS RECEIVABLE
The Company regularly reviews accounts and records an allowance for
doubtful accounts based on a specific identification basis of those accounts
that they consider to be uncollectible. As of September 30, 2004, no allowance
for doubtful accounts was considered necessary.
STOCK-BASED COMPENSATION
The Company measures compensation expense related to the grant of stock
options and stock-based awards to employees in accordance with the provisions of
Accounting Principles Board ("APB") Opinion No. 25, under which compensation
expense, if any, is generally based on the difference between the exercise price
of an option, or the amount paid for the award and the market price or fair
value of the underlying common stock at the date of the award. Stock-based
compensation arrangements involving non-employees are accounted for under
Statement of Financial Accounting Standards ("SFAS") No. 123, "ACCOUNTING FOR
STOCK-BASED COMPENSATION," under which such arrangements are accounted for based
8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
on the fair value of the option or award. The Company adopted the disclosure
requirements of SFAS No. 148, "ACCOUNTING FOR STOCK-BASED COMPENSATION -
TRANSITION AND DISCLOSURE," an amendment of SFAS No. 123 as of January 1, 2003,
which require certain disclosures about stock-based employee compensation plans
in an entity's accounting policy note. The adoption of SFAS No. 148 did not have
a material impact on these consolidated financial statements and the disclosure
requirements are included below.
On November 10, 2003, the Board of Directors adopted the VisiJet, Inc.
2003 Stock Option Plan. The Option Plan provides for the grant of incentive and
non-qualified stock options to selected employees, the grant of non-qualified
options to selected consultants and to directors and advisory board members. The
Option Plan is administered by the Compensation Committee of the Board of
Directors and authorizes the grant of options for 3,000,000 shares. The
Compensation Committee determines the individual employees and consultants who
participate under the Plan, the terms and conditions of options, the option
price, the vesting schedule of options and other terms and conditions of the
options granted pursuant thereto.
During the third quarter of 2004, no new options were granted by the
Company, and as of September 30, 2004, a total of 1,145,000 options to purchase
shares of the Company's common stock were outstanding pursuant to the 2003 Plan.
The following table summarizes information about stock options
outstanding at September 30, 2004:
Weighted
Average Weighted Weighted
Remaining Average Average
Exercise Number Life in Exercise Number Exercise
Price Outstanding Years Price Exercisable Price
----- ----------- ----- ----- ----------- -----
1.10 1,145,000 9.12 1.10 370,000 1.10
SFAS No. 123 requires the Company to provide pro forma information
regarding net income (loss) and income (loss) per share as if compensation cost
for the Company's stock option issuances had been determined in accordance with
the fair value based method prescribed in SFAS No. 123. The Company estimates
the fair value of each stock option at the grant date by using the Black-Scholes
option-pricing model with the following assumptions used for grants in fiscal
2003: dividend yield of zero percent, risk-free interest rate of 3.29%, expected
life of five years, and expected volatility of 83.82%.
9
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Under the accounting provisions of SFAS No. 123, as amended by SFAS No.
148, the Company's pro forma net loss and loss per share for the three and nine
months ended September 30, 2004 and 2003, would have been as follows:
For the Three Months For the Nine Months
Ended September 30, Ended September 30,
-------------------------------- --------------------------------
2004 2003 2004 2003
------------- ------------- ------------- -------------
Net Loss $ (1,531,148) $ (1,155,378) $ (7,599,514) $ (2,886,090)
As reported
SFAS No. 123 effect (84,499) -- (253,498) --
------------- ------------- ------------- -------------
Pro forma net loss $ (1,615,647) $ (1,155,378) $ (7,853,012) $ (2,886,090)
Loss per share, basic and diluted
As reported $ (0.05) $ (0.06) $ (0.29) $ (0.15)
============= ============= ============= =============
Pro forma $ (0.05) $ (0.06) $ (0.30) $ (0.15)
============= ============= ============= =============
Basic and diluted weighted
average common shares
Outstanding 29,429,663 20,468,856 26,069,227 18,707,993
============= ============= ============= =============
DEPRECIATION
Depreciation of property and equipment is computed using the
straight-line method over estimated useful lives ranging from three to seven
years.
USE OF ESTIMATES
The preparation of the financial statements in conformity with
accounting principles generally accepted in the United States of America
requires management to make estimates and assumptions that affect the amounts
reported in the financial statements and accompanying notes. Actual results
could differ from those estimates.
IMPAIRMENT OF LONG-LIVED ASSETS
The Company reviews long-lived assets and certain identifiable
intangibles for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable.
Recoverability of assets to be held and used is measured by a
comparison of the carrying amount of an asset to the future net cash flows
expected to be generated by the asset. If such assets are considered to be
impaired, the impairment to be recognized is measured by the amount by which the
carrying amount of the assets exceeds the fair value of the assets. Assets to be
disposed of are reported at the lower of the carrying amount or fair value less
costs to sell.
10
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
LOSS PER SHARE
The Company calculates loss per share in accordance with SFAS No.
128,"EARNINGS PER SHARE," and Securities and Exchange Commission ("SEC") Staff
Accounting Bulletin ("SAB") No. 98. Accordingly, basic loss per share is
computed using the weighted average number of common shares and diluted loss per
share are computed based on the weighted average number of common shares and all
common equivalent shares outstanding during the period in which they are
dilutive. Common equivalent shares consist of shares issuable upon the exercise
of stock options, using the treasury stock method, or warrants; common
equivalent shares are excluded from the calculation if their effect is
anti-dilutive.
INCOME TAXES
The Company utilizes the asset and liability method of accounting for
income taxes. Under this method, deferred tax assets and liabilities are
recognized for the estimated future tax consequences attributable to differences
between the financial statement carrying amounts of existing assets and
liabilities and their respective tax basis and operating loss and tax credit
carryforwards. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those
temporary differences are expected to be recovered or settled. The effect on
deferred tax assets and liabilities of a change in tax rates is recognized in
income in the period that includes the enactment date.
RECLASSIFICATIONS
Certain reclassifications have been made to the financial statement of
the prior year in order to conform to current year presentation.
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
There are no recent accounting pronouncements that have had, or are
expected to have, a material effect on the Company's financial statements.
NOTE 3 - INVENTORY
Inventory includes finished goods of ophthalmic surgical products
purchased pursuant to the Manufacturing, Supply and Distribution Agreement
completed in May 2004, and consists of the following at September 30, 2004 and
December 31, 2003:
September 30, 2004 December 31, 2003
------------------ -----------------
Completed units and disposable
supplies $ 164,121 $ -
Demonstration units 152,882 -
-------------- --------------
$ 317,003 $ -
============== ==============
11
NOTE 4 - PROPERTY AND EQUIPMENT
Property and equipment consist of the following at September 30, 2004
and December 31, 2003:
September 30, 2004 December 31, 2003
------------------ -----------------
Computer and test equipment $ 98,195 $ 82,584
Furniture and fixtures 33,505 33,505
Trade show equipment 47,002 47,002
-------------- --------------
178,702 163,091
Less: Accumulated depreciation (82,180) (58,651)
-------------- --------------
$ 96,522 $ 104,440
============== ==============
Depreciation expense for the three and nine months ended September 30,
2004, was $8,682 and $23,529, respectively.
NOTE 5 - DISTRIBUTION AND PATENT AGREEMENTS
In May 2004, the Company entered into a Manufacturing, Supply and
Distribution Agreement with a German company ("licensor") pursuant to which the
Company acquired exclusive worldwide distribution, sales and marketing rights
for certain ophthalmic surgical products used in LASIK refractive surgery
procedures.
The Company capitalized a total of $1,901,400 in connection with this
agreement based on non-refundable cash license fee paid, plus the fair market
value of 750,000 shares of common stock issued to the licensor, as consideration
under the agreement. The total capitalized amount is being amortized on a
straight-line basis over the term of the agreement.
During 2003, the Company entered into a patent license agreement with
the inventor of a patented technology through which the Company obtained
exclusive worldwide rights for all medical applications for the technology that
provides for the sterile flow of fluid through a surgical water jet apparatus.
The purchase price of the license has been capitalized and is being amortized on
a straight-line basis over the remaining life of the patent. The license
agreement provides for royalty payments based on the sale of products utilizing
licensed technology and for minimum annual royalty payments.
Distribution and Patent agreements consist of the following at
September 30, 2004 and December 31, 2003:
September 30, 2004 December 31, 2003
------------------ -----------------
Distribution agreements $ 1,901,400 $ --
Patent agreements 100,000 100,000
Less: accumulated amortization (161,955) (2,756)
------------ ------------
$ 1,839,445 $ 97,244
============ ============
12
DISTRIBUTION AND PATENT AGREEMENTS (Continued)
Amortization expense for the three and nine months ended September 30,
2004 was $97,433 and $159,199, respectively. In connection with these
agreements, the Company expects to record the following amortization expense
over the next five years:
Fiscal Year Ended Amortization Total
------------------------------ -------------------
12/31/04 97,432
12/31/05 389,729
12/31/06 389,729
12/31/07 389,729
12/31/08 389,729
12/31/09 137,822
-------------------
Total 1,794,170
===================
NOTE 6 - ACCRUED EXPENSES
Accrued expenses consist of the following at September 30, 2004 and
December 31, 2003:
September 30, 2004 December 31, 2003
------------------ -----------------
Payroll and related taxes $ 463,010 $ 55,191
Consulting fees 270,000 135,000
Litigation settlement fees 201,117 170,066
Other accruals 84,054 120,849
-------------- --------------
$ 1,018,181 $ 481,106
============== ==============
NOTE 7 - SECURED DEBENTURES
In February 2004, the Company entered into bridge financing agreements
with five investors pursuant to which the Company issued a total of $500,000 of
secured subordinated debentures and received net proceeds of $447,500 after
subtracting related placement agent fees and legal expenses totaling $52,500.
The debentures bear interest at an annual rate of 24%, which is payable
monthly beginning April 1, 2004. In addition, the debenture holders received
warrants to purchase 250,000 shares of the Company's common stock, exercisable
through March 1, 2009, at an exercise price of $1.10 per share.
The principal balance of the debentures is due and payable on the
earlier of (i) thirty (30) days from the date the Registration Statement is
declared effective by the Securities and Exchange Commission, provided that a
specified affiliate of the investors has not defaulted in its obligation to
purchase shares of the Company's common stock, or (ii) twelve (12) months from
the date the Registration Statement is declared effective, or (iii) eighteen
(18) months from the date of the debenture agreement.
The debentures are secured by all accounts and equipment of the
Company, now owned, existing or hereafter acquired.
The debenture debt was recorded net of discounts totaling $230,668
recorded in connection with the $52,500 of loan fees and expenses, and $178,168,
based on a Black-Scholes model valuation, related to the 250,000 warrants issued
13
SECURED DEBENTURES (Continued)
to debenture holders. During the nine months ended September 30, 2004, the
Company recorded total interest expense of $206,616 in connection with the
debenture debt, of which $146,616 resulted from the non-cash amortization of
debt discount and $60,000 related to interest accrued during the period on the
outstanding principal balance. Of the interest accrued, $49,700 was paid during
the period, and $10,300 was payable as of September 30, 2004. In October 2004,
the Company received a notice of default from the holders of an aggregate of
$400,000 of these debentures due to the non-timely payment of interest that was
owed under the debenture agreements. Subsequent to the receipt of notice, the
Company made the required interest payments and the Company is in discussions
with the debenture holders regarding a resolution of this matter.
In May 2004, the Company entered into an agreement with an
institutional lender pursuant to which the Company issued a total of $750,000 of
secured subordinated debentures and received net proceeds of $662,188 after
subtracting related placement agent fees and expenses totaling $80,000 and
prepaid interest totaling $7,812.
The principal balance of the debentures was due and payable on July 5,
2004, and the debentures bear interest at an annual rate of 15%, which is
payable monthly beginning June 1, 2004. In addition, the debenture holder
received a warrant to purchase 500,000 shares of the Company's common stock,
exercisable through May 6, 2009, at an exercise price of $0.90 per share.
The debentures are secured by an aggregate of 1,500,000 shares of the
Company's common stock, of which 750,000 shares were issued by the Company and
750,000 shares were borrowed by the Company pursuant to a security lending
agreement between the Company and a third party.
The debenture debt was recorded net of discounts totaling $319,807
recorded in connection with the $80,000 of loan fees and expenses, and $239,807,
based on a Black-Scholes model valuation, related to the 500,000 warrants issued
to the debenture holder. During the nine months ended September 30, 2004, the
Company recorded total interest expense of $365,120 in connection with the
debenture debt, of which $319,807 resulted from the non-cash amortization of
debt discount and $45,313 related to interest accrued during the period on the
outstanding principal balance. Of the interest accrued, $35,938 was paid during
the period, and $9,375 was payable as of September 30, 2004. The Company did not
repay the principal on the scheduled maturity date of July 5, 2004, and such
failure to pay constitutes a default under the obligation. In October 2004 the
debenture holder entered into a forbearance agreement with the holders of
convertible debentures entered into in June and July 2004 with an aggregate
principal amount of $2,000,000, pursuant to which the debenture holder agreed
not to take any action with respect to the non-payment of the $750,000 principal
balance until the earlier of (i) February 2, 2005 and (ii) the date of notice of
default from the convertible debenture holders to the Company.
As of September 30, 2004 and December 31, 2003, secured debenture debt
balance consists of the following:
Sept. 30, 2004 December 31, 2003
--------------- -----------------
Secured subordinated debenture $ 1,250,000 $ --
Secured debenture discount ( 84,051) --
-------------- ----------------
Secured debenture debt $ 1,165,949 $ --
============== ================
14
Note 8 - CONVERTIBLE DEBENTURES
In May 2004, the Company entered into convertible debenture agreements
with two private lenders with an aggregate principal balance of $800,000, and
received net proceeds of $695,000 after subtracting related placement agent fees
and expenses totaling $105,000.
The debentures bear interest at an annual rate of 10%, which is due and
payable on the maturity date. In addition, the debenture holders received an
aggregate of 533,000 warrants to purchase shares of the Company's common stock,
exercisable through May 6, 2009 at an exercise price of $0.90 per share.
The principal balance of the debentures is due and payable on the
earlier of (i) one hundred and five (105) days from the issue date, or (ii) ten
(10) business days from the date the Company's Registration Statement is
declared effective by the Securities and Exchange Commission.
The debentures are secured by an aggregate of 800,000 shares of the
Company's common stock borrowed by the Company pursuant to a security lending
agreement between the Company and a third party. Under certain circumstances,
the outstanding principal of the debentures may be converted into shares of the
Company's common stock based on an initial conversion price of $0.90, (which was
equal to the market price of the Company's common stock on the commitment date),
subject to adjustment as defined in the agreement.
The debenture debt was recorded net of discounts totaling $360,793
recorded in connection with the $105,000 of loan fees and expenses, and
$255,793, based on a Black-Scholes model valuation, related to the 533,000
warrants issued to debenture holders.
During the nine months ended September 30, 2004, the Company recorded
total interest expense of $393,012 in connection with the debenture debt, of
which $360,793 resulted from the non-cash amortization of debt discount and
$32,219 related to interest accrued during the period on the outstanding
principal balance.
In connection with these debentures, the Company entered into a
registration rights agreement with the debenture holders covering 533,333 shares
of common stock underlying the warrants issued in connection with these
debentures. Pursuant to this agreement, the Company was obligated to file a
Registration Statement with the Securities and Exchange within 30 days of the
closing of the transaction.
The Company was not in compliance with terms of these debenture
agreements due to the non-payment of the principal balance by the scheduled
maturity date in August 2004, and due to its failure to file a Registration
Statement with the Securities and Exchange Commission covering warrants issued
to debenture holders pursuant to the debenture agreement by June 6, 2004, as
required by the registration rights agreement entered into between the Company
and the debenture holders in connection with the debenture agreement. The
failure to pay the principal balance when due and to file the Registration
Statement on a timely basis are events of defaults under the agreement. The
Company is in discussions with the debenture holders regarding a resolution of
these matters.
In June 2004, the Company entered into convertible debenture agreements
with two private lenders with an aggregate principal balance of $1,000,000, and
received net proceeds of $880,000 after subtracting related placement agent fees
and expenses totaling $120,000. The principal balance of the debentures is due
and payable on June 24, 2006.
The debentures bear interest at an annual rate of 8%, which is payable
quarterly beginning December 31, 2004. In addition, the debenture holders
received an aggregate of 150,000 shares of the company's common stock, and an
aggregate of 750,000 warrants to purchase shares of the Company's common stock,
15
CONVERTIBLE DEBENTURES (Continued)
exercisable through June 24, 2009, at an exercise price of $1.50 per share,
provided however that the exercise price with respect to an aggregate of 500,000
of the warrants is reduced to $0.60 per share during the period from the date of
issuance through the date twelve (12) months after the Securities and Exchange
Commission declares effective a registration statement registering the resale of
shares underlying the warrants.
The debenture debt was recorded net of discounts totaling $541,714
recorded in connection with the $120,000 of loan fees and expenses, $106,500
recorded based on the fair market value of the common stock on the date of
issuance and $315,214, based on a Black-Scholes model valuation, related to the
533,000 warrants issued to debenture holders.
The debentures are secured by an aggregate of 350,000 shares of the
Company's common stock issued by the Company, and the outstanding principal of
the debentures may be converted, subject to redemption rights of the Company,
into shares of the Company's common stock based on an initial conversion price
of $0.50, subject to adjustment as defined in the agreement.
The market price of the Company's common stock on the date of issuance
of the debentures was $0.71 per share. In accordance with EITF 98-5, as amended
by EITF 00-27, because the debentures were sold at an effective conversion price
less than the market value of the underlying components of the security, a
beneficial conversion to the holders of the debentures occurred. Accordingly,
the Company recorded a discount to the principal of the debenture and a
corresponding amount to common stock additional paid in capital. The recorded
discount resulting from the beneficial conversion is recognized as non-cash
interest expense from the date of issuance to the earliest date on which the
debt is convertible by note holders. Since the debt was convertible, at the
option of the note holders, at any time following issuance, the entire discount
recorded, $578,286, was recognized as non-cash interest expense during the
second quarter of 2004.
During the three months ended September 30, 2004, the Company recorded
total interest expense of $89,194 in connection with the debenture debt, of
which $67,714 resulted from the non-cash amortization of debt discount recorded
in connection with loan fees and the value of stock and warrants issued to note
holders, and $21,480 resulted from interest accrued during the period on the
outstanding principal balance.
In connection with these debentures, the Company entered into a
Registration Rights Agreement with the debenture holders related to the warrants
and shares underlying the conversion feature of the debentures that required the
Company to file a Registration Statement with the Securities and Exchange within
30 days of the closing of the transaction. Due to the Company's failure to file
the Registration Statement within 30 days, the Company was not in compliance
with this requirement of the agreement. As discussed in more detail in Note 16,
in October 2004 and November 2004 the Company received a waiver of the
non-compliance in connection with an amendment to the debenture agreements and
an extension of the required Registration Statement filing date deadline to
November 15, 2004.
In July 2004, the Company entered into convertible note agreements with
a private lender with an aggregate principal balance of $1,000,000, and received
net proceeds of $896,125 after subtracting related placement agent fees and
expenses totaling $103,875. The note bears interest, at an annual rate of 8%,
which is due and payable quarterly beginning on October 31, 2004. In addition,
the debenture holders received warrants to purchase 750,000 shares of the
Company's common stock, exercisable through July 23, 2011, at an exercise price
of $1.00 per share.
The principal balance of the note, plus any accrued and unpaid
interest, is due and payable on July 23, 2014, provided however, that on or
after July 31, 2007 the Company, at the option of the note holder, may be
obligated to repurchase the note at a price equal to 100% of the outstanding
principal and interest. The outstanding principal of the debentures may be
converted into shares of the Company's common stock, at the option of the note
holder, based on an initial conversion price of $0.54 per share, subject to
adjustment as defined in the agreement.
The debenture debt was recorded net of discounts totaling $310,182
recorded in connection with the $103,875 of loan fees and expenses $206,307,
based on a Black-Scholes model valuation, related to the 750,000 warrants issued
to debenture holders.
16
CONVERTIBLE DEBENTURES (Continued)
The market price of the Company's common stock on the date of issuance
of the debentures was $0.57 per share. In accordance with EITF 98-5, as amended
by EITF 00-27, because the debentures were sold at an effective conversion price
less than the market value of the underlying components of the security, a
beneficial conversion to the holders of the debentures occurred. Accordingly,
the Company recorded a discount to the principal of the debenture and a
corresponding amount to common stock additional paid in capital. The recorded
discount resulting from the beneficial conversion is recognized as non-cash
interest expense from the date of issuance to the earliest date on which the
debt is convertible by note holders. Since the debt was convertible, at the
option of the note holders, at any time following issuance, the entire discount
recorded was recognized as non-cash interest expense during the second quarter
of 2004.
During the three months ended September 30, 2004, the Company recorded
total interest expense of $262,540 in connection with the debenture debt. Of
this total, $242,853 resulted from non-cash amortization of the discount
recorded in connection with the beneficial conversion, $4,354 resulted from the
non-cash amortization of debt discount recorded in connection with loan fees and
the value of stock and warrants issued to note holders, and $15,333 resulted
from interest accrued during the period on the outstanding principal balance.
In connection with these debentures, the Company entered into a
Registration Rights Agreement with the debenture holders related to the warrants
and shares underlying the conversion feature of the debentures that required the
Company to file a Registration Statement with the Securities and Exchange within
30 days of the closing of the transaction. Due to the Company's failure to file
the Registration Statement within 30 days, the Company was not in compliance
with this requirement of the agreement. As discussed in more detail in Note 16,
in October 2004 and November 2004 the Company received a waiver of the
non-compliance in connection with an amendment to the debentures agreements and
an extension of the required Registration Statement filing date deadline to
November 15, 2004.
As of September 30, 2004 and December 31, 2003, convertible debenture
debt balances consists of the following:
Current:
September 30, 2004 December 31, 2003
------------------ -----------------
Convertible debenture $ 1,800,000 $ --
Convertible debenture discount --
-------------- ---------------
Convertible debenture - net $ 1,330,513 $ --
============== ===============
Long Term:
September 30, 2004 December 31, 2003
------------------ -----------------
Convertible debenture $ 1,000,000 $ --
Convertible debenture discount --
-------------- ---------------
Convertible debenture - net $ 694,172 $ --
============== ===============
NOTE 9 - NOTES PAYABLE - RELATED PARTIES
SURGIJET, INC. AND RELATED PARTIES
In October 1998, the Company issued a demand promissory note in the
amount of $400,000, plus interest at a variable rate, based on the prime rate to
of SurgiJet, Inc. ("SurgiJet"), VisiJet's former parent company. In connection
with the Merger Agreement, an amendment to the note agreement was executed in
February, 2003 under which the accrual of additional interest was halted, and
scheduled principal and interest payments were established.
During 2002, the Company entered into a promissory note in the amount
of $91,000 plus interest at the rate of 10% per annum with DentaJet, Inc.
("DentaJet"), a Company then related through common shareholders. During 2002
and 2003, the Company borrowed an additional $72,000 from, and made payments
totaling $27,482, to DentaJet, resulting in an outstanding principal balance of
$135,518 at December 31, 2003
During 2002, the Company entered into a promissory note with Lance
Doherty, a principal of SurgiJet and shareholder of the Company, for a principal
sum of $19,000 plus interest at the rate of 10% per annum. At December 31, 2003
the outstanding principal balance of this note was $19,000.
17
NOTES PAYABLE - RELATED PARTIES (Continued)
During 2002, the Company recorded a liability of $2,967 related to
expenses paid by Rex Doherty, a principal of SurgiJet and shareholder of the
Company. At December 31, 2003 the outstanding liability balance was $2,967.
During 2003 the Company initiated litigation against SurgiJet,
challenging the validity of the SurgiJet Note, as well as other notes and
liabilities to DentaJet, Lance Doherty and Rex Doherty.
As discussed in more fully Note 11, in October 2004, the parties to the
litigation entered into a settlement agreement pursuant to which revised note
payable amounts and payment schedules were agreed upon. Based on this agreement,
outstanding
principal and accrued interest balances related to these notes as of September
30, 2004 have been adjusted to reflect the agreed upon amounts, and as a result,
the balances at September 30, 2004 and December 31, 2003 are as follows:
September 30, 2004 December 31, 2003
Principal Interest Principal Interest
---------------------------------------------------------------------------
SurgiJet $ 579,774 $ 3,574 $ 360,976 $ 43,676
DentaJet - - 135,518 24,745
Lance Doherty 19,000 3,775 19,000 3,920
Rex Doherty - - 2,967 298
---------------------------------------------------------------------------
Total $ 598,774 $ 7,349 $ 518,461 $ 72,639
===========================================================================
FINANCIAL ENTREPRENEURS, INC. ("FEI")
In connection with the Merger Agreement in 2003, the Company assumed a
promissory note during 2003 originally entered into between PNAC and FEI, a
significant shareholder of the Company, during 2002. The note bears interest at
an annual rate of 7.5%, and matures on April 3, 2009. Upon consummation of the
merger in February 2003, the outstanding principal and accrued interest payable
balances were $206,649 and $11,462, respectively. During 2003, the Company added
net borrowings of $43,476 to the note, and accrued additional interest expense
of $17,072, resulting in an outstanding principal balance and accrued interest
payable balances at December 31, 2003 of $250,125 and $28,534, respectively.
During the nine months ended September 30, 2004, net activity resulted in an
increase to the outstanding principal of $28,761 and $17,257 of interest expense
related to this note. As of September 30, 2004 the outstanding principal and
accrued interest payable on this note were $278,886 and $45,791, respectively.
18
NOTE 10 - COMMITMENTS
LICENSE AGREEMENTS
Under the terms of the technology license agreements with SurgiJet, the
Company is obligated to pay a royalty of 7% of revenues received from sales of
the products, up to $400 million of revenues over the course of the agreements,
and 5% of revenues thereafter. The license agreements with SurgiJet also provide
for a minimum royalty of $60,000 per year that may be used as a credit toward
payment of future royalties due on product sales.
Under the terms of the patent license agreement entered into during
2003, the Company is obligated to pay a royalty of 6% of net sales of products
utilizing the licensed patent technology. The license agreement also provides
for a minimum royalty of $24,000 per year that may be used as a credit toward
payment of future royalties due on product sales.
Under the terms of the Manufacturing, Supply and Distribution Agreement
entered into in May 2004, the Company is obligated to purchase specified minimum
monthly and annual quantities of licensed products from the Licensor. There are
no royalties on product sales due or payable by the Company under this
agreement.
NOTE 11 - SHAREHOLDERS' EQUITY (DEFICIT)
COMMON STOCK ACTIVITY
During the third quarter of 2004, the Company cancelled 2,300,000
shares of common stock that had been issued during the second quarter as
collateral under a pending debt agreement. The cancellation of these shares was
recorded as a reversal of the reduction to Additional Paid in Capital based on
the par value of shares issued that was recorded when the shares were originally
issued.
WARRANT ACTIVITY
During the third quarter of 2004, the Company issued 5-year warrants to
purchase an aggregate of 832,500 shares of its common stock at an average
exercise price of $0.72 per share and 7-year warrants to purchase an aggregate
of 825,000 shares of its common stock at an average exercise price of $1.00 per
share.
In connection with warrants issued during this period, the Company
recorded debt discount totaling $206,307 related to 750,000 warrants issued in
connection with convertible debenture agreements completed during the quarter,
professional fees totaling $231,228 related to an aggregate of 850,000 warrants
issued as commissions on debenture and Preferred Stock agreements completed
during the quarter and professional fees totaling $ 13,153 related to an
aggregate of 57,500 warrants issued for consulting services. All amounts
recorded in connection with these warrants were based on the fair value of the
warrants issued using a Black-Scholes model valuation.
The following table summarizes the number of outstanding common stock
warrants as of September 30, 2004:
Weighted Average
Number Exercise Price
----------- ------------
Outstanding at December 31, 2003 12,102,480 $ 2.53
Granted 825,000 1.87
Forfeited -- --
Exercised -- --
----------- ------------
Outstanding at March 31, 2004 12,927,480 $ 2.49
Granted 2,080,833 1.00
Forfeited -- --
Exercised -- --
---------- ------------
Outstanding at June 30, 2004 15,008,313 $ 1.87
Granted 1,657,500 0.86
Forfeited -- --
Exercised -- --
---------- ------------
Outstanding at September 30, 2004 16,665,813 $ 1.77
19
NOTE 12 - SETTLEMENT AGREEMENTS AND LOAN PAYABLE
In November 2002, the Company entered into settlement agreements with
an officer and an employee related to accrued but unpaid fees for consulting
services rendered by them prior to the consummation of the Merger in the
aggregate of $700,000. Under the agreements a total of $450,000 was converted
into 211,267 shares of the Company's common stock, during 2003, based upon the
closing price on the effective date the Merger Agreement. The balance owed of
$250,000 was converted into two notes payable that bear interest at an annual
rate of 3.5% and provide for the principal to be paid over equal installments
for the duration of the loans. At September 30, 2004 and December 31, 2003, the
aggregate balances on these notes were $68,563 and $104,166, respectively and
the respective accrued interest payable balances were $8,999 and $6,330.
NOTE 13 - CONTINGENCIES
In October 2004, the Company and SurgiJet, its former parent company
entered into a settlement agreement covering all previously outstanding
litigation between the two companies, as well as with SurgiJet's principal
owners and its subsidiary, DentaJet.
In accordance with the settlement agreement, the Company, agreed to pay
a total of $579,774, plus accrued interest at an annual rate of 7.5% from August
31, 2004 ($3,574 through September, 30, 2004), as full settlement of previously
disputed notes payable to SurgiJet and DentaJet and related accrued interest
which the Company was carrying on its books in the aggregate amount of $580,718.
In addition, the Company agreed to pay a previously disputed note payable to a
shareholder of the Company, who is also a principal owner of SurgiJet, $19,000
plus accrued interest at an annual rate of 10% from December 31, 2002 ($3,775
through September 30, 2004), which the Company was carrying on its books in the
aggregate amount of $24,678.
In addition, the Company agreed to issue 75,000 shares of its Common
Stock to SurgiJet, granted SurgiJet a security interest in all of its assets and
agreed to provide SurgiJet with a stipulated judgment, which can only be filed
by SurgiJet upon an event of default which remains uncured following 10 days
after receipt of written notice of such default.
Payments on all obligations due pursuant to the settlement agreement
will be made in monthly installments commencing December 1, 2004. The first
payment is in the amount of $30,000, thereafter monthly payments are $20,000
through December 2005, and $25,000 from January 1, 2006 until the obligations
are paid in full.
In accordance with the settlement agreement, SurgiJet and its
principals agreed to waive, subject to completion and final report from an
independent accounting firm, claims for additional monies owed to them, and to
drop their cross-complaint against the Company, its directors and certain of its
officers seeking additional monetary damages and rescission of the Merger
Agreement.
In February 2004, the Company was served a summons which named the
Company as one of several defendants in an action filed by an individual seeking
damages of approximately $450,000 based on claims including breach of contract,
promissory fraud and negligent misrepresentation related to activities that
occurred, and involving owners and management of the Company, prior to the
effective date of the Merger Agreement. The Company denies any involvement in
the activities included in the allegations, and does not anticipate the
necessity to defend this action.
20
NOTE 14 - RELATED PARTY TRANSACTIONS
During the three and nine months ended September 30, 2004 the Company
recorded $17,250 and $62,250, respectively, of consulting fees to a corporation
owned by a director of the Company. As of September 30, 2004, $6,500 related to
this agreement was included in accounts payable.
During the three and nine months ended September 30, 2004 the Company
recorded $45,000 and $135,000, respectively of consulting fees and expenses of
$2,291 and $17,395, respectively, in connection with this agreement. As of
September 30, 2004, $28,509 related to this agreement was included in accounts
payable.
During the three and nine months ended September 30, 2004 the Company
recorded $45,000 and $135,000, respectively, of consulting fees in connection
with an agreement with a corporation controlled by two shareholders, each of
whom own beneficially in excess of 5% of the outstanding shares of the Company's
common stock. Pursuant to this agreement, entered into in April 2003, the
Corporation is entitled to receive a monthly fee of $15,000, provided however
that payment of accrued fees is not payable by the Company until such time as
the Company has a minimum cash balance of $2.5 million. At September 30, 2004 a
total of $270,000 in fees recorded pursuant to this agreement is included in
accrued expenses.
During the three and nine months ended September 30, 2004 the Company
reimbursed a corporation controlled by an individual who beneficially owns in
excess of 5% of the outstanding shares of common stock of the Company for travel
expenses related to business of the Company totaling $5,626 and $15,592,
respectively. As of September 30, 2004, $656 of these expenses was included in
accounts payable.
NOTE 15 - Security Lending Agreement
In April 2004, the Company and a corporation that beneficially owns in
excess of 5% of the outstanding shares of common stock of the Company entered
into an agreement pursuant to which the corporation agreed to make available 3
million shares of the Company's common stock, for use by the Company as
collateral in subsequent financing transactions. In accordance with the terms of
this agreement, the Company is obligated to pay interest on the value of shares
borrowed (assuming a value of $1.00 per share) based on the LIBOR rate plus 50
basis points, and must return the borrowed shares by November 30, 2004. In the
event of default, the Company has agreed to file a Registration Statement and to
return any shares, within 72 hours, that had not previously been returned by the
due date. As of September 30, 2004 the Company had borrowed a total of 800,000
shares pursuant to this agreement, and the Company had accrued interest expense
totaling $ 25,725.
NOTE 16 - SUBSEQUENT EVENTS
CONVERTIBLE DEBENTURE AGREEMENTS
In October 2004, the Company entered into convertible debenture
agreements with four private lenders with an aggregate principal balance of
$850,000, and received net proceeds of $788,000 after subtracting related
placement agent fees and expenses totaling $62,000. The notes bear interest, at
an annual rate of 8%, which is due and payable quarterly beginning on December
31, 2004. The principal balance of the note, plus any accrued and unpaid
interest is due and payable on October 6, 2014, provided however, that on or
after October 6, 2007 the Company, at the option of the note holder, may be
obligated to repurchase the note at a price equal to 100% of the outstanding
principal and interest. In addition, the note holders received warrants to
purchase 850,000 shares of the Company's common stock, exercisable through
October 6, 2009 at an exercise price of $0.40 per share.
21
CONVERTIBLE DEBENTURE AGREEMENTS - AMENDMENTS
In connection with the Convertible Debenture Agreements entered into in
October 2004, the Company agreed to modify certain terms and conditions included
in convertible debenture agreements with an aggregate principal balance of
$2,000,000 entered into in June and July 2004. The modifications included a
reduction in the exercise prices of an aggregate of 1,500,000 previously issued
warrants to $0.40 per share, a reduction of the initial conversion price of
these debentures to $0.35 per share, the issuance of warrants to purchase
500,000 shares at an exercise price of $0.40 per share and the issuance of
261,428 shares of common stock as full payment of accrued liquidated damages. As
a result of these modifications, the debenture holders agreed to waive all
events of default and non-compliance under the covenants of those agreements,
and to extend the required Registration Statement filing date deadline to
November 1, 2004, and in November 2004, the filing date deadline was further
extended to November 15, 2004.
PREFERRED STOCK
In October 2004, the Company consummated the sale of 450,000 shares of
Series A Convertible Preferred Stock ("Series A Shares") to a corporation
organized under the laws of England and Wales pursuant to a Convertible
Preferred Stock Purchase Agreement (the "Stock Purchase Agreement"). Under the
Stock Purchase Agreement, the Company agreed to sell the Series A Shares to the
corporation in return for the corporation issuing to the Company 2,477,974 of
its Ordinary Shares. Consummation of the transaction was subject to admission of
the corporation's shares to the London Stock Exchange ("LSE"), which occurred on
September 30, 2004 and the initiation of trading on the LSE, which began on
October 7, 2004. In accordance with the Stock Purchase Agreement, the Company
may sell the shares received by it in the open market on the LSE at any time.
The Series A Shares are non-voting, except as required by Delaware law,
and the holders of the Series A Shares are not entitled to receive any
dividends. The Series A Shares, which have a "stated value" for purposes of
conversion and redemption of $10.00 per share, are convertible at any time for a
period of three years from the date of issuance into shares of the Company's
common stock ("Common Stock"). The number of shares of Common Stock to be issued
upon conversion is determined by dividing the aggregate stated value of the
Series A Shares being converted by the conversion price then in effect, which is
to be the lesser of $0.609 (the "Fixed Conversion Price"), or eighty percent
(80%) of the lowest closing bid price of the Common Stock in the ten (10)
trading days preceding the date of conversion, but in no event less than 30
percent (30%) of the Fixed Conversion Price. However, the corporation may not
convert to the extent that conversion would result in owning more than 4.99% of
the outstanding Common Stock of the Company. The conversion price is subject to
further adjustment based on anti-dilution provisions that require an adjustment
to the conversion price based on certain events, including the issuance of
common stock or convertible securities at a price per share below market value,
stock dividends and combinations and certain distributions to shareholders. Any
shares not previously converted will be automatically converted at the
expiration of the three year period. The Series A Shares carry a liquidation
preference equal to the stated value. If the Company defaults under certain
covenants in the Certificate of Designation, the holder of the Series A Shares
may compel redemption at the stated value.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 24. Indemnification of Directors and Officers.
The certificate of incorporation and the by-laws of the registrant
provide that the registrant shall indemnify its officers, directors and certain
others to the maximum extent permitted by the General Corporation Law of the
State of Delaware.
Section 145 of the General Corporation Law of the State of Delaware
provides in relevant part as follows:
(a) A corporation shall have power to indemnify any person who was or
is a party or is threatened to be made a party to any threatened, pending or
completed action, suit or proceeding, whether civil, criminal, administrative or
investigative) other than an action by or in the right of the corporation) by
reason of the fact that the person is or was a director, officer, employee or
agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation, partnership,
joint venture, trust or other enterprise, against expenses (including attorneys'
fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred by the person in connection with such action, suit or proceeding if the
person acted in good faith and in a manner the person reasonably believed to be
in or not opposed to the best interests of the corporation, and, with respect to
any criminal action or proceeding had no reasonable cause to believe the
person's conduct was unlawful. The termination of any action, suit or proceeding
by judgment, order, settlement, conviction, or upon a plea of nolo contendere or
its equivalent, shall not, of itself, create a presumption that the person did
not act in good faith and in a manner which the person reasonably believed to be
in or not opposed to the best interests of the corporation, and, with respect to
any criminal action or proceeding, had reasonable cause to believe that the
person's conduct was unlawful.
(b) A corporation shall have power to indemnify any person who was or
is a party or is threatened to be made a party to any threatened, pending or
completed action or suit by or in the right of the corporation to procure a
judgment in its favor by reason of the fact that the person is or was a
director, officer, employee or agent of the corporation, or is or was serving at
the request of the corporation as a director, officer, employee or agent of
another corporation, partnership, joint venture, trust or other enterprise
against expenses (including attorneys' fees) actually and reasonably incurred by
the person in connection with the defense or settlement of such action or suit
if the person acted in good faith and in a manner the person reasonably believed
to be in or not opposed to the best interest of the corporation and except that
no indemnification shall be made in respect of any claim, issue or matter as to
which such person shall have been adjudged to be liable to the corporation
unless and only to the extent that the Court of Chancery or the court in which
II-1
such action or suit was brought shall determine upon application that, despite
the adjudication of liability but in view of all the circumstances of the case,
such person is fairly and reasonably entitled to indemnity for such expenses
which the Court of Chancery or such other court shall deem proper.
The General Corporation Law does not allow for the elimination or
limitation of liability of a director: (i) for any breach of a director's duty
of loyalty to the corporation or its stockholders; (ii) acts or omissions not in
good faith or which involve intentional misconduct or a knowing violation of
law; (iii) arising under Section 174 thereof; or (iv) for any transaction from
which the director derived an improper personal benefit. The General Corporation
Law provides further that the indemnification permitted thereunder shall not be
deemed exclusive of any rights to which the directors and officers may be
entitled under the corporation's bylaws, any agreement, a vote of stockholders
or otherwise.
In addition, pursuant to our certificate of incorporation and by-laws,
we shall indemnify our directors and officers against expenses (including
judgments or amounts paid in settlement) incurred in any action, civil or
criminal, to which any such person is a party by reason of any alleged act or
failure to act in his capacity as such, except as to a matter as to which such
director or officer shall have been finally adjudged not to have acted in good
faith in the reasonable belief that his action was in the best interest of the
corporation.
Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers and controlling persons pursuant to
the foregoing provisions, or otherwise, we have been advised that in the opinion
of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable.
Item 25. Other Expenses of Issuance and Distribution.
SEC registration fee $ 3,083
Printing and duplication expenses $ 2,000
Legal fees and expenses $ 45,000
Accounting Fees $ 22,000
Miscellaneous $ 2,917
-----------
TOTAL $ 75,000
===========
Item 26. Recent Sales of Unregistered Securities.
The securities of the Company that were issued by it within the past
three years and were not registered with the SEC are described below.
In April 2002, the Company issued 300,000 shares of restricted Common
stock to an investor in consideration for the investor's cancellation of an
outstanding warrant to purchase 5,500,000 shares of the Company's Common Stock
for an exercise price of $100,000.
In May 2002, the Company issued 135,000 shares of restricted Common Stock,
and a five-year warrant to purchase an additional 135,000 shares of Common Stock
at an exercise price of $2.50 per share, to a single private investor. The
purchase price was $150,000.
II-2
In August 2002, the Company issued an additional 100,000 shares of
restricted Common Stock, and a five year warrant to purchase an additional
100,000 shares of Common Stock, at an exercise price of $2.50 per share, to a
single private investor. The purchase price was $100,000.
In February 2003 the Company issued 12,128,481 shares of Common Stock
to 217 persons upon the acquisition of its predecessor, VisiJet, Inc. through a
statutory merger. The Company believes the transaction was exempt from the
registration requirements of the Securities Act of 1933, as amended, by reason
of Section 3(a)(10) thereof.
During 2003 the Company received gross proceeds of $4,575,000 from the
sale of 5,749,987 shares and warrants to purchase 6,249,986 shares of Common
Stock to 47 private investors.
During the first and second quarters of 2004 the Company received gross
proceeds of $585,000 from the sale of 585,000 shares and warrants to purchase
585,000 shares of Common Stock to 12 private investors.
In May 2004, the Company issued a $750,000 debenture to a group of five
private investors. The principal balance of the debenture is due and payable on
July 5, 2004, and the debenture bears interest at an annual rate of 15%. In
addition, the debenture holders received warrants to purchase 500,000 shares of
the Company's common stock, exercisable through May 6, 2009, at an exercise
price of $0.90 per share.
In May 2004, the Company issued $800,000 in convertible debentures to
two private lenders. The principal balance of the debentures is due and payable
on the earlier of (i) one hundred and five (105) days from the issue date, or
(ii) ten (10) business days from the date the Company's Registration Statement
is declared effective by the Securities and Exchange Commission. The debentures
bear interest at an annual rate of 10%, which is due and payable on the maturity
date. In addition, the debenture holders received an aggregate of 533,000
warrants to purchase shares of the Company's common stock, exercisable through
May 6, 2009 at an exercise price of $0.90 per share.
In June 2004, the Company issued $1,000,000 in convertible debentures
to two private lenders. The principal balance of the debentures is due and
payable on June 24, 2006 and the debentures bear interest at an annual rate of
8%. In addition, the debenture holders received an aggregate of 150,000 shares
of the company's common stock, and an aggregate of 750,000 warrants to purchase
shares of the Company's common stock, exercisable through June 24, 2009, at an
exercise price of $1.50 per share, provided however that the exercise price with
respect to an aggregate of 500,000 of the warrants is reduced to $0.60 per share
during the period from the date of issuance through the date twelve (12) months
after the Securities and Exchange Commission declares effective a registration
statement registering the resale of shares underlying the warrants.
In July 2004, the Company entered into convertible debentures
agreements with a private lender with an aggregate principal balance of
$1,000,000, and received net proceeds of $900,000 after subtracting related
placement agent fees and expenses totaling $100,000. The note bears interest, at
an annual rate of 8%, which is due and payable quarterly beginning on October
31, 2004. In addition, the debenture holders received warrants to purchase
750,000 shares of the Company's common stock, exercisable through July 23, 2011,
at an exercise
II-3
price of $1.00 per share. The principal balance of the note, plus any accrued
and unpaid interest, is due and payable on July 23, 2014, provided however, that
on or after July 31, 2007 the Company, at the option of the note holder, may be
obligated to repurchase the note at a price equal to 100% of the outstanding
principal and interest. The outstanding principal of the debentures may be
converted into shares of the Company's common stock, at the option of the note
holder, based on an initial conversion price of $0.54 per share, subject to
adjustment as defined in the agreement.
In October 2004, the Company entered into convertible debenture
agreements with four private lenders with an aggregate principal balance of
$850,000, and received net proceeds of $788,000 after subtracting related
placement agent fees and expenses totaling $62,000. The notes bear interest, at
an annual rate of 8%, which is due and payable quarterly beginning on December
31, 2004. The principal balance of the note, plus any accrued and unpaid
interest is due and payable on October 6, 2014, provided however, that on or
after October 6, 2007 the Company, at the option of the note holder, may be
obligated to repurchase the note at a price equal to 100% of the outstanding
principal and interest. In addition, the note holders received warrants to
purchase 850,000 shares of the Company's common stock, exercisable through
October 6, 2009 at an exercise price of $0.40 per share. In connection with
these agreements, the Company agreed to issue a total of 500,000 additional
warrants to the holders of an aggregate of $2,000,000 of convertible debenture
agreements entered into in June and July 2004, and to reduce the initial
conversion price of these debentures to $0.35 per share.
On October 7, 2004 the Company issued 450,000 shares of Series A
Convertible Preferred Stock ("Series A Shares") to Langley Park Investments,
PLC, a United Kingdom corporation. The Company issued the Series A Shares in
exchange for 2,477,974 newly issued Ordinary Shares of Langley Park Investments,
PLC, with an agreed value of (pound)1.00 (pound) per share. While the share
certificates were issued, no Certificate of Designation establishing the rights,
privileges and preferences of the Series A Preferred Stock has been filed with
the Delaware Secretary of State as of the date of this Registration Statement.
In December 2004 the Company issued a Convertible Note for $500,000 to
Alpha Capital Aktiengesellschaft. The note was due on January 27, 2005, but the
holder had the option to exchange it for $500,000 in Convertible Debentures. In
connection with the issuance of the Convertible Note, the Company issued 142,857
shares of Common Stock, as well as a Warrant to purchase 1,250,000 shares at an
exercise price of $ .40 per share.
In January of 2005 the Company consummated a transaction with Renn
Capital Group, Inc. and a group of investment funds, under which the investment
funds purchased an aggregate of $7,695,000 in principal amount of convertible
debentures from the Registrant. The Convertible Debentures are convertible into
Common Stock of the Company at a rate of $ .35 per share, subject to
antidilution adjustments. The purchase price consisted of cash of $4,845,000 and
the exchange of $2,850,000 in previously issued convertible debentures.
In connection with the transaction the Registrant also issued to the
Investors warrants to purchase 7,695,000 shares of Common Stock, at an exercise
price of $.40 per share. Outstanding warrants to purchase 2,850,000 shares were
surrendered as part of the transaction, so the net amount of warrants issued to
the investors was 4,845,000. The exercise price of the warrants is reduced to $
.01 per share if the Company does not file a Registration Statement covering the
shares issuable upon exercise on or before January 31, 2005. The warrants expire
on the fifth anniversary of the date of issuance. The Company also issued
970,714 shares of Common Stock and warrants to purchase an additional 1,762,857
shares to a finder in connection with the transactions.
Except as noted above, the Company believes that each of the foregoing
transactions was exempt from the registration requirements of the Securities Act
of 1933, as amended, by reason of either (i) Section 4(2) thereof, (ii)
Regulation D thereunder, or Regulation S thereunder. In the case of sales
relying on the exemption provided by Section 4(2), where the purchasers were not
personally known to officer or directors of the Company, it investigated the
background of the purchasers, and had each complete questionnaires or
Subscription Agreements in which they disclosed information on their investment
background and sophistication. The great majority of these investors were
professional investment funds.
II-4
Item 27. Exhibits.
Exhibit No. Exhibit Description
----------- -------------------
2.1 Second Amended and Restated Agreement and Plan of Merger, dated
December 20, 2002 among Ponte Nossa Acquisition Corp., VisiJet,
Inc., and VisiJet Acquisition Corporation (1)
2.2 Amendment No. 1, dated January 15, 2003, to Second Amended and
Restated Agreement and Plan of Merger (2)
3.1 Restated Certificate of Incorporation of the Company (3)
3.2 Certificate of Designation of Rights and Preferences of Series A
0% Convertible Preferred Stock
3.3 Certificate of Amendment of Certificate of Incorporation
3.4 Amended and Restated Bylaws (4)
5.1 Form of Opinion of Haddan & Zepfel LLP
10.1 Patent License Agreement between SurgiJet, Inc. and VisiJet, Inc.,
dated October 23, 1998 (4)
10.2 Amendment No. 1 to Patent License Agreement, dated November 6,
2002 (3)
10.3 Technology License Agreement between SurgiJet, Inc. and VisiJet,
Inc., dated October 23, 1998 (4)
10.4 Amendment No. 1 to Technology License Agreement, dated November 6,
2002 (3)
10.5 Trademark License Agreement between SurgiJet, Inc. and VisiJet,
Inc., dated October 23, 1998 (4)
10.6 Amendment No. 1 to Trademark License Agreement, dated November 6,
2002 (3)
10.7 Warrant, dated February 11, 2003, issued to PCL Associates (4)
10.8 Warrant, dated February 11, 2003, issued to David E. Eisenberg
Trust (4)
10.9 Warrant, dated February 11, 2003, issued to Laurence Schreiber (4)
10.10 Warrant, dated February 11, 2003, issued to Financial
Entrepreneurs Incorporated (4)
10.11 Form of Stock Purchase Warrant Used in February 2004 Private
Placement(5)
10.12 Form of 24% Secured Subordinated Debenture Used in February 2004
Private Placement(5)
10.13 Securities Purchase Agreement, dated June 24, 2004, between the
Company, Bushido Capital Master Fund, L.P. and Bridges & Pipes,
LLC (6)
10.14 Form of Convertible Debenture Issued Pursuant to June 24, 2004
Stock Purchase Agreement (6)
10.15 Form of Warrant (stepped price) issued pursuant to June 24, 2004
Stock Purchase Agreement (6)
10.16 Form of Warrant (fixed price) issued pursuant to June 24, 2004
Stock Purchase Agreement (6)
10.17 Registration Rights Agreement, dated June 24, 2004, between the
Company, Bushido Capital Master Fund, L.P. and Bridges & Pipes,
LLC (6)
II-5
10.18 Pledge and Escrow Agreement, dated June 24, 2004, between the
Company, Bushido Capital Master Fund, L.P., Bridges & Pipes, LLC,
and Tarter Krinsky & Drogin LLP, as Escrow Agent (6)
10.19 Term Credit Agreement, dated May 6, 2004, between the Company Inc.
and HIT Credit Union (7)
10.20 Form of $750,000 Term Note, dated May 6, 2004, issued by the
Company to HIT Credit Union(7)
10.21 Security Agreement, dated May 6, 2004, between the Company and HIT
Credit Union(7)
10.22 Stock Purchase Agreement, dated May 6, 2004 between the Company,
Platinum Long Term Growth LLC and Rock II, LLC (7)
10.23 10% Convertible Debenture for $550,000,dated May 6, 2004, issued
by the Company to Platinum Long Term Growth LLC (7)
10.24 10% Convertible Debenture for $250,000,dated May 6, 2004, issued
by VisiJet, Inc., to Rock II, LLC (7)
10.25 Warrant To Purchase 366,666 Shares of Common Stock of the Company,
issued to Platinum Long Term Growth LLC (7)
10.26 Warrant To Purchase 166,667 Shares of Common Stock of the Company,
issued to Rock II, LLC (7)
10.27 Form of Registration Rights Agreement, dated May 6, 2004 between
the Company, Platinum Long Term Growth LLC and Rock II, LLC (7)
10.28 Manufacturing, Supply and Distribution Agreement, dated May 7,
2004 between the Company and Gebauer Medizintechnik GmbH (7)
10.29 Securities Purchase Agreement, dated July 23, 2004 between the
Company and Libertyview Special Opportunities Fund, LP (7)
10.30 8% Convertible Note for $1,000,000, dated July 23, 2004, issued by
the Company to Libertyview Special Opportunities Fund, LP (7)
10.31 Warrant To Purchase 750,000 Shares of Common Stock of the Company,
issued to Libertyview Special Opportunities Fund, LP (7)
10.32 Registration Rights Agreement, dated July 23, 2004, between the
Company and Libertyview Special Opportunities Fund, LP (7)
10.33 Convertible Preferred Stock Purchase Agreement, dated August 24,
2004 between the Company and Langley Park Investments PLC
10.34 Securities Purchase Agreement, dated October 6, 2004, between the
Company and certain investors relating to $885,000 in convertible
debentures (8)
10.35 Form of Convertible Debenture issued under October 6, 2004
Securities Purchase Agreement (8)
10.36 Form of Stock Purchase Warrant issued under October 6, 2004
Securities Purchase Agreement (8)
10.37 Registration Rights Agreement, dated October 6, 2004 between the
Company, Bushido Capital Master Fund L.P., Bridges & Pipes LLC,
Libertyview Special Opportunities Fund, LP, Gamma Opportunity
Capital Partners LP, Blue Fin Partners, Inc. and Little Gem Life
Sciences Fund, LLC (8)
10.38 Amendment To Securities Purchase Agreement dated October 6, 2004
between the Company, Gamma Opportunity Capital Partners L.P.,
Bridges & PIPES LLC, LibertyView Special Opportunities Fund, LP,
Blue Fin Partners, Inc. and Little Gem Life Sciences Fund, LLC (8)
II-6
10.39 Securities Purchase Amendment Agreement dated October 7, 2004,
between the Company, Bushido Capital Master Fund L.P., Bridges &
Pipes LLC, and Libertyview Special Opportunities Fund, LP (8)
10.40 Amended Convertible Debenture, dated October 7, 2004, issued to
Bridges & Pipes LLC (8)
10.41 Amended Convertible Debenture, dated October 7, 2004, issued to
Bushido Capital Master Fund LP (8)
10.42 $1,000,000 Convertible Note, dated July 23, 2004, as amended
October 6, 2004, issued to Libertyview Special Opportunities Fund,
LP (8)
10.43 Warrant to Purchase 750,000 shares, dated October 6, 2004, issued
to Libertyview Special Opportunities Fund, LP (8)
10.44 Warrant to Purchase 250,000 shares, dated October 6, 2004, issued
to Libertyview Special Opportunities Fund, LP (8)
10.45 Patent License Agreement, dated September 17, 2003, between the
Company and Robert M. Campbell, M.D.
10.46 Subscription Agreement, dated December 30, 2005 between the
Company and Alpha Capital Aktiengesellschaft.
10.47 Form of International Distributor Agreement
10.48 Form of Securities Purchase Agreement used in January 2005
Financing
10.49 Form of Convertible Debenture used in January 2005 Financing
10.50 Form of Stock Purchase Warrant used in January 2005 Financing
10.51 Amended and Restated Registration Rights Agreement, dated January
14, 2005, between the Company and the Investors named therein
10.52 Amended and Restated Security Agreement, dated January 14, 2005,
between the Company and the Investors named therein
14 Code of Ethics(5)
23.1 Consent of Peterson & Co. LLP, Certified Public Accountants
23.2 Consent of Haddan & Zepfel LLP (included in Exhibit 5.1)
----------------
(1) Incorporated by reference from Report on Form 8-K of the Company,
filed January 7, 2003
(2) Incorporated by reference from Report on Form 8-K of the Company,
filed February 14, 2003
(3) Incorporated by reference from Quarterly Report on Form 10-QSB of
the Company for the quarter ended June 30, 2003, filed August 15,
2003
(4) Incorporated by reference from Annual Report on Form 10K-SB of the
Company for the year ended December 31, 2002, filed on April 14,
2003.
(5) Incorporated by reference from Annual Report on Form 10-KSB for the
fiscal year ended December 31, 2003, filed April 14, 2004.
(6) Incorporated by reference from Report on Form 8-K of the Company,
dated June 24, 2004, filed on August 18, 2004
(7) Incorporated by reference from Quarterly Report on Form 10-QSB for
the quarter ended June 30, 2004, filed on August 18, 2004.
(8) Previously filed.
II-7
Item 28. Undertakings.
The undersigned registrant hereby undertakes that:
(1) It will file, during any period in which it offers or sells
securities, a post-effective amendment to this Registration Statement to:
(i) Include any prospectus required by Section 10(a)(3) of
the Securities Act of 1933;
(ii) Reflect in the prospectus any facts or events which,
individually or together, represent a fundamental
change in the information in the Registration
Statement; notwithstanding the foregoing, any increase
or decrease in volume of securities offered (if the
total dollar value of securities offered would not
exceed that which was registered) and any deviation
from the low or high end of the estimated maximum
offering range may be reflected in the form of
prospectus filed with the Commission pursuant to Rule
424(b) if, in the aggregate, the changes in the volume
and price represent no more than a 20% change in the
maximum aggregate offering price set forth in the
"Calculation of Registration Fee" table in the
effective registration statement; and
(iii) Include any material information with respect to the
plan of distribution not previously disclosed in the
Registration Statement or any material change to such
information in the Registration Statement;
(2) For the purpose of determining any liability under the Securities
Act of 1933, treat each such post-effective amendment as a new
registration statement relating to the securities offered therein,
and the offering of such securities at that time to be the initial
bona fide offering thereof; and
(3) It will remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold
at the termination of the offering.
Insofar as indemnification for liabilities arising under the Securities Act
of 1933, as amended, may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise,
the registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the Act and is,
therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the
successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being
registered, the registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Act and will be governed by the final adjudication of
such issue.
II-8
SIGNATURES
In accordance with the requirements of the Securities Act of 1933, the
Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form SB-2 and has authorized this registration
statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Irvine, State of California, on January 31, 2005.
VISIJET, INC.
By: /s/ Randal A. Bailey
----------------------------------------
Randal A. Bailey,
President
II-9
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears
below constitutes and appoints Randal A. Bailey his true and lawful
attorney-in-fact, with full power of substitution and resubstitution, for him
and in his name, place and stead, in any and all capacities to sign any and all
amendments (including post- effective amendments) to this registration statement
and to sign a registration statement pursuant to Section 462(b) of the
Securities Act of 1933, and to file the same with all exhibits thereto, and
other documents in connection therewith, with the Securities and Exchange
Commission, granting unto said attorneys-in-fact, full power and authority to do
and perform each and every act and thing requisite and necessary to be done in
and about the premises, as fully to all intents and purposes as he might or
could do in person, hereby ratifying and confirming all that said
attorney-in-fact or his substitute or substitutes, may lawfully do or cause to
be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this
registration statement has been signed by the following persons in the
capacities and on the dates indicated.
Signature Title Date
--------- ----- ----
/s/ Randal A. Bailey President and a Director January 31, 2005
------------------------- (Principal Executive Officer)
Randal A. Bailey
/s/ Laurence M. Schreiber COO, Corporate Secretary and a January 31, 2005
------------------------- Director (Principal Financial
Laurence M. Schreiber and Accounting Officer)
Directors:
/s/ Richard H. Keates Chairman of the Board of Directors January 31, 2005
-------------------------
Richard H. Keates
/s/ Norman Schwartz Director January 31, 2005
-------------------------
Norman Schwartz
II-10